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Résumé 
Cette thèse traite de la résistance du VIH-1 aux antirétroviraux, en particulier de l'activité 
antivirale de plusieurs inhibiteurs non nucléosidiques de la transcriptase inverse (INNTI) 
ainsi que des inhibiteurs de protéase (IP). Nous avons exploré l‟émergence et la 
spécificité des voies de mutations qui confèrent la résistance contre plusieurs nouveaux 
INNTI (étravirine (ETR) et rilpivirine (RPV)) (chapitres 2 et 3). En outre, le profil de 
résistance et le potentiel antirétroviral d'un nouvel IP, PL-100, est présenté dans les 
chapitres 4 et 5.  
Pour le premier projet, nous avons utilisé des sous-types B et non-B du VIH-1 pour 
sélectionner des virus résistants à ETR, et ainsi montré que ETR favorise l‟émergence des 
mutations V90I, K101Q, E138K, V179D/E/F, Y181C, V189I, G190E, H221H/Y et 
M230L, et ce, en 18 semaines. Fait intéressant, E138K a été la première mutation à 
émerger dans la plupart des cas. Les clones viraux contenant E138K ont montré un faible 
niveau de résistance phénotypique à ETR (3,8 fois) et une diminution modeste de la 
capacité de réplication (2 fois) par rapport au virus de type sauvage. Nous avons 
également examiné les profils de résistance à ETR et RPV dans les virus contenant des 
mutations de résistance aux INNTI au début de la sélection. Dans le cas du virus de type 
sauvage et du virus contenant la mutation unique K103N, les premières mutations à 
apparaître en présence d‟ETR ou de RPV ont été E138K ou E138G suivies d‟autres 
mutations de résistance aux INNTI. À l‟inverse, dans les mêmes conditions, le virus avec 
la mutation Y181C a évolué pour produire les mutations V179I/F ou A62V/A, mais pas 
E138K/G. L'ajout de mutations à la position 138 en présence de Y181C n'augmente pas 
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les niveaux de résistance à ETR ou RPV. Nous avons également observé que la 
combinaison de Y181C et E138K peut conduire à un virus moins adapté par rapport au 
virus contenant uniquement Y181C. Sur la base de ces résultats, nous suggérons que les 
mutations Y181C et E138K peuvent être antagonistes. 
L‟analyse de la résistance au PL-100 des virus de sous-type C et CRF01_AE dans les 
cellules en culture est décrite dans le chapitre 4. Le PL-100 sélectionne pour des 
mutations de résistance utilisant deux voies distinctes, l'une avec les mutations V82A et 
L90M et l'autre avec T80I, suivi de l‟addition des mutations M46I/L, I54M, K55R, L76F, 
P81S et I85V. Une accumulation d'au moins trois mutations dans le rabat protéique et 
dans le site actif est requise dans chaque cas pour qu‟un haut niveau de résistance soit 
atteint, ce qui démontre que le PL-100 dispose d'une barrière génétique élevée contre le 
développement de la résistance. Dans le chapitre 5, nous avons évalué le potentiel du PL-
100 en tant qu‟inhibiteur de protéase de deuxième génération. Les virus résistants au PL-
100 émergent en 8-48 semaines alors qu‟aucune mutation n‟apparaît avec le darunavir 
(DRV) sur une période de 40 semaines. La modélisation moléculaire montre que la haute 
barrière génétique du DRV est due à de multiples interactions avec la protéase dont des 
liaison hydrogènes entre les groupes di-tétrahydrofuranne (THF) et les atomes d'oxygène 
des acides aminés A28, D29 et D30, tandis que la liaison de PL-100 est principalement 
basée sur des interactions polaires et hydrophobes délocalisées à travers ses groupes 
diphényle. Nos données suggèrent que les contacts de liaison hydrogène et le groupe di-
THF dans le DRV, ainsi que le caractère hydrophobe du PL-100, contribuent à la liaison 
à la protéase ainsi qu‟à la haute barrière génétique contre la résistance et que la refonte de 
6 
 
la structure de PL-100 pour inclure un groupe di-THF pourrait améliorer l‟activité 
antivirale et le profil de résistance. 
 
Mot-clés: VIH-1 sous-type, le traitement antirétroviral, la résistance aux médicaments, 
l'activité antivirale, la résistance croisée, la deuxième génération, la capacité de 
réplication, barrière génétique, l'étravirine, rilpivirine, PL-100. 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Abstract 
This thesis focuses on HIV-1 drug resistance and on the antiviral activity of several non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). We 
have explored the mutational pathways and resistance patterns of several new NNRTIs 
(etravirine (ETR) and rilpivirine (RPV)) (Chapters 2 and 3). In addition, the drug 
resistance profile and potential of a novel protease inhibitor (PI) PL-100 is presented in 
Chapters 4 and 5. In the first project, we used both B and non-B subtypes of HIV-1 to 
select for ETR resistance and showed that ETR selected for mutations at positions V90I, 
K101Q, E138K, V179D/E/F, Y181C, V189I, G190E, H221H/Y and M230L within 18 
weeks of commencing drug pressure. Interestingly, E138K was the first mutation to 
emerge in most instances. Viral clones containing E138K displayed low-level phenotypic 
resistance to ETR (3.8-fold) and modestly impaired replication capacity (2-fold) 
compared to wild-type virus. We also examined resistance patterns to ETR and RPV in 
viruses containing NNRTI mutations at baseline. In wild-type (wt) viruses and viruses 
containing K103N alone, E138K or E138G mutations were observed in the presence of 
either ETR or RPV drug pressure followed by the appearance of other NNRTI resistance 
mutations. Alternatively, subtype B viruses containing Y181C generated V179I/F or 
A62V/A on exposure to ETR or RPV drug pressure, respectively, but not E138K. The 
addition of mutations at position 138 to Y181C did not significantly enhance levels of 
resistance to ETR or RPV. We also observed that the combination of Y181C and E138K 
may lead to a less fit virus compared to virus containing Y181C alone. Based on these 
findings, we suggest that Y181C may be antagonistic to E138K. 
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The tissue culture drug resistance analysis of PL-100 in subtype C and CRF01_AE 
viruses is described in Chapter 4. PL-100 selected for PI resistance mutations along either 
of two distinct pathways, one of which involved resistance mutations at positions V82A 
and L90M while the other involved a mutation at position T80I, with other mutations 
being observed at positions M46I/L, I54M, K55R, L76F, P81S and I85V. An 
accumulation of at least three mutations in the protease flap and enzyme active sites were 
required in each case for high-level resistance to occur, demonstrating that PL-100 has a 
high genetic barrier against the development of drug resistance.  In Chapter 5, we 
evaluated the potential of PL-100 as a second generation HIV-1 protease inhibitor. PL-
100 resistant variants emerged within 8-48 weeks while darunavir (DRV) did not select 
for resistance mutations over a period of 40 weeks. Structural modeling demonstrated that 
the high genetic barrier of DRV is due to numerous interactions with protease that 
include hydrogen-bonding to PR backbone oxygens at amino acid positions A28, D29 
and D30 via di-tetrahydrofuran (THF) groups, while binding of PL-100 was 
predominantly based on polar interactions and delocalized hydrophobic interactions 
through its diphenyl groups. Our data suggest that hydrogen bonding contacts and the di-
THF group in DRV, as well as the hydrophobic nature of PL-100, contribute to PI 
binding and a high genetic barrier for resistance and that redesigning the structure of PL-
100 to include a di-THF group might improve it antiviral potency and drug resistance 
profile. 
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Chapter 3: Asahchop EL, Wainberg MA, Oliveira M, Xu HT,
 
Brenner BG, Moisi D, 
Ibanescu IR, and Tremblay CL. Distinct Resistance Patterns to Etravirine and Rilpivirine 
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CHAPTER 1 
1.0 INTRODUCTION 
This chapter intends to give a brief overview of the life cycle, structure and epidemiology 
of Human Immunodeficiency virus (HIV) and to summarize those aspects of HIV 
research that are relevant to the original work presented in subsequent chapters. The main 
focus is placed on antiretroviral (ARV) therapy and mechanisms of resistance. Aspects of 
replication capacity and fitness in the presence of mutations are also discussed.  
 
 
Sections of this chapter were published as a review entitled “Antiviral Drug Resistance 
and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors”, 
authored by Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. Antimicrobial 
Agents and Chemotherapy. June 2012. 
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1.1 Historical Background of HIV/AIDS  
In 1981, the Acquired Immunodeficiency Syndrome (AIDS) was first reported among the 
male homosexual community of San Francisco with immunodeficiency associated with 
conditions such as Kaposi‟s sarcoma, pneumocystis pneumonia, and mucosal candidiasis 
[1,2,3]. Later on, other groups like haemophiliacs [4], intravenous drug users [3], 
immigrants or residents from Haiti and Africa [5] and infants born from infected mothers 
were also found affected by the same syndrome [6]. It is now well established through 
epidemiological and public health studies that transmission of human immunodeficiency 
virus (HIV) occurs by sexual contact, blood or blood product transfusion, intravenous 
drug use by needle sharing and from infected mother to her child through breast feeding 
or pre- or perinatal contact [2,3,7,8,9]. Human immunodeficiency virus type 1 (HIV-1) 
was later identified as the pathogenic cause of AIDS in 1983 [10]. AIDS is a disease 
characterized by a decreased T-helper (CD4+) cell subset leading to impaired immune 
function [11]. Clinical manifestations of immunodeficiency syndrome are weight loss, 
adenopathy, malignancies, neural syndrome and development of opportunistic infections 
[12]. In 1986, another type of human immunodeficiency virus (HIV-2), was identified in 
Portugal from AIDS patients from West Africa [13]. In HIV-2, disease progression and 
eventual progression to AIDS is much slower [14].  
 
The most plausible origins of HIV-1 and HIV-2 transmission to humans are from Simian 
Immunodeficiency Virus (SIV) infected Chimpanzees (SIVcpz) and SIV sooty mangabeys 
(SIVsm) respectively [15,16]. Simian Immunodeficiency Virus (SIV) is a retrovirus that 
infects non-human primates. Phylogenetic analysis has shown that SIV clusters closely 
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with HIV. HIV is a retrovirus and belongs to the genus Lentivirus and family 
Retroviridae: these are viruses, which have single-stranded RNA as their genetic material, 
but replicate via a double stranded DNA intermediate. To date no vaccine has been 
developed that can protect against HIV. This is largely due to the variability of the HIV 
virus which changes or mutates over time. 
 
1.2 Epidemic in 2011 
At the end of 2011, a total of 34.2 million people were living with HIV worldwide 
according to the joint UNAIDS/WHO report [17]. Amongst these, 30.8 million are adults 
and 3.4 are children less than 15 years old. In 2011, 1.7 million deaths due to AIDS and 
2.5 million new HIV infections were registered, with 7000 new HIV infections per day. 
The highest burden is within Sub-Saharan Africa where the mortality rate due to AIDS is 
high. This region alone harbored about 23.5 million (68% of all cases worldwide) HIV 
infected people in 2011, followed by South and Southeast Asia with 4.2 million cases. 
There are an estimated 3.4 million orphans as a result of AIDS mortality in this region. 
Worldwide, an increase from 1.5 million in 2001 to 3.4 million in 2011 has been 
observed in children (under 15 years) living with HIV. The burden falls most heavily on 
poor countries and on the poorest individuals within those countries. Regional summaries 
of the HIV epidemic in 2011 are shown in Figure 1. 
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Figure 1: Adults and Children Estimated to be living with HIV in 2011. Regional 
summaries (Adapted from the joint UNAIDS/WHO 2012 HIV/AIDS report). 
 
1.3 Structure of HIV-1 Virion 
All lentiviruses have an envelope. The envelope contains a lipid bilayer that originates 
from the host cell membrane. HIV-1 has an icosahedral structure containing 
approximately 10 spikes per virion and an overall diameter of 100 nm (Figure 2) 
[18,19,20]. The surface glycoprotein (SU, gp120) and the transmembrane glycoprotein 
(TM, gp41) form the two major proteins on the viral envelope. The gp120 protein is the 
external (exposed) region of viral envelope while the gp41 portion attaches the env gene 
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to the surface of the cell membrane. An infectious virus contains three structural Gag 
proteins: the matrix (MA, p17) protein forms the inner shell in the virus particle next to 
the lipid envelope, capsid (CA, p24) protein is the cone shaped structure that surrounds 
the viral genomic RNA and nucleocapsid (NC, p7) encodes viral RNA within the capsid. 
The PTAPP and YSPTL motifs in p6 of Gag each interact with an endosomal sorting 
complex required for transport i.e. (ESCRT) I and III respectively [21,22,23]. The 
cellular proteins TSG 101 and ALIX are found in ESCRT I and ESCRT III respectively. 
Specifically the PTAPP motif in the p6 of Gag binds with TSG 101 while the YSPTL 
motif binds to ALIX [23]. These interactions facilitate the recruitment and assembly of 
host proteins on the cell membrane and thus the budding of viral particles. It has been 
shown that when the TSG 101 pathway for budding is defective (HIV-1 PTAPP mutant), 
cellular expression of ALIX can rescue this virus release defect and this rescue depends 
on an unaltered ALIX binding site on p6 [21]. The capsid contains two copies of viral 
genomic RNA, the viral enzymes reverse transcriptase (RT), protease and integrase, and 
approximately 2000 molecules of the processed nucleocapsid (NC) p7 [24,25]. The 
proteolytic cleavage of the 55 kD Gag precursor by HIV-1 protease yields p17, p24 and 
p7 [26]. The two copies of single-stranded HIV-1 RNA molecules located inside the core 
are about 9.2 kilobases each. In general, a single HIV-1 virion is estimated to contain 
2400 Gag molecules, roughly 80 RT molecules, and up to three molecules each of gp120 
and gp41 that form one heterotremiric glycoprotein spike [19,27,28,29]. 
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Figure 2: Structure of HIV Virus. 
 
1.4 Genome Organization 
The genomic organization of HIV-1 is illustrated in Figure 3. During the process of 
reverse transcription of the viral RNA, two identical elements, the long terminal repeats 
(LTRs), are generated at each end of the provirus. Promoters and transcriptional enhancer 
sequences of the LTR include;  a TATA promoter, polyadenylation signal sequences, cis-
acting elements, negative regulatory elements and NF-kB binding regions, and have been 
shown to be necessary for efficient viral replication  [30,31]. The two LTRs are flanked 
by genes encoding structural proteins and viral enzymes, and genes coding for a series of 
regulatory and accessory proteins. HIV-1 exhibits three essential regions located between 
the 5'-and the 3'LTRs. The gag gene is situated at the 5' end of the genome and codes for 
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a Pr55 polyprotein. The proteolytic cleavage of the Gag precursor p55 results in smaller 
proteins, including p24, p17, p9, p6, p2 and p1. The Pol gene is cleaved into three 
enzymes including; reverse transcriptase (RT) for conversion of RNA to DNA, integrase 
(IN) that is responsible for the integration of viral DNA into host cell and protease (PR) 
for processing of polyprotein precursors. The proteolytic processing site of Gag and Gag-
pol polyprotein is unique to the protease that is encoded by HIV-l [32]. The precursor of 
env gene gp160 is cleaved into surface protein gp120 and transmembrane protein gp41.  
The endoprotease furin, is responsible for the cleavage of gp160 [33]. Extracellular 
gp120 is involved in recognition and binding, while transmembrane protein gp41 in 
membrane fusion. Specific conserved regions within the gp120 of Env are responsible for 
binding to the CD4 receptor [19,34]. The gp120 layers that are involved in binding also 
regulate the interaction of gp41 [35]. The binding of gp120 to the CD4 receptor exposes 
the co-receptor binding site. Macrophage (M)-tropic HIV-1 viruses use CCR5 as a co-
receptor while T-cell tropic HIV-1 uses CXCR4 [19]. It has been shown that the V3 loop 
of Env plays a role in fusion and is co-receptor specific [36,37]. The complete binding of 
gp120 to the CD4 receptor and co-receptor results in a change in the conformation of 
gp41, leading to the release of the fusion peptide that penetrates into the cell membrane 
and forms a fusion pore [19]. 
 
 
37 
 
 
 
Figure 3: Genomic organization of HIV-1. (Adapted from the Los Alamos Laboratory 
HIV Sequence Book). 
 
In addition to the prototypic gag, pol and env coding sequences, HIV-1 possesses at least 
six other genes coding for auxiliary proteins namely: Tat, Rev, Vif, Vpr, Vpu and Nef 
(reviewed in [38,39,40,41]). The classification of these proteins into two groups depends 
on the time of their regulatory expression during HIV replication. For example, early in 
the viral life cycle, Tat, Rev, and Nef are synthesized from Rev-independent multiply 
spliced mRNA while at late stages of HIV-1 replication, Vif, Vpr, and Vpu are expressed 
from a Rev dependent singly spliced mRNAs (reviewed in [38,39]). The function of the 
Tat protein is to enhance transcriptional elongation by binding to the TAR (trans -
activating response element) and is a major protein involved in up-regulating HIV 
replication. Another viral regulatory protein, Rev (regulator of viral protein expression) 
plays a role in the export of unspliced and singly spliced viral mRNAs into the cytoplasm 
[42,43]. The functions of the viral protein Nef (negative factor) include cell activation 
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and enhanced infectivity. Nef plays a role in signal transduction and cell activation by 
interacting with cellular proteins (serine kinases) [44]. Another function of Nef is the 
down regulation of CD4 surface expression by mediating endocytosis and lysosomal 
degradation of CD4 [45]. The Vif protein is also called viral infectivity factor and is 
produced from a singly spliced mRNA that accumulates late in HIV life cycle [46]. Vif 
acts during assembly by allowing the generation of particles (viral proteins) that allow a 
new cycle of infection to be initiated [47]. APOBEC3G/3F (apolipoprotein B mRNA-
editing enzyme catalytic polypeptide 1-like protein 3G or 3F) has been described as a 
host restriction factor. HIV containing Vif counteracts the antiviral effect of APOBEC 
leading to infection while HIV delta Vif has been shown to be non-infectious [48,49]. 
CD4 is down regulated by vpu at the surface of the endoplasmic reticulum (ER), thus 
preventing any premature binding of viral gp160 to CD4. In addition, Vpu facilitates the 
release of HIV-1 virons by counteracting the host protein tetherin [50,51]. Vpr is 
responsible for the transport of the preintegration complex, after reverse transcription, 
from the cytoplasm into the nucleus in non-dividing target cells [52]. The proteins Vpr 
and Matrix independently permit import of the preintegration complex to the nucleus via 
distinct nuclear localization signal (NLS) sequences [52]. Vpr has also been reported to 
play an important role in G2 cell cycle arrest by formation of foci and recruitment of the 
DNA Damage-Binding protein 1-cullin 4A (DDB1-CUL4A (VPRBP)). The presence of 
E3 ubiquitin ligase in these nuclear foci can activate the host cell response leading to cell 
cycle arrest [53,54]. Vpx is a viral protein expressed in HIV-2 and not HIV-1 [55]. In 
HIV-2, Vpx counteracts the effect of the restriction factor SAMHD1 for proteasomal 
degradation in the nucleus and thus induces an antiviral innate immune response [55,56].    
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1.5. HIV-1 Life Cycle 
The life cycle of HIV begins when the viral particle binds to host cell receptors on the 
cell membrane (Figure 4). Specifically, the viral gp120 envelop protein recognizes host 
cell surface receptor proteins.  
  
1.5.1. Attachment, Entry and Uncoating 
Entry of HIV-1 into the host cell involves binding of glycoprotein gp120 with the  
cellular receptor CD4 on helper T lymphocytes [57]. A conformational change occurs on 
the surface of gp120, exposing new epitopes that can interact with a co-receptor (either 
CXCR4 or CCR5 or both) (Figure 4) [58,59,60]. The co-receptors for HIV are members 
of seven-transmembrane domain proteins,  (CXCR4) and  (CCR5) chemokines. 
Macrophage tropic (M-tropic) are non-syncytium inducing viruses that uses CCR5 for 
replication in primary infection while T-cell-line tropic (T-tropic) are syncytium inducing 
viruses that replicates with CXCR4 during the late stage of the disease. The significant 
role of CCR5 in HIV entry is shown by individuals who are homozygous for mutations 
(32 bp deletion) within CCR5 develop resistance to infection by HIV-1 [61,62]. Recently, 
Hutter et al were able to show HIV remission in a patient with acute myeloid leukemia 
and HIV-1 infection after transplantation of stem cells from a donor who was 
homozygous for CCR5 delta32 [63]. This patient discontinued antiretroviral therapy 
without any viral rebound for several years. Entry of HIV-1 into the host cell occurs via 
two mechanisms which can either be a fusion process by a clathrin-mediated endocytosis 
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at a low PH or a PH-independent fusion of virus with the cell membrane  [19,64,65]; as a 
result, the viral core and associated RNA are engulfed. 
 
 
Figure 4: HIV-1 Replication cycle [66]. (Reproduced from Held DM et al, 2006 with 
permission).  
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1.5.2. Reverse transcription and Integration 
Once inside the cell, viral RT transcribes the viral genome into cDNA, using a cellular 
lysine tRNA molecule as a primer [67]. The process involves the synthesis of double 
stranded DNA from single stranded RNA by the enzyme DNA polymerase, and the 
degradation of RNA from the RNA:DNA duplexes by RNase H.  The synthesized viral 
DNA moves to the host cell nucleus (a process facilitated by the HIV proteins Vpr and 
Vif as well as Vpr and p17) as a pre-integration complex (PIC). The movement of the 
PIC into the cell nucleus is facilitated by viral and cellular factors. Once inside the 
nucleus, the viral integrase enzyme integrates proviral cDNA into the host genome, using 
the 3‟ processing and strand transfer mechanism [68]. This integrated form of HIV called 
provirus has two identical long terminal repeats (LTR) flanking the coding regions. 
Eradication of HIV-1 from infected patients has not been achieved so far. This is in part 
due to the fact that HIV-1, like all retroviruses, integrates into the host genome. 
 
1.5.3. Virus Expression 
After cDNA integration, viral gene expression commence in the presence of cellular 
transcription machinery. HIV-1 gene expression is initiated by two regulatory protein Tat 
and Rev. Cellular transcription factors are recruited to the promoter, leading to increased 
viral gene transcription by host RNA polymerase II by the HIV regulatory protein Tat 
(reviewed in [69,70]). Specifically, Tat induces transcriptional elongation through 
interaction with HIV-1 transactivation response element (TAR) RNA [69]. P-TEFb is a 
factor that binds Tat and has two components involved in Tat binding; Cyclin T 1 and 
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CDK9 kinase. CycT1 has been shown to form a stable complex with CDK9, Tat and 
TAR RNA [71]. When Tat is formed, it binds to CycT1 and CDK9 components of the P-
TEFb, and the resulting complex then binds to TAR RNA [69,71]. The formation of an 
active preinitiation complex (PIC) involves the recruitment of TATA-binding protein 
(TBP) and TFIIB by the Tat-CycT1-CDK9 bound TAR. Here phosphorylation of the C-
terminal domain of the RNA polymerase II (RNAPII) by CDK9 occurs [69]. The activity 
of Tat on transcriptional elongation is evidence by the formation of a highly competent 
PIC that recruit TFIIH and it kinase CDK7 to hypophorylates the RNAPII. This complex 
of activities brought on the PIC by Tat triggers polymerase departure [69]. 
Another regulatory protein Rev and the Rev response element (RRE) play a role in export 
of mRNA from the nucleus to the cytoplasm [23]. HIV-1 has developed a mechanism to 
export unspliced and partially spliced RNA from the nucleus to the cytoplasm.  In this 
mechanism, Rev bind to RRE and interacts with chromosome maintenance region 1 
(CRM-1) protein and exportin 1 protein which in turn interacts with phenylalanine-
glycine (FG) repeats of nucleoporins [23,72]. This pathway of export is energy-dependent 
requiring Ran GTPase [73,74]. This interaction mediates the export of unspliced and 
partially spliced RNA. A number factor have also been described to play a role directly or 
indirectly in Rev-mediated transport/expression [72]. The Rev/RRE mediated export of 
unspliced and partially spliced RNA from nucleus to cytoplasm occurs when the nuclear 
matrix protein matrin 3 binds to Rev/RRE containing viral RNA [75,76].  
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1.5.4. Virus Assembly and Budding 
The transcribed viral cDNA can serve as either a viral genome copy or an unspliced, 
singly-spliced or multi-spliced mRNA used for viral protein translation. The unspliced 
viral mRNA expresses the Gag and Gag-Pol precursor polyproteins that are subsequently 
directed to the cell plasma membrane for virion assembly ([77,78] reviewed in [79]). 
Genomic RNA associates with Gag precursor polyproteins through the packaging 
sequence present in NC [80] while the interactions of CA and Gag transport the Gag-Pol 
into assembling virions [81]. The MA protein of Gag interacts with Env and directs Env 
incorporation into virions [82,83]. The p6 protein of Gag interacts with endosomal 
sorting complexes required for transport (ESCRT) and initiates release of viral particles 
from the plasma membrane [23,84] The viral protease is derived from the Gag-Pol 
precursor through self-cleavage. This viral protease functions in the proteolytic cleavage 
of other viral polyproteins that result in viral  maturation, to  eventually generate an 
infectious viral particle ([85,86] reviewed in [82]). 
 
1.6. Natural History of HIV Infection. 
The course of HIV infection in the absence of treatment follows the trends shown in 
Figure 5. This involves three stages of infection. The acute infection occurs within the 
first 12 weeks of infection, when viral load (red line) rapidly increases in the plasma, 
peaks, and declines to a level known as the viral set point. HIV-specific CD8+ T-cells 
(not shown) peak within a few weeks, decline and remain at low levels throughout the 
infection. Early intervention with therapy has shown a significant increase in CD8+ T-
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cells [87]. At the peak of viremia there is a drastic decrease in CD4+ T-cell counts (blue 
line) [88,89]. The acute phase ends when HIV specific antibodies emerge [90,91,92]. 
This is known as seroconversion. An asymptomatic period of chronic infection develops 
in the presence of continued antibody production, fluctuating viral loads, persistent CTL 
responses and a slow decline of CD4+ T cell counts (reviewed in [93,94]).  
 
 
Figure 5: The Relationship between HIV copies (viral RNA) and CD4 counts during the 
course of infection. (Source: 
http://www.thenakedscientists.com/HTML/uploads/tx_naksciimages/Hiv-
timecourse.png).   
 
Depending on the individual, the chronic period can lasts on average 7-9 years. This 
ranges from one to 15 years in rapidly progressing and slowly progressing patients, 
respectively. The length of the chronic phase correlates inversely with the viral set point 
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[95,96]. A decreased CD4+ counts lead to failure of the adaptive immune response, and 
individuals tend to acquire opportunistic infections and thus enter the third phase of 
infection i.e. the acquired immunodeficiency syndrome (AIDS). Pneumocystis carinii 
pneumonia, cytomegalovirus disease, systemic fungal infections and atypical 
Mycobacterium infections are the most common opportunistic infections seen in AIDS; 
and if untreated, these HIV infected individuals will die of an AIDS-related illness after a 
median of 10 years (reviewed in [97]). In some individuals, the asymptomatic stage does 
not progress to AIDS [98,99,100]. These individuals, known as elite controllers or long-
term non-progressors (LTNP), are able to sufficiently maintain  high CD4+ T cell levels  
and low level or undetectable viral loads [101].  
 
1.7 Structure of HIV-1 RT 
HIV-1 RT is encoded by the pol gene and expressed from the unspliced mRNA in the 
context of the Gag-Pol precursor by a frameshift event [102]. The HIV-1 RT consists of 
two subunits; the p66 and the p51-KD subunits. The p66 includes functions for reverse 
transcription, the DNA polymerase and RNase H domains while p51 is a carboxy-
terminal end of p66 without the RNase H domain. Using subunit site directed 
mutagenesis, it has been confirmed that both the DNA polymerase and RNase H 
activities of RT reside within the p66 subunit [103]. The p51 subunit of RT plays a role in 
maintaining the conformation of the p66 subunit and in tRNA Lys3 binding 
[104,105,106]. Crytallographic data show that HIV-1 RT resembles a right hand 
[107,108]. The subdomains have been described as the fingers, palm, thumb, and 
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connection domains (Figure 6) [108]. Within the p66 subunit, the polymerase and RNase 
H domains are linked by the connection domain that may play a structural role [109]. 
 
 
Figure 6:  Structure of HIV-1 RT (Reproduced  with permission from Sarafianos SG, 
2009 [110]). Ribbon representation of HIV-1 RT in a complex with nucleic acid. The 
fingers, palm, thumb, connection, and RNase H subdomains of the p66 subunit are 
shown. The p51 subunit is shown, as well as the template and primer DNA strands. 
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1.8. Protease 
The HIV-1 protease (PR) is a 99-amino acid, symmetrical and obligate homodimer. It is 
structurally similar to other aspartyl proteases [111,112], as well as those from other 
retroviruses including: HIV-2 [113] and simian immunodeficiency virus (SIV) [114]. The 
HIV-1 PR consists of three domains: the flaps, active site and dimerization domain 
(Figure 7). The dimerization process leads to a mechanism that regulates and controls 
activation of the enzyme (reviewed in [115]). In a concentrated environment (e.g. in the 
budded virion), the protease is activated, and in a highly dilute environment (e.g. in the 
host cell), the protease is inactivated. The substrate-binding cleft forms the centre of the 
enzyme. The centre of the enzyme then interplays with a variety of substrate cleavage site 
sequences in the Gag and Gag-Pol proteins. Cleavage of the Gag and Gag-Pol 
polyproteins at specific sites by HIV-1 protease results in mature viral proteins. This 
cleavage is for specific HIV-1 protease at these sites in vivo.[116]. 
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Figure 7: Structure of HIV-1 PR (Reproduced with permissionfrom Ali A 2010 [117]). 
The catalytic active site formed at the dimeric interface. Red spheres represent amino 
acid positions. 
 
1.9. Recombination 
Retroviral recombination is the combination of two regions of the viral genome during 
reverse transcription. Although recombination can occur within all regions of the viral 
genome, it is more specific in the gag and envelope regions [118,119,120]. For 
recombination to occur, two non-identical viruses need to successfully infect the same 
cell and the two diverse genomic RNA should have the capacity to form heterodimers  
[121]. This phenomenon could take place early in the infection process, with a latently 
infected cell or a cell in which virus is suppressed [122,123]. Some studies have shown 
that HIV-1 recombines about two to three times per genome per replication cycle, 
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indicating that it has a higher recombination rate than other retroviruses [124,125]. 
During recombination, the RT uses the plus-strand genomic RNA variants in the cell as a 
template to start the synthesis of minus strand DNA. As synthesis proceeds, 
homopolymeric nucleotide tracks cause pausing of the reverse transcriptase and thereby 
promoting template switch and recombination and the nascent minus-strand DNA copied 
from the first variant to transfer to the genomic RNA of second variant [126]. Once 
copied, the genomic RNA is degraded by the RNase H enzyme during reverse 
transcription. Efficient degradation of the template by the RNase H enzyme (which can 
occur during transcription pausing) promotes recombination [121]. The process of 
homologous recombination could allow two defective viruses to become cytopathic [127] 
and could introduce new strains into the population, thereby challenging therapy (via 
drug resistance) and vaccine approaches [118,128,129].  
 
1.10 Variability and Global Distribution of HIV 
HIV possesses an extremely high genetic variability. This extensive heterogeneity is due 
to several factors. First, genetic diversity is the result of the high error rate of reverse 
transcriptase that lacks proofreading capacity [130,131,132] and the fast turnover of 
virions (approximately 10 billion copies) in HIV infected individuals [133]. Secondly, the 
genetically diverse simian viruses that have been introduced into humans [15] could 
cause this heterogeneity. Lastly, the highly recombinogenic property of the virus results 
to intra and interpatients recombination [124,134]. The variability of HIV is of particular 
importance since it may affect a protein‟s structure, function and 
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antigenicity/immunogenicity with respect to therapy, vaccine development and diagnostic 
tests. Point mutations occur frequently during reverse transcription leading to quasi-
species [135]. Thus, a patient is generally infected with a homogenous population which 
gradually changes over time to produce a heterogeneous virus population (qausi-species) 
[136,137,138]. The homogenous population is known as transmitted/founder virus. As 
the transmitted/founder (T/F) virus replicates, the virus selects for mutations due to 
immune pressure. This eventually results to a diverse viral population with  impaired 
replication [139]. It has also been shown that the transmitted/founder virus Env uses the 
CCR5 co-receptor [140]. In a recent study Parrish et al showed that the ability with which 
the envelope gene of T/F and chronic controls use CD4 and CCR5 were similar [141]. In 
addition the authors demonstrated that in both the T/F and chronic controls the CD4+ T 
cell subset tropism and sensitivity to neutralization by CD4 binding site were the same 
[141]. Two recent studies showed that the ability of  both T/F virus and chronic controls 
to replicate in T-lymphocytes was the same, whereas T/F virus replicated less efficiently 
in monocytes derived macrophages than chronic controls [142,143]. It has also been 
demonstrated that the glycosylation pattern of envelope of T/F virus is markedly different  
from that of chronic in the degree of occupancy and levels of complex gycans [144]. 
Recently it was shown that African Green Monkeys can acquire SIV infection through 
the mucosal routes (intrarectal and intravaginal) by one or two T/F virus and that 
susceptibility to infection was proportional to the number of CD4+ expressing CCR5 in 
the mucosal [145]. Another study has identified neutralizing antibodies in SIVmac-
infected with T/F virus after 5 to 8 months of infection [146]. Although their emergence 
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was slow and titer was low, these neutralizing antibodies induced escape mutants 
harboring mutations and deletions in the variable region of the envelope.   
 
The AIDS epidemic is caused by HIV-1 and HIV-2. HIV-1 can be classified into four 
groups: group M (major), O (outlier), N (new, non-M, non-O) and group P. The new HIV 
(group P) was recently isolated and found to be closely related to gorilla SIV [147,148]. 
Group M is the most diverse that is further classified into nine genetic subtypes; A, B, C, 
D, F, G, H, J and K and four sub-subtypes; A1, A2, F1 and F2 [149,150,151]. The 
heterogeneity of HIV-1 group M subtypes in amino acid substitutions in the env and gag 
genes is 20% and 15%, respectively [149,152]. In addition, 51 circulating recombinant 
forms (CRFs) have been reported to date [153]. The identification of a new subtype, sub-
subtype or CRFs requires the identification of three complete identical genome sequences 
from individuals not known to be linked in a direct chain of transmission that results in 
the identified sequences (epidemiological linkage) [154].  
 
HIV-1 subtype distribution and prevalence vary in the different regions of the globe 
(Figure 8). The world-wide distribution of HIV subtypes and recombinants is relatively 
stable, although CRFs are playing an increasing role in the HIV pandemic [155]. The 
most prevalent HIV-1 genetic subtypes worldwide are subtype C (48%), subtype A 
(12%), subtype B (11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%) [155]. 
Central Africa has the greatest diversity, where all major subtypes and groups M, O, N 
and P are circulating [147,148,155]. In West Africa, the dominant variants are 
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CRF02_AG and subtype G although all subtypes have been identified, while subtype B is 
the dominant subtype in North America, the Caribbean, Latin America, western and 
central Europe and Australia [155]. In southern Africa, Ethiopia and India, subtype C is 
the major cause of the epidemic. Additional subtypes and CRFs are regularly identified, 
and migrating populations have been observed to play a greater role in the patterns of 
new subtype identification and distribution [156,157,158]. There is particular concern in 
regard to HIV-1 subtype C, A, and the AG recombinant forms that are predominant in 
Africa where HIV is rapidly spreading. 
 
 
Figure 8: Geographic Distribution of HIV subtypes [159]. (Reproduced with permission 
from Thomson MM et al 2002). 
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1.11. HIV Drug Classes  
The success of HIV research today has been the availability of new classes of drugs, 
allowing the introduction of combination antiretroviral (ARV) therapy [highly active 
antiretroviral therapy (HAART)] and the gradual evolution of HIV infection into a 
chronic, usually non-fatal condition [160]. Antiretroviral drugs are classified according to 
the step they inhibit in the viral life-cycle. Most of these drugs target viral enzymes (RT, 
PR and IN inhibitors) or important steps in the viral life cycle (entry and maturation 
inhibitors). Entry, RT, PR and IN inhibitors are currently approved for treatment of HIV 
patients while maturation inhibitors are under pre-clinical and clinical development. 
The five different classes of approved anti-HIV drugs for treatment of HIV infected 
patients include; nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), Entry Inhibitors 
(EIs), and integrase inhibitors (INI). Each antiretroviral drug class targets the HIV life 
cycle differently. These drug classes differ at the stage of HIV replication at which each 
acts. 
 
1.11.1. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 
NRTIs block the reverse transcription process of HIV RT. These chemically modified 
nucleosides and nucleotides (analogs) compete with the natural building blocks (dNTPs). 
This results to binding of the compound to the viral DNA in the place of the dNTPs. The 
structure of these compounds are different from the natural dNTPs and do not allow any 
further replication of HIV, thus helping to stop the replication of the virus (competitive 
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inhibitors of natural dNTPs). NRTIs are dideoxy compounds that lack a 3‟-OH group, 
stopping DNA synthesis when they are bound into the growing DNA strand 
[161,162,163]. They act as chain terminators, causing premature termination of the 
proviral DNA chain. Nucleoside analogues undergo three phosphorylation steps for HIV 
inhibition to occur. Nucleotide analogues do not need the first phosphorylation step 
because they are already phosphorylated. Six nucleosides are currently approved by the 
US Food and Drug Administration (FDA) and Health Canada (Table 1). They include; 
abacavir (ABC), didanosine (ddI), emtricitabine (FTC), lamivudine (3TC), stavudine 
(d4T) and zidovudine (ZDV) while tenofovir (TDF) is the only approved nucleotide 
analogue. Second (next) generation nucleosides inhibitors in clinical development 
include; elvucitabine (ELV) and Aprecitabine (ATC) (Table 2). 
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Table 1: Represents first generation NRTIs that have been approved for treatment of HIV patients.  
Drug  
Candidate 
ZDV ddI d4T 3TC FTC 
Chemical  
Structure 
  
   
Date of 
FDA/Health 
Canada 
approval 
1987/1990 1991/2002 1994/1996 1995/1995 2003/2006 
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 Table 1: Represents first generation NRTIs that have been approved for treatment of HIV patients (cont.). 
Drug 
Candidate 
ABC TDF 
Chemical 
Structure 
  
Date of 
FDA/Health 
Canada 
approval 
1998/1999 2001/2004 
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Table 2: Represents second generation NRTIs undergoing clinical development. 
Drug Candidate ELV ATC 
Chemical Structure 
 
 
Phase of Development IIb IIb 
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1.11.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 NNRTIs also target the reverse transcriptase enzyme by a mechanism of action that is 
different from that used by NRTIs. NNRTIs are not derivatives of natural dNTPs. They 
are non-competitive inhibitors of HIV-1 RT and do not require metabolic activation. 
Moreover they show extremely diverse molecular structures that play an important role in 
binding. The structure of NNRTIs allows them to bind to the hydrophobic pocket within 
the p66 subunit of RT enzyme which is close to the polymerase active site [108,164,165], 
inhibiting HIV-1 replication by preventing the conversion of viral RNA into DNA  
[108,166,167,168]. Crystallographic and biochemical studies have revealed that NNRTIs 
may interrupt with the binding between the 3‟ end of the primer and the incoming dNTP, 
thus decreasing the efficiency of the chemical step [169]. Four NNRTIs are currently 
approved by the US FDA and Health Canada. They include first generation drugs 
efavirenz (EFV) and nevirapine (NVP) (Table 3), while etravirine (ETR) and rilpivirine 
(RPV) are second generation drugs (Table 4). Dapivirine (TMC120) is a second 
generation NNRTI license for microbicide development. Novel second generation 
NNRTIs under clinical development include; Lersivirine and RDEA 806 (Table 4). 
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Table 3: Represents first generation NRTIs that have been approved for treatment of HIV 
patients. 
Drug Candidate NVP EFV 
Chemical Structure 
  
Date of FDA/Health 
Canada approval 
1996/1998 1998/1999 
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Table 4: Represents second generation NNRTIs that have been approved or are undergoing clinical development 
Drug 
candidate 
ETR RPV TMC 120 
RDEA806 
Lersivirine (UK-
453061) 
Chemical 
structure 
 
 
  
 
Phase of 
development 
FDA (2008),  
Health Canada 
(2008) 
FDA  (2011), 
Health Canada (2011) 
License for HIV-1 
microbicide development  IIb IIb 
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1.11.3. Protease Inhibitors (PIs) 
The role of the HIV protease enzyme is to cleave immature viral proteins to produce 
mature infectious virus particles [32]. PIs inhibit the cleavage of immature Gag and Gag-
Pol precursor protein (prevent maturation) and thus render the virus non-infectious. The 
US Food and Drug Administration (FDA) and Health Canada has approved eight PIs for 
treatment of HIV patients [170] (Table 5 and 6). They include; saquinavir (SQV), 
indinavir (IDV), nelfinavir (NFV), amprenavir (APV), lopinavir (LPV), atazanavir 
(ATV), tipranavir (TPV) and darunavir (DRV). PI treatment is accompanied by a low 
dose of ritonavir (RTV) as a boosting agent (a compound that inhibits the host enzyme 
that metabolizes other PIs and thus leads to higher concentrations of PIs in blood). All PIs 
are known as competitive peptidomimetic inhibitors, except tipranavir. These competitive 
inhibitors mimic the natural substrate of the viral protease. A hydroxyethylene core 
present in the peptidomimetic inhibitors prohibits cleavage of the inhibitor by the HIV-1 
protease. In tipranavir a dihydropyrone ring replaces the peptidomimetic hydroxyethylene 
core (reviewed in [171]). 
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Table 5: Represents first generation PIs that have been approved for treatment of HIV patients.  
Drug  
Candidate 
SQV IDV NFV 
Chemical  
Structure 
 
 
 
Date of 
FDA/Health 
Canada approval 
1995/1996 1996/1996 1997/1998 
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Table 5: Represents first generation PIs that have been approved for treatment of HIV patients (cont.).  
Drug  
Candidate 
LPV APV Fosamprenavir 
Chemical  
Structure 
 
  
Date of 
FDA/Health 
Canada approval 
2000/2001 1999/none 2003/2004 
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Table 6: Represents second generation PIs that have been approved or are undergoing pre-clinical development 
Drug 
candidate 
ATV TPV DRV PL-100 
Chemical 
structure  
 
 
 
Phase of 
development 
2003/2004 2005/2005 2006/2009 Pre-clinical development 
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1.11.4. Integrase Inhibitors (INIs) 
Integrase inhibitors are a novel class of ARV drugs recently included in HIV 
management [172]. The role of the integrase enzyme is to integrate viral genetic material 
into the host cell genome. This serves as an important drug target. The HIV integrase has 
essentially two important catalytic functions which include; 3‟-processing and strand 
transfer. Raltegravir is an INI approved by FDA in 2007 (reviewed in [173,174]) and 
elvitegravir recently approved (August 2012) are targeted at strand transfer reaction while 
dolutegravir, a second generation INI in clinical development also target the strand 
transfer reaction.   
 
1.11.5. Entry Inhibitors (EIs) and Fusion Inhibitors (FIs) 
EIs prevent HIV entry into the cell. FIs inhibit HIV by targeting and blocking HIV entry 
into CD4 cells. FIs block fusion by binding to gp41, which is involved in the fusion of 
the viral particle and the membrane of the CD4 cell [175]. Blocking the fusion process by 
FIs prevents the HIV genetic material from entering the CD4 cells. The only FI that is 
FDA approved to date is enfuvirtide (T-20) [176,177]. T-20 is a C-peptide of the HIV-1 
gp41 C-terminal heptad repeat (CHR) region. It also contains partial N-terminal heptad 
repeat (NHR) and lipid binding domains. The N- and C- terminal sequences of T-20 bind 
with the NHR of gp41 and cell membrane respectively, and thus inhibit the fusion 
process [178].  
 A new entry inhibitor, maraviroc was recently approved. It is the only antiretroviral that 
targets the host cell rather than the virus. It binds to the CCR5 co-receptor (CCR5 
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antagonist) and thus prevents HIV from entering the cell. However, the activity of 
maraviroc is specific to patients with R5-tropic viruses. CXCR4-CCR5 mixed tropic 
viruses and X4-using viruses are resistant to maraviroc treatment [179]. 
 
1.12. Antiretroviral (ARV) Therapy  
HAART is the standard treatment for HIV patients. It involves the use of three anti-HIV 
drugs e.g. two NRTIs in combination with either a non-nucleoside reverse transcriptase 
inhibitor (NNRTI), protease inhibitor or, most recently, integrase inhibitor [180]. The 
goal of HAART is the maximal and long term inhibition of HIV replication with an 
improved immune function [181]. Rational drug selection is necessary for optimal 
therapy response, reduced toxicity and cross resistance, in order to preserve options for 
future treatment and increase overall duration of viral suppression [reviewed in [182]].  
Although numerous antiretroviral combinations may provide potent suppression of viral 
replication, therapeutic choices necessitate careful consideration of the potential impact 
of viral resistance on subsequent treatment options. 
Potential causes of therapy failure during antiretroviral therapy include insufficient viral 
suppression (virological failure), a continuous decrease in CD4 cell counts 
(immunological failure), adverse drug effects (toxicity) and progression of clinical 
disease [reviewed in [182]]. Virological failure results from pre-existing drug resistance 
or suboptimal drug levels and may lead to further accumulation of resistance mutations 
[183].   
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1.12.1. HIV Drug Resistance during Antiretroviral Therapy 
Despite the successes in antiretroviral therapy that have improved the lives of HIV-
infected patients, the selection of drug resistance mutations is inevitable [160]. The 
emergence of resistance variants is facilitated by the error-prone reverse transcriptase that 
has an impaired ability to proofread [132] together with an increased number of 
replication cycles occurring in an infected individual [184]. Sub-optimal drug levels 
within certain compartments allows viral replication to occur and can also lead to 
selection of resistance mutations [185]. In a review by Asahchop et al 2012, it was 
reported that “these selected mutations are located on the genes that encode antiretroviral 
targets such as RT, PR, IN and gp41 resulting in the production of viral proteins that are 
subtly different than their wild-type counterparts in structure and function. Although 
these proteins are still able to play their role in HIV replication, they are not targeted as 
effectively as wild-type proteins by the ARV drugs. The number of mutations required 
for resistance to occur varies from drug to drug. Many factors determine the relative rate 
of resistance selection with different drugs and drug combinations, and this is reflected in 
the `genetic barrier' to resistance. Interactions between mutations and the effects of 
individual resistance mutations on viral replication and fitness influence mutational 
pathways and the overall impact of resistance mutations on viral phenotype”. Certain 
mutations such as K65R and thymidine analog mutations (TAMs) may be antagonistic 
[186], whereas others may confer resistance to some drugs while conferring 
hypersusceptibility to others. An example is the K103N mutation that confers high level 
resistance to both NVP and EFV but is susceptible to ETR [187]. 
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Different mechanisms through which HIV-1 escapes from drug pressure have been 
described. These mechanisms differ from one drug class to another and sometimes differ 
even between drugs of the same class. 
 
1.12.2. Changes in Viral Population Dynamics during ARV Therapy 
Due to the high error rate of HIV RT, the rate of mutations within the viral genome is 
high during HIV infection. Although most of these mutations do not have an effect on 
viral function, some at specific sites may be lethal to the virus or affect drug 
susceptibility. Genetically diverse HIV populations harbor drug resistance mutations. 
However, in the absence of ARV therapy, these diverse viral variants containing 
mutations possess a decreased replication ability compared to wild-type viruses (i.e. they 
are less fit). They are only present at low levels in the viral population (i.e. minority 
populations) [188,189]. The administration of ARV therapy results in strong selective 
pressure on the HIV population, stopping replication of susceptible variants [184,188]. In 
the case of sub-optimal therapy, residual viral replication will occur resulting in mutant 
virus strains that will replicate and dominate the viral population. If drug therapy is 
withdrawn, resistant variants will continue to dominate. However, the wild-type virus 
will eventually predominate the viral population due the absence of therapy [184,190]. 
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1.12.3. Mechanism of NRTI Resistance 
HIV can become resistant to NRTIs via two distinct mechanisms as described by 
Asahchop et al 2012. The first is discrimination, whereby the mutated viral RT can 
selectively avoid incorporating NRTIs in favor of natural dNTPS; this mechanism is 
typified by such mutations as K65R, L74V, Q151M and M184V [191]. The second 
mechanism of resistance allows a mutated RT to enact the phosphorolytic excision of 
NRTIs from the 3‟ end of the viral DNA chain that extends from the primer, a process 
referred to as „primer unblocking‟. Examples of mutations involved in this process are 
those selected by zidovudine (ZDV) and stavudine (d4T) that are termed thymidine 
analogue mutations (TAMs), e.g. M41L, D67N, K70R, L210W, T215Y/F and K219Q/E 
[186,192]. TAMs confer resistance to all NRTIs except lamivudine (3TC) and 
emtricitabine (FTC). Although, there is a degree of cross-resistance associated with 
TAMs, ultimate levels of resistance depend on the specific NRTI and the number of 
TAM mutations found in the viral RT (reviewed in [192]). The two NRTI resistance 
mechanisms of discrimination and excision can also influence each other. For example, 
the M184V/I mutation that is selected by 3TC and FTC is a discrimination mutation but 
viruses that contain M184V/I are less likely to quickly develop TAMs under selective 
pressure with such drugs as ZDV. Viruses containing M184V/I are also more susceptible 
to ZDV and d4T than wild-type viruses (reviewed in [192]). 
 
1.12.3.1. Resistance to First Generation NRTIs 
The NRTI ZDV was the first HIV drug approved for treatment of HIV infected patients. 
Monotherapy with ZDV lead to the selection of single amino acid substitution with high 
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level resistance. Additional drugs in this class have also been approved and possess low 
genetic barrier to resistance as well as cross-resistance.   
1.12.3.1.1. Resistance to ZDV and d4T 
Among the recognized NRTI-associated mutations are the amino acid substitutions at 
codons 41, 67, 70, 210, 215 and 219, which are selected by ZDV or d4T [193,194]. 
TAMs are selected by and cause resistance to the thymidine analogues (ZDV and d4T). 
The timing and rates of selection of these particular mutations may differ between ZDV 
and d4T, although both agents show reduced susceptibility in their presence. Decreased 
activity of ZDV increases with accumulation of mutations. A mutation at codon 70 
(K70R) results to ZDV failure, the emergence of mutations such as T215Y/F, D67N, 
M41L and K219Q/E follow later. TAMs confer cross-resistance to ZDV and d4T, and 
other NRTIs at varying degrees. Two distinct TAM pathways have been identified:  the 
first consist of mutations M41L, L210W and T215Y and, the second involves D67N, 
K70R, T215F and K219Q/E [195,196].  The second pathway is more frequently observed 
than the first one and even result to higher level resistance to ZDV. However, several 
mutations from one group can co-exist with those from the other. Furthermore, these 
pathways may in some cases overlap, especially for viruses with five or six TAMs.  
 
1.12.3.1.2. Resistance to 3TC and FTC  
The M184V/I mutation is selected in all patients receiving therapy containing 3TC or 
FTC [197]. The M184V mutation results to approximately 100-fold resistance to 3TC and 
FTC, low-level resistance to ABC in vitro, but seem clinically not important except in the 
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presence of mutations such as TAMs, K65R or L74V. M184V acts antagonistically with 
TAMs mutations to improve susceptibility to ZDV. Its presence has been observed to 
delay the accumulation of TAMs. M184V results to reduced viral fitness. A decreased 
viral load with 3TC monotherapy was observed in HIV-1 infected patients compared to 
pre-treatment level despite the presence of M184V [198]. This data provide evidence for 
maintaining 3TC in a failing regimen.  
1.12.3.1.3. Resistance to ddI 
Antiretroviral therapy with ddI leads to the emergence of L74V mutation and rarely 
selects for K65R mutation [199]. In vivo, isolates containing the L74V alone has been 
observed to impact on the susceptibility to ddI. The L74V can confer cross-resistance to 
ABC and TDF if present together with TAMs.  In vitro, the L74V mutation is associated 
with an increased susceptibility to ZDV [200]. 
1.12.3.1.4. Resistance to ABC 
Treatment failure with ABC leads to the emergence of the following mutations: K65R, 
L74V, Y115F and M184V [201]. L74V and M184V are the most frequently observed 
mutations. It has been demonstrated that the combination of L74V and M184V shows 
increased susceptibility to ZDV and d4T. ABC seems to be able to select K65R only 
rarely.  
1.12.3.1.5. Resistance to TDF 
TDF selects the K65R mutation in vitro, which reduces susceptibility to TDF by 3- to 6-
fold [202,203]. In vitro, this mutation shows decreased susceptibility to ddI, 3TC and 
ABC, but not to ZDV [204]. The selection of K65R in patients failing TDF has been 
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influenced by the presence or absence of TAMs at baseline and the use of NRTIs (TDF, 
ABC, d4T and ddI) [205,206,207,208]. Both in vitro and biochemical studies have shown 
that the selection K65R is facilitated in subtype C than in subtype B [202,209]. Recent 
studies revealed that the increased selection of K65R in subtype C depends on the nature 
of the subtype C RNA template rather the than subtype origin of the viral reverse 
transcriptase [209,210,211]. This is due to the pausing events that occur at codon 65 of 
subtype C viruses resulting in a high rate of K65R selection during reverse transcription 
[209,210]. In contrast, subtype B template pausing is observed at codon 67, resulting in 
generation of D67N and TAMs, and not K65R [209,210,212].  
Clinical studies revealed that patients previously treated with ABC or ddI- containing 
regimen were not at higher risk to select K65R [213]. The existence of an antagonistic 
interaction between K65R and TAMs limit the coexistence of K65R and TAMs. The 
strongest antagonism is observed between K65R and T215Y [203]. This antagonism is 
the result of a K65R-mediated reduction of the excision resistance mechanism induced by 
TAMs [186]. In addition, biochemical studies have also shown that there is an 
antagonism between K65R and L74V. The presence of both mutations induces a deep 
loss of viral replicative capacity that is correlated with a low propensity of K65R + L74V 
double mutants to incorporate natural nucleotides relative to wild-type RT [214]. These 
results are in accordance with most clonal analyses performed on plasma samples 
[215,216]. More rarely, the K70E mutation can be selected by TDF in vivo.   
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1.12.3.2. Resistance to Second Generation NRTIs 
Currently approved NRTIs have safety precautions. Limitations are specific to certain 
population such as children infected with HIV, HIV-infected pregnant women or those 
with NRTI resistance [217]. There is thus the need to develop new NRTIs with better 
pharmacological profiles. Several NRTIs are in various stages of clinical development. 
 
1.12.3.2.1. Resistance to Elvucitabine 
Elvucitabine (Table 2) is a novel NRTI currently in the late phase II study and developed 
by Achillion Pharmaceuticals. In a review by Asahchop et al in 2012, it was reported that   
only two amino acid substitutions, M184I and D237E, were identified in the resultant 
variant in an in vitro selection study [218,219]. The double mutation conferred moderate 
resistance to elvucitabine (about 10 fold) and cross-resistance to lamivudine but not to 
other nucleoside inhibitors tested. Elvucitabine shows more potent anti-HIV activity than 
3TC, in part because of high intracellular levels of its triphosphate metabolite [220]. 
Elvucitabine has also demonstrated potent antiviral activity in HIV-infected patients with 
resistance to 3TC and other NRTIs. The drug has good oral bioavailability and an 
intracellular half life of >24 hours [221].  
1.12.3.2.2. Resistance to Apricitabine 
Apricitabine (ATC) (Table 2) is a novel deoxycytidine NRTI currently in clinical 
development for the treatment of HIV infection. In a review by Asahchop et al 2012, it 
was reported that, in vitro selection for resistance with ATC selected for M184V, V75I 
and K65R [219,222]. The resulting mutants from this selection conferred low-level 
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resistance of less than 4 fold. Others showed that continuous passage of HIV-1 already 
containing M184V, K65R or combinations of M41L, M184V and T215Y did not result in 
any additional mutations [223]. In vitro ATC has shown favorable antiviral activity 
against HIV-1 wt strains and clinical isolates containing NRTI mutations including 
M184V, L74V, and TAMs (TAMs) [224]. ATC yielded virological response in 
treatment-naïve and treatment-experienced HIV-1 infected patients whose viruses 
contained M184V and up to 5 TAMs. Resistance to ATC was reported to be slow to 
develop in vitro, and there is little evidence of the development of resistance to this drug 
in patients [225,226].   
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Table 7: Clinically Approved NRTIs and corresponding resistance –conferring mutations. 
(Adapted from Johnson VA et al 2011 [227]).  
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1.12.4. Mechanism of NNRTI Resistance 
Mutations that are selected by NNRTIs are all located in the enzyme binding pocket and 
result in decreased interaction between the inhibitor and the enzyme [228,229,230]. 
These mutations decrease the ability of the inhibitors to bind to the enzyme. High level 
resistance resulting from a single mutation in the NNRTI-binding pocket may affect one 
or more NNRTIs. Amino acid residues that form the NNRTI binding pocket within the 
p66 subunit include; 95, 100, 101, 103, 106, 108, 179, 181, 188, 190, 227, 229, 234, 236 
and 318 [107,108,168]. Some residues from p51, such as 138, also contribute to the 
NNRTI binding. Resistance to NNRTIs is a direct result of conformational change in the 
NNRTI binding pocket that prevents the binding of inhibitors (steric hindrance) 
[228,231]. All NNRTI mutations confer resistance by disrupting the interactions between 
the inhibitor and the enzyme. Structural studies have revealed three mechanisms of 
NNRTI resistance including; steric hindrance at the NNRTI binding pocket, abolishing 
key contacts between inhibitor and the NNRTI binding pocket, and overall change in 
architecture of the binding pocket [232]. The NNRTI mutation K103N can block the 
entry of inhibitor into the NNRTI binding pocket through steric hindrance [231]. 
Mutations such as Y181C can affect contacts (abolish key contacts) between the inhibitor 
and residues that line the NNRTI binding pocket. The Y188L and G190A mutations can 
alter the conformation or size (change in architecture) of the NNRTI binding pocket so 
that it becomes less specific for the inhibitor (reviewed in [232,233]). Some resistance 
mutations can affect the binding of NNRTIs through more than one mechanism. 
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 1.12.4.1. Resistance to First Generation NNRTIs  
First generation NNRTIs include NVP and EFV. The administration of NNRTIs as 
monotherapy or in the presence of sub-optimal concentrations of drug results in the rapid 
emergence of resistance [234,235,236]. Studies in which a single dose of NVP is used to 
prevent mother-to-child transmission of HIV-1 have shown the selection for NNRTI-
resistant mutants [234,237]. The presence of a single amino acid substitution usually 
results to high level resistance. Additionally, a high degree of cross-resistance is seen 
among first generation NNRTIs [238,239]. 
1.12.4.1.1. Resistance to Nevirapine 
The mutations K103N and Y181C remain the most common NNRTI mutations and most 
commonly selected in patients containing NVP regimen ([240] and reviewed in [241]). 
These mutations are responsible for high level phenotypic resistance to NVP [242]. The 
selection of K103N alone is often enough for treatment failure with first generation 
NNRTIs to occur [240] due to high level resistance and the fact that it is as fit as the wild-
type [243,244]. Other amino acid substitutions conferring resistance to NVP occur at 
positions 106, 108, 188 and 190 [245]. In monotherapy of NVP to prevent mother to 
child transmission of HIV-1, these mutations have been selected in both mothers and in 
children postpartum [246,247,248,249]. The use of ZDV together with NVP results in a 
different pattern of mutations that does not involve the amino acid substitutions at 
position 181, demonstrating an interaction between NRTI and NNRTI mutations [245]. 
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1.12.4.1.2. Resistance to Efavirenz 
The most frequently selected mutation in EFV treatment failure and in in vitro studies is 
K103N [250,251,252,253]. The NNRTI resistance mutations V108I, P225H, L100I, 
K101E, K101Q, Y188H, Y188L, G190S, G190A and G190E were also selected in phase 
II trials [252,253]. In addition the V106A mutation has been observed to confer low level 
resistance to EFV [254]. This mutation is not frequently selected due to its negative 
impact on fitness [255]. The M230L is a rare NNRTI mutation because it decreases 
fitness compared to wild-type as observed in patients with EFV and NVP therapy 
[256,257] and confers a 15-20 fold resistance to EFV [258]. The selection of V106M 
mutation is common in subtype C viruses after exposure to NNRTIs such NVP or EFV. 
This subtype specific mutation is facilitated by a subtype C specific polymorphism within 
the RT at codon 106 [259,260]. Clinical relevance has been observed in regions where 
subtype C is endemic [261,262]. 
 
1.12.4.2. Resistance to Second Generation NNRTIs 
The low genetic barrier to resistance and cross-resistance among first generation NNRTIs 
serves as a major limitation for prolong antiretroviral therapy and sequential use of 
inhibitors of this class [239,259,263]. Notably, a single point mutation in the RT enzyme 
is often associated with the development of high-level resistance and therapy failure. This 
has driven NNRTI drug development research towards the development of a new set of 
compounds known as second (next) generation NNRTIs. These compounds possess a 
high genetic barrier to resistance and improved pharmacological properties. This section 
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on resistance to approve second generation NNRTIs and those in preclinical development 
was reported in a review by Asahchop at al 2012.  
 
1.12.4.2.1. Resistance to Etravirine 
Etravirine (ETR) (Table 4), formerly known as TMC125, is a diarylpyrimidine (DAPY)-
based NNRTI that possesses potent antiviral activity against both wild-type (wt) HIV-1 
of multiple subtypes as well as against some viruses containing NNRTIs resistance 
mutations [187,264]. Specifically, ETR retains full activity against viruses containing the 
most prevalent NNRTI mutation, K103N [187]. In vitro, it is more difficult to develop 
resistance to ETR compared to first generation NNRTIs [264]. Clinical studies of ETR in 
combination with potent background regimens that included NRTIs, integrase and 
protease inhibitors, showed significant decrease in viral load in patients with resistance to 
older NNRTIs and some PIs [265,266,267]. 
In vitro and clinical studies have identified 20 ETR resistance-associated mutations 
(RAMs) (V90I, A98G, L100I, K101E/H/P, V106I, E138A/K/G/Q, V179D/F/T, 
Y181C/I/V, G190A/S, and M230L) and have allowed a weighted score to be assigned to 
each mutation [268,269,270]. A second score by Monogram has identified 30 ETR 
RAMs based on a correlation of phenotype and genotype results of 4,923 samples 
containing at least one NNRTI mutation [271]. Of these ETR RAMs, three or more are 
required for high level resistance to occur, thus demonstrating a high genetic barrier to 
resistance compared to older NNRTIs. The structure of ETR allows it to bind to the RT 
enzyme, such that mutations in the NNRTI-binding pocket do not compromise binding 
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and, thus, activity is maintained. ETR can rotate within the pocket allowing multiple 
interactions despite the presence of mutations in the binding pocket [272]. Because of its 
unique characteristic, ETR is the only NNRTI approved for treatment-experienced 
patients. Only a few studies have prospectively studied the efficacy of ETR in 
combination with other background regimen in NNRTI-experience patients [273,274]. In 
the phase 3 DUET-1 and DUET-2 studies, 57% of patients in the ETR arm versus 36% in 
the placebo had a viral load <50 copies/ml after 96 weeks of treatment [273]. In these 
DUET-1 and DUET-2 clinical studies, it was found that patients who experienced 
virologic failure had greater numbers of ETR resistance mutations at baseline than 
treatment successes. Furthermore, patients who experienced virologic failure were often 
found to have received less efficient background regimens compared to those who did not 
fail therapy [275]. In these studies, the V179F, V179I and Y181C mutations in RT were 
commonly associated with treatment failure alongside changes at positions K101 and 
E138 [275]. The authors concluded that these mutations usually emerge in a background 
of other multiple NNRTI mutations and were, in most cases, associated with a decrease in 
phenotypic sensitivity to ETR. Another sub-analysis of the DUET trial studied the impact 
of background regimen on virologic response to ETR, and the authors further confirmed 
that a higher virologic response rate was observed in patients who demonstrated an 
increased activity of the background regimen, with the highest responses being achieved 
in patients who used more than two active agents in addition to ETR [276]. In the 
TMC125-C227 (ETR) trial, ETR was inferior to a protease inhibitor (PI) in PI-naïve 
patients with a history of previous NNRTI failure [277]. In a post-hoc analysis of baseline 
resistance data for the TMC125-C227 trial, a diminished virological response was 
81 
 
 
observed in patients who possessed the following characteristics at baseline; the presence 
of Y181C, a baseline ETR fold change of ≥ 10, and a higher number of ETR resistance 
mutations [277].   
 
1.12.4.2.2. Resistance to Rilpivirine 
Rilpivirine (RPV) (Table 4), also known as TMC278, is another DAPY compound that 
was recently approved for treatment of NNRTI-naïve patients. The structure and binding 
of RPV in the NNRTI binding pocket is similar to that of ETR, which allows 
reorientation of both compounds within the pocket. In vitro RPV possess subnanomolar 
activity against wild-type HIV-1 of multiple subtypes and shows antiviral activity against 
viruses containing many NNRTI resistance-associated mutations [278]. NNRTI RAMs 
emerging in culture under RPV selective pressure included combinations of V90I, L100I, 
K101E, V106A/I, V108I, E138G/K/Q/R, V179F/I, Y181C/I, V189I, G190E, H221Y, 
F227C, and M230I/L. The resistance profile and genetic barrier to the development of 
resistance to RPV are comparable to those of ETR. In the ECHO and THRIVE phase 3 
trials [279,280], resistance analysis showed a slightly higher proportion of treatment 
failures in the RPV arm compared to the EFV arm. The most frequent NNRTI mutation 
in the RPV arm was E138K in addition to mutations such as Y181C, K101E, H221Y, 
V901, E138Q, and V189I. Also the proportion of NRTI mutations that emerge in the 
study was higher in the RPV arm than EFV arm. The NRTI mutations selected includes 
M184I/V, K65R, K219E and Y115F. 
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The IAS-USA has published a total of 15 mutations (K101E/P, E138A/G/K/Q/R, V179L, 
Y181C/I/V, H221Y, F227C, and M230I/L) associated with decreased susceptibility to 
RPV [227]. These mutations have been described based on in vitro studies and in patients 
in who RPV was failing. The quantitative impact of each of these mutations on RPV 
resistance differs.  
1.12.4.2.3. Resistance to Dapivirine (TMC 120) 
Dapivirine (TMC 120) (Table 4) is another DAPY compound that can accommodate 
some mutations within the NNRTI binding site without significant loss of activity 
[263,281]. TMC 120 has shown potent antiviral activity against both wt and NNRTI-
resistant HIV-1 strains [282,283]. In 2004, Janssen officially licensed the further 
development of TMC 120 for use as a vaginal microbicide to the International 
Partnership for Microbicides (IPM) to help prevent sexual transmission of HIV-1. The 
results of both phase I and II studies have shown that TMC 120 was widely distributed 
through the lower genital tract with low systemic absorption when administered as a 
vaginal gel formulation for up to 42 days [284,285]. The gel was safe and well tolerated. 
In vitro selection studies have identified drug resistance mutations in the presence of 
TMC 120, notably L100I, K101E, V108I, E138K/Q, V179M/E, Y181C and F227Y 
[286,287]. Most of these TMC 120 resistance-associated mutations occur at exactly the 
same position as many of the mutations associated with ETR and RPV resistance 
[268,269,278]. However, in one of these studies, it was shown that sub-optimal 
concentrations of TMC 120 alone facilitated the emergence of common NNRTI 
resistance mutations while sub-optimal concentrations of TMC 120 plus tenofovir (TFV) 
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gave rise to fewer mutations [287]. Due to the likelihood of transmitted resistant strains in 
HIV-1 infected individuals, resistance mutations might impact the ability of a single drug 
in preventing HIV-1 as a microbicide. Using a combination of antiviral drugs of different 
classes may be useful. Another study showed in an in vitro model that using TMC 120 in 
combination with TFV as a microbicide was more potent and exhibited synergy in 
comparison with either drug alone [283].   
1.12.4.2.4. Resistance to Lersivirine 
Lersivirine (Table 4) is a new NNRTI belonging to the pyrazole family and is being 
developed by Pfizer. In an in vitro resistance study, lersivirine selected for the amino acid 
substitutions; V108I, E138K, V179D, F227L and M230I [288]. In a phase II b trial, 
Pozniak and colleagues reported better responses in patients with EFV compared to 
lersivirine, i.e. 86% versus 79% respectively [289]. Amongst patients who failed 
lersivirine, the mutations identified included K101E, V106M, V108I, H221Y, Y188H, 
F227C/L and L234I.   
1.12.4.2.4. Resistance to RDEA806 
RDEA806 (Table 4) is a novel NNRTI developed by Ardea Biosciences. In a genotypic 
and phenotypic analysis of mutant viruses selected by RDEA806; the K104E, E138K, 
T240I, V179D and F227L substitutions were identified [290]. Phenotypic analysis of 
these mutations demonstrated that RDEA806 requires at least 3 mutations for greater than 
10 fold loss of susceptibility. In a phase 2a trial, RDEA806 was well tolerated and 
exhibited robust antiviral activity with no genotypic or phenotypic changes [291]. 
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Table 8: Clinically Approved NNRTIs and corresponding major resistance–conferring 
mutations. (Adapted from Johnson VA et al 2011 [227]). 
 
 
1.12.5. Mechanism of resistance of connection domain and RNase H mutations 
A number of studies continue to identify new mutations aside from those currently known 
to be involved in the development of drug resistance to RT inhibitors. Mutations at the C-
terminal RT domains i.e. connection domain (amino acids 293-426) and RNase H domain  
(amino acids 427-560) have recently been shown to be involved in HIV drug resistance. 
Amino acid substitutions at position A371V and Q509L in the connection and RNase H 
domains respectively are co-selected on the same genome as TAMs and increase ZDV 
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resistance [292,293]. The connection domain mutations (E312Q, G335C/D, N348I, 
A360I/V, V365I, and A376S) together with the presence of TAMs have been shown to 
increase resistance to ZDV [294]. However, the clinical importance of connection domain 
mutations is still unknown and there is currently a debate whether these regions should be 
included in routine HIV genotyping for drug resistance ([294] and reviewed in [295]). A 
recent study demonstrated that patients who fail more than one NRTI-containing regimen 
with different TAM and NAM profiles confer varying levels of resistance to ZDV. In this 
study, the level of phenotypic resistance to ZDV was not affected by mutations in the 
RNase H domain. Interestingly, the co-presence of L74V and M184V contributed 
significantly to the phenotypic resistance of ZDV in patients with TAMs even in the 
presence of connection domain mutations [226]. RNase H mutations confer resistance to 
NRTIs through a mechanism that involves decreased degradation of RNA either in the 
presence or absence of TAMs by increasing the time required for excision of incorporated 
NRTIs [296]. Similarly, one of the most studied connection domain mutation, N348I, was 
shown to confer ZDV resistance by increasing nucleotide excision [297].  
 
Connection domain (CN) mutations and RNase H mutations including; N348I, T369V/I, 
A376S, D549N have also been shown to play a role in NVP and EFV resistance 
[298,299,300]. Furthermore, CN mutations (G333D, N348I, A360V, T369I, and A376S) 
either decrease susceptibility to ETR or increase in the level of resistance in the presence 
of both combination of CN mutations and ETR RAMs [299,301,302]. To date, it is well 
established that CN and RNase H domain mutations exhibit dual resistance to both 
NRTIs and NNRTIs. The CN mutation N348I confers resistance to NNRTIs (NVP) by 
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more than one mechanism. These mechanisms include decreased affinity for inhibitor to 
the NNRTI binding pocket, decreased RT/RNase H activity, and affecting the orientation 
of the NNRTI binding site [303]. The mechanism of resistance of RNase H mutations is  
decreased activity of RNase H and thus a reduced degradation of RNA:DNA substrate 
[232]. However, this mechanism of resistance leads to low levels of resistance to NNRTIs 
compared to NRTIs. Recently, Nikolenko et al proposed that the mechanism for dual 
resistance to both NRTIs and NNRTIs is the interaction that exists between RNase H 
cleavage and NRTI excision/NNRTI dissociation [299]. The authors confirmed the 
proposed model by analysis of patient samples and showed that the ability of each 
NNRTI to bind to the RT is important in determining the reduction in RNase H cleavage 
that results in NNRTI resistance.  
 
1.12.6. Mechanism of Protease Inhibitor (PI) Resistance 
HIV-1 protease inhibitors play an important role in the management of both HIV-1 
infected and AIDS patients. However, their therapeutic efficacy is affected by the 
selection of drug-resistant mutants, cross-resistance and by issues of patient compliance. 
Selection of resistance to PIs is considered to be a stepwise process during which 
mutations accumulate [304,305,306]. Clinical and biochemical studies have demonstrated 
that the initial PI selected mutations affect the binding of the PI to the viral PR, and the 
accumulation of additional mutations results in PI resistance [307,308,309]. The selected 
mutations are found in the substrate-binding cleft of the PR. Subsequently, the levels of 
resistance conferred by the initially selected resistance mutations are enhanced by the 
87 
 
 
selection of additional resistance mutations in PR [309]. These additional resistance 
mutations, when compared to the initially selected resistance mutations, are often located 
at a more distant position from the substrate-binding cleft. 
Since mutations in the active site directly affect the drug/target interface, their mode of 
action has been interpreted in terms of loss of interactions or steric effects created by 
altered site geometries (reviewed in [310]). The role of non-active site mutations in 
inhibitor binding has remained largely elusive, but a few recent studies have suggested 
that when mutations are selected by PIs, accumulation of these mutations within the core 
of the protease molecule affects binding by altering the geometry of the binding site 
cavity [311,312]. PI resistance mutations are often designated as major (mutations which 
on their own can cause resistance) or minor (mutations that further increase the level of 
resistance induced by major mutations) resistance mutations.     
 
1.12.6.1. Resistance to First Generation PIs 
The initial resistance mutations that are selected can differ between the PIs. First 
generation PIs generally have a low genetic barrier to resistance. The selection and 
eventual accumulation of major PI resistance mutations in the binding cavity often result 
in loss of hydrophobic contacts with these PIs, thus leading to resistance [313,314].  
Because most PIs differ only slightly in their chemical structure, cross-resistance is a 
common phenomenon amongst PIs [315].  
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1.12.6.1.1. Resistance to Saquinavir  
Saquinavir (SQV) developed by Roche, was the first approved PI for treatment of HIV 
infected patients. In vitro, the most frequent mutations or variants selected for by SQV 
are G48V and L90M and the less frequent G48V/L90M double mutant [316,317,318]. 
The amino acid residues 48 and 90 are found in the flexible flap of the protease and 
outside the binding pocket of the enzyme, respectively. A substitution at position 48 may 
affect the flexibility of the flap while the L90M mutation could induce conformational 
changes in the enzyme, impacting on inhibitor binding at the active site. The L90M 
mutation further reduces the catalytic activity and structural stability of the protease 
[319]. Other PI mutations that have been observed in vitro, although at a lower frequency, 
include M36I, A71V/T and G73S.  
1.12.6.1.2. Resistance to Indinavir  
The third HIV PI licensed in the United States, indinavir (IDV), was developed by Merck 
& Co. A report of phase I/II clinical studies with IDV by Condra et al demonstrated that 
the rapid development of resistance occurs at suboptimal doses of the drug [306]. 
Phenotypic resistance was observed to correlate with multiple substitutions in the 
protease: L10I/V/R, K20M/R, L24I, M46I/L, I54V/A, L63P, I64V, A71V/T, V82A/F/T, 
I84V and L90M [320]. The emergence of mutations was random. i.e., resistance was the 
combined effect of multiple and variable combinations of amino acid substitutions. Most 
of the viral isolates displaying resistance to IDV also showed SQV and APV resistance. 
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1.12.6.1.3. Resistance to Nelfinavir 
Nelfinavir (NFV), developed by Agouron Pharmaceuticals, demonstrated antiviral 
activity with EC50 of 9 nM and 60 nM against HIV-1 and HIV-2 strains, respectively 
[321]. Genotyping identified the D30N mutation in resistant variants from patients 
receiving NFV therapy [322,323]. Mutations that occurred at a low frequency included: 
E35D, M36I, M46I, A71T/V, V77I, I84V, N88D and L90M [321,322]. 
1.12.6.1.4. Resistance to Amprenavir 
Amprenavir (APV) is a drug from GlaxoSmithKline, which belongs to a class of 
sulfonamide PIs and possesses antiviral activity against HIV-1 and HIV-2. The EC50 
values for HIV-1 and HIV-2 are 48 nM and 420 nM, respectively [324]. Genotyping of 
HIV-1 protease of resistant variants showed a sequential selection of mutations at 
position L10F, M46I, I47V and I50V. For APV, the predominant resistant mutation in the 
binding site appears to be the I50V [325]. Furthermore, amino acid changes at position 54 
and 84 were associated with the I50V mutation [325,326]. 
1.12.6.1.5. Resistance to Lopinavir 
Lopinavir (LPV) was developed by Abbott Laboratories. It has a very high antiviral 
activity against HIV-1 and HIV-2 [327]. Decreased sensitivity to LPV results from the 
mutations M46I, I54V, A71V, V82A and I84V [327,328]. Other mutations involved in 
decreased susceptibility to LPV include L10F/I/R/V and L90M, as well as amino acid 
substitutions at codons 20, 24, 32, 33, 46, 47, 50, 53, 58,  63 and 90 [329,330]. These 
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mutations have shown decreased susceptibility or a combination is associated with 
complete resistance to LPV [331,332]. V47A also causes resistance to LPV in patients 
infected with HIV-2 [333]. 
 
1.12.6.2. Resistance to Second Generation PIs 
Resistance to all the protease inhibitors is inevitable as shown in both in vitro and in vivo 
studies. In the absence of antiviral therapy or sub-optimal therapy in infected individuals, 
the high replication rate increases the diversity of the viral population, eventually leading 
to viral quasi-species [334]. As a result of resistance mutations, the development of novel 
PIs is focused on  structural designing of HIV PIs that can form molecular bonds with the 
enzyme backbone atoms and possess a high genetic barrier to the development of 
resistance [335]. DRV possess a high genetic barrier to resistance and activity against 
multi-PI-resistant HIV-1 variants, because its forms bond with the main chain of the PR 
active-site amino acid (Asp-29 and Asp-30) [336]. An additional advantage is its 
molecular flexibility that can allow it to adapt to the changing shape of a mutant PR 
[337,338,339].   
1.12.6.2.1. Resistance to Atazanavir 
Atazanavir (ATV), a second generation HIV-1 protease inhibitor, was developed by 
Bristol-Myers Squibb as an alternative option for initial PI-based therapy. In a study by 
Collono et al, the authors showed that the resistance profile of ATV is different from that 
of other PIs based on phenotypic susceptibility results of resistant isolates 
[340].  Genotypic analysis of viral variants from patients failing ATV therapy showed 
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that patients selected for mutations at specific residues (10I/V/F, 20R/M/I, 24I, 33I/F/V, 
36I/L/V, 46I/L, 48V, 54V/L, 63P, 71V/T/I, 73C/S/T/A, 82A/F/S/T, 84V, and 90M) and 
displayed decreased susceptibility to ATV. No single mutation or a combination of 
mutations led to high level resistance to ATV, while five of these mutations were 
required for loss of ATV susceptibility [340]. The I50L mutation was also observed in 
treatment naïve patients who experienced virological failure during unboosted atazanavir-
based regimens. This mutation confers phenotypic resistance to ATV and impaired viral 
replication, but increases susceptibility to other PIs [341]. Viruses containing I50L confer 
resistance specifically to ATV while those with I50V confer resistance to APV, without 
evidence of cross-resistance [341]. 
1.12.6.2.2. Resistance to Tipranavir 
Tipranavir (TPV) was developed as a second generation HIV-1 protease inhibitor by 
Boehringer Ingelheim. It is a dihydropyrone that is structurally similar to coumadin that 
shows activity against HIV protease (reviewed in [342]. It is effective against HIV-1 
isolates that are resistant to other PIs [343]. However, resistance to TPV can still occur 
and requires the accumulation of up to ten mutations for a high level of resistance to 
develop. In an in vitro selection experiment, accumulation of 10 mutations in the protease 
(L10F, I13V, V32I, L33F, M36I, K45I, I54V, A71V, V82L, I84V) together with 
mutations in the CA/SP1 gag cleavage site were identified and showed 87-fold impact on 
resistance to TPV. With the exception of SQV, Tipranavir resistant variants have been 
shown to display cross-resistance to other PIs [344]. The L33F and I84V are the 
dominant mutations that lead to the development of TPV resistance. 
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1.12.6.2.3. Resistance to Darunavir 
Darunavir developed by Tibotec Inc. is a broad-spectrum potent protease inhibitor against 
HIV-1 isolates including multi-drug resistant clinical strains with minimal cyto-toxicity 
[336]. It also has higher genetic barrier for resistance development compared to existing 
PIs. Genotypic analysis of patients failing therapy identified amino acid substitutions 
including: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V and L89V. The 
presence of three or more of these mutations leads to a DRV fold change of greater than 
10 and a decreased virological response [345]. 
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Table 9: Clinically Approved PIs and corresponding major resistance–conferring 
mutations. (Adapted from Johnson VA et al 2011 [227]). 
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1.12.7. Mechanism of resistance of Gag cleavage site mutations 
In HIV naïve patient treated with a boosted PI, mutations in the protease might be 
uncommon immediately after therapy failure [346]. It has been hypothesized that  
virological failure in isolates lacking protease mutations may be due to the fact that 
mutations are selected not in the protease region but within the gag gene [347]. 
Gag cleavage site mutations (V128T, E428D, A431V, I437V, L449P/F, S451N, P453L) 
have been reported in virologic failure of HIV patients containing PI regimen [346,348]. 
The mutations at the p1/p6 cleavage site (L449F or P453L), individually do not confer PI 
resistance. However, in the presence of the background PI mutation I50V, decreased drug 
sensitivity is observed, demonstrating that the level of resistance is enhanced when 
mutations in the viral protease and Gag protein interact [349]. Two mechanisms leading 
to PI resistance have been proposed, first the drug selects for specific resistance 
mutations in Gag, aside from those in the protease gene resulting in an increased 
processing efficiency of the altered substrate by wt protease [347,350]. Secondly, the 
emergence of amino acid substitutions within the protease gene may exert selective 
pressure on the gag gene through compensatory mutations. 
 
1.12.8. Resistance to INIs 
Raltegravir (RAL) and elvitegravir (EVG) are integrase strand-transfer inhibitors 
(INSTIs) approved for clinical use. Though effective in first line and HIV experienced 
patients, resistance mutations can impact on the susceptibility of virus to INSTIs. The 
selection of single point mutations in the presence of RAL pressure can confer high level 
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resistance (fold change FC >5). Thus, the genetic barrier for resistance development to 
RAL is low. Three resistance pathways for resistance development to RAL have been 
identified; E92QV/N155H, T97A/Y143CHR and G140CS/Q148HKR [351]. These 
resistance pathways can either emerge separately or may be linked. The G140S/C and 
E92Q/V single mutations confer 5-10 fold resistance to RAL [352], but usually emerge as 
secondary mutations after the N155H and Q148HKR mutations are selected [353], 
leading to FC>100 for these combination of mutations. Some polymorphic and non-
polymorphic residues such as T66I/L have been observed to decrease the susceptibility of 
RAL [354]. All major INSTIs resistance mutations play a role in IN activity and viral 
replicative capacity [355]. All mutations that confer resistance to RAL have also been 
observed to decreased the susceptibility to EVG with the exception of amino acid 
substitutions at position 143 [356]. Thus, there is a potential for cross-resistance for RAL 
and EVG. Dolutegravir is a next generation INSTIs in clinical development. 
 
Table 10: Clinically Approved INIs and corresponding major resistance–conferring 
mutations. (Adapted from Johnson VA et al 2011) [227]. 
 
 
1.12.9. Resistance to EIs and FIs 
Viral entry is an important drug target for the development of new HIV drugs. Molecular 
mechanisms have identified several steps that block the entry process. First, the viral 
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glycoprotein gp120 attaches to the membrane of CD4 cell. Secondly, binding of the 
gp120 to co-receptors CCR5 or CXCR4 occurs. Lastly, the gp41 mediates the fusion of 
the viral and cellular membranes. Compounds (attachment inhibitors) such as BMS-
488043 and NBD-556 have been identified to inhibit binding of gp120 to the membrane 
of the CD4 cell [357,358,359]. These compounds are in preclinical development. It has 
been shown that amino acid substitutions in gp120 can decrease the sensitivity of these 
compounds [358]. Enfuvirtide was the first fusion inhibitor to be approved for treatment 
of AIDS and HIV infected patients [175,360]. In patients failing enfuvirtide containing 
regimens, the emergence of mutations in a larger fragment of the first heptad repeat 
(HR1), from codons 36 to 45 of gp41, was observed [361,362]. The decreased 
susceptibility to enfuvirtide was caused by a variety of mutations, with changes in simple 
amino acids resulting in high-level resistance [363]. The importance of the surface 
expression level of the co-receptor on target cells and fusion kinetics is seen when high 
levels of CCR5 on the cellular surface results in more rapid membrane fusion, thus 
decreasing the time required for gp41 to be targeted by enfuvirtide [364,365].  
 
Table 11: Clinically Approved EIs and corresponding major resistance–conferring 
mutations. (Adapted from Johnson VA et al 2011) [227]. 
 
 
97 
 
 
 
The CCR5 antagonist maraviroc is another entry inhibitor approved for clinical use. 
Maraviroc inhibits HIV entry by binding to the co-receptor CCR5 on the membrane of 
CD4 cells thus preventing the binding of gp120 and CCR5 [366]. Two main resistance 
pathways have been described. The first and most important is when there is a shift in co-
receptor usage from R5 to X4. The second results from amino acid substitutions within 
the viral envelope that permit the interaction of gp120 and the co-receptor even in the 
presence of the inhibitor. A high affinity of gp120 for CCR5 allows HIV-1 and CCR5 
inhibitors to compete for binding to the CCR5 co-receptor (reviewed in [367]). It has 
been shown that CCR5 antagonist-resistant variants allows the binding of gp120 and 
CCR5 co-receptor to occur in the presence of the inhibitor, and that the amino acids 
substitutions in the gp120 [V3, V2 and constant regions 2 and 4 (C2 and C4)] are 
responsible for the observed resistance [368,369]. Another compound that inhibits 
binding of another co-receptor (CXCR4) is AMD3100 [370]. This compound is not yet 
approved for treatment of AIDS and HIV infected patients. 
 
1.12.10. Replication Capacity and Fitness of HIV-1 
Fitness is a measure of the ability of an organism to replicate within a specific 
environment (reviewed in [188]). HIV fitness is the continuous production of infectious 
viral particles in a given environment. Replication capacity is a comparison of the 
replication ability of two or more viral variants in an experimentally defined in vitro host 
cell system  (reviewed in [371]). The selection of resistance to antiretroviral drugs leads 
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to decreased fitness and the subsequent emergence of compensatory mutations in the 
targeted gene that will eventually improve fitness. A number of methods have been 
employed to study viral fitness including replication kinetics, single-cycle replication 
assays and growth competition assays. In replication kinetic assays, the rate of HIV-1 
replication is quantified after infection of either cell lines (e.g. MT-2 and MT-4) or 
primary cells [372]. Cultures of these variants are grown in separate wells. Measurements 
of p24 antigen or the RT activity in culture supernatants at chosen time points are then 
used to determine the replication capacity of each virus  [373]. A single-cycle replication 
assay is a modified assay used to measure antiretroviral phenotypic susceptibility that 
uses luciferase as a  reporter gene [374]. Here, replication capacity can be measured in 
the absence or the presence of different drug concentrations  [375]. In growth competition 
culture assays, two viral variants (e.g. wild-type and mutant) are co-cultured in the same 
well. Genotypic or phenotypic analysis is used to measure the proportions of the 
competing viruses [376,377]. 
 
Viral fitness and virulence are determined by the features present in individual HIV-1 
variants. It might be possible to conclude that viral fitness determines the pathogenicity 
of a given variant (reviewed in [371]. A majority of resistance mutations have deleterious 
effects due to poor replication capacity and decreased fitness [378,379,380]. For example, 
the combination of K65R and M184V or L74V has been shown to decrease viral fitness 
due to the low processivity of the double mutant RT  K65R/M184V  [381]. The impact of 
viral fitness on HIV disease progression has not been clearly defined. However, drug 
selected mutant viruses that possesses a decreased pol replication capacity might 
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contribute to decreased plasma HIV-1 RNA level in patients with selected resistance 
mutations during HAART [378,382]. Nevertheless, data demonstrating a correlation 
between replicative capacity and plasma HIV-1 RNA levels in patients with viremia has 
been either weak [383] or limited to small pilot cohorts [377]. Viral replication fitness 
could be involved in the transmission of drug-resistant HIV. It has been suggested that a 
less fit virus has a low probability to be transmitted compared to a highly fit virus that is 
more easily transmitted  (reviewed in [371]). 
 
1.12.11. The Significance of minority drug-resistant Variants. 
Routine genotyping for the detection of drug-resistant HIV-1 is based on direct 
population sequencing. Using this method, only viral variants that represent at least 20–
25% of the viral population can be detected  [384]. More sensitive methods such as allele 
specific real time PCR and pyrosequencing have been employed with sensitivity of 0.2 to 
1% [385,386]. Clinical studies in antiretroviral experienced individuals have shown that 
drug-resistant HIV-variants exist at frequencies undetectable by routine population 
sequencing for prolonged durations not only after therapy failure [387,388,389,390], but 
also after interruption of therapy in patients initially infected with wt virus  [391]. Using 
two different methods, (single genome sequencing and allele specific real time PCR) 
Halvas et al, identified  higher percentages of these minority NNRTI-resistant variants in 
NNRTI-experienced patients compared to NNRTI-naïve patients [392]. At a frequency of 
0.5%–1% of K103N variants, the efficacy of therapy containing efavirenz was 
significantly decreased while Y181C minority variants were not associated with virologic 
failure. In a recent study of 13 NNRTI treatment-naïve patients and 20 NNRTI-
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experienced patients who developed a K103N mutation by routine genotyping, Varghese 
et al showed that the use of ultra deep pyrosequencing (UDPS) led to additional 
mutations being detected at low frequencies and this was associated with decreased 
resistance to the new-generation NNRTI ETR amongst NNRTI-experience patients [393]. 
In contrast, UDPS could not detect additional major NNRTI mutations as minorities in 
treatment naïve patients. A dose dependent increased risk of virologic failure after first-
line therapy is significantly associated with low-frequency HIV-1 NNRTI resistance 
mutations  (reviewed in [394]). 
 
It has been observed that routine genotyping may underestimate the rates of transmitted 
drug resistance. In a study to investigate the prevalence of selected drug-resistance 
mutations as minority quasi-species by allele-specific real-time PCR, the protease L90M 
mutation and the RT K103N mutation were detected as minority quasi-species in two 
patients, whereas the RT M184V mutation represented a minority quasi-species in five 
patients [395]. These mutations were not detected by routine genotyping.  
 
1.12.12. Transmitted Resistance 
HIV resistance can either be transmitted (primary) or acquired (secondary). Transmitted 
resistance is the presence of drug resistant mutations (DRMs) in treatment naïve HIV 
infected patients while acquired drug resistance is the emergence of drug resistance in a 
background of transmitted virus in the presence of drugs [396,397]. The ability to 
transmit a virus containing resistance mutation is impaired compared to a wt virus. This is 
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probably due to decreased fitness of mutant variants in the absence of therapy [398]. In 
the viral population, the drug-resistant virus has impaired replication and is thus not 
transmitted at high frequency [396,398,399]. Transmitted resistance mutations are 
unstable in the absence of drug pressure [400], as seen in the transmitted mutation 
M184V that is less fit and reverts back to wild-type [401]. In patients with transmitted 
drug-resistant virus, the response to therapy is suboptimal [402,403].   
 
1.12.13. Antiretroviral Drug Resistance to different HIV subtypes 
The dominant HIV-1 subtype in the developed world is subtype B and differs from 
subtypes and recombinants that exist in Africa and Asia that harbor the greatest burden of 
infection. HIV subtypes contain nucleotide changes (silent mutations), polymorphisms 
and secondary mutations within RT and PR. Some of these silent mutations and 
polymorphisms have been shown to impact on resistance to NRTIs, NNRTIs and PIs. 
Many of these changes are known to facilitate the development of resistance but will not 
confer resistance to drugs on its own (reviewed in[404]). 
 
Two clinical studies from Botswana and Malawi reported 30% and 23% of K65R in 
subtype C patients after failure of first line therapy containing d4T/ddI plus NVP or EFV 
and d4T/3TC/NVP, respectively [205,206]. The presence of higher rates of the K65R 
mutation in subtype C suggests that these viruses possess some factors that facilitate 
acquisition of this mutation, as has been described in vitro [202]. Importantly, 
biochemical data has shown that a subtype C RNA template mechanism is involved. 
There is a higher frequency of K65R mutagenesis in subtype C viruses than in other 
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subtypes [209,211]. Tissue culture selection and clinical studies have shown that in the 
presence of NVP or EFV drug pressure, a V106M mutation is commonly selected in 
subtype C viruses whereas the V106A mutation develops in subtype B. The basis for this 
difference is a nucleotide polymorphism at codon 106 in RT [259,260,261]. Natural 
resistance of HIV-2 to NNRTIs is determined by the presence of the Y188L natural 
polymorphism in HIV-2 isolates.  HIV-2 has been shown to be sensitive after this amino 
acid position is reversed [405]. With respect to PR, D30N is preferentially selected by 
NFV in subtype B than non-B subtypes. As explained by molecular dynamic simulations, 
this predominance of D30N in subtype B appears to increase the flexibility of the PR flap 
region and destabilizes the PR-inhibitor complex, thus conferring resistance to NFV  
[406]. In addition, competition assays have shown that subtype C viruses bearing the 
D30N mutation replicate poorly and thus confirm the above findings [407]. A recent 
paper suggests that the selection of specific patterns of protease resistance mutations in 
different HIV-1 subtypes is influenced by polymorphisms at position 36 in PR [331]. 
 
 
1.13. Hypothesis 
As exposed in the introduction to this thesis, PIs and NNRTIs are an important 
component in the treatment of both naïve and experienced patients and have shown a 
profound impact on disease progression and transmission. Our studies focused on next 
generation NNRTIs and PIs. Long term therapy and drug toxicity in HIV-positive 
individual‟s lead to adherence problems during treatment.  Non-adherence to therapy and 
the error prone RT enzyme results in the selection of resistance mutations. Both B and 
non-B HIV-1 subtypes can develop resistance to all currently approved drugs. New anti-
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retroviral should be active against multi-resistant viral strains and possess unique 
resistance pathways in both B and non-B subtypes. It is therefore necessary to determine 
the potential benefit of new drugs against viruses harboring known drug resistance 
mutations. The second generation NNRTIs (ETR and RPV) and a novel PI (PL-100) 
based lysine sulphonamide possess high activity for both resistant and wild-type viruses. 
Because these drugs have been designed based on structural data from subtype B viruses 
we wanted to explore how HIV genetic diversity (represented by different non-B 
subtypes) and viruses harboring known drug resistance mutations impact on the 
emergence of resistance under drug selective pressure.  
We therefore hypothesize that the mutational pathways and resistant patterns to ETR, 
RPV and PL-100 in both B and non-B HIV-1 subtypes might be driven by the natural 
HIV-1 genetic diversity and/or baseline resistance mutations.  
 
The aims of this project were to determine: 1) what mutations emerge under drug 
pressure in different subtypes and in the presence of baseline resistant mutations, 2) how 
rapidly they emerge upon drug pressure; and 3) what cross-resistance they confer (how 
could the efficacy of other NNRTIs or PIs be affected). Additionally, we also studied the 
replicative capacity of resistant variants. The first objective was to identify mutations 
selected under ETR, RPV and PL-100 drug pressure in B and non-B HIV-1 subtypes 
using wt and resistant clones, compared resistance profile and time to development of 
resistance. The second was to compare phenotypic susceptibility of the drug selected 
viruses to ETR, RPV and NNRTIs or to PL-100 and other PIs. Lastly, we wanted to study 
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the impact of novel mutations on the replication capacity and susceptibility of ETR, RPV 
or PL-100 by site directed mutagenesis.  
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Abstract 
We have selected for resistance to etravirine (ETR) and efavirenz (EFV) in tissue culture 
using three subtype B, three subtype C and two CRF02_AG clinical isolates, grown in 
cord blood mononuclear cells. Genotypic analysis was performed at baseline and at 
various weeks of selection. Phenotypic resistance in regard to ETR, EFV and nevirapine 
(NVP) was evaluated at weeks 25 to 30 for all ETR selected viruses and in viral clones 
that contained specific resistance mutations that were inserted by site-directed 
mutagenesis into pNL-4.3 and AG plasmids. The results show that ETR selected 
mutations at positions V90I, K101Q, E138K, V179D/E/F, Y181C, V189I, G190E, 
H221H/Y and M230L and that E138K was the first of these to emerge in most instances. 
Time to emergence of resistance was longer in the case of ETR (18 weeks) compared to 
EFV (11 weeks) and no differences in the patterns of emergent mutations could be 
documented between the B and non-B subtypes. Viral clones containing E138K 
displayed low-level phenotypic resistance to ETR (3.8 fold) and modestly impaired 
replication capacity (2 fold) compared to wild-type virus. ETR-selected virus showed a 
high degree of cross-resistance to NVP but not to EFV.  We identified K101Q, E138K, 
V179E, V189I, G190E and H221Y as mutations not included among the 17 currently 
recognized resistance-associated mutations (RAMs) for ETR.  
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Introduction 
HIV-1 reverse transcriptase (RT) is responsible for the conversion of the single-stranded 
RNA genome into double-stranded DNA and is therefore an important target of anti-
HIV-1 therapy (16). Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are 
noncompetitive inhibitors of HIV-1 RT that bind to the polymerase active site and disrupt 
enzyme function.  NNRTIs represent an important component of standard antiretroviral 
(ARV) therapy in HIV-1 infected patients. NNRTIs can also exert additive effects when 
combined with nucleoside reverse transcriptase inhibitors (NRTIs) (5) and have potency 
comparable to that of protease inhibitors (PIs) (39, 41). However, the efficacy of first-
generation NNRTIs such as nevirapine (NVP) and efavirenz (EFV) is often hindered by 
their low genetic barrier for resistance, since only a single amino acid substitution in the 
NNRTI binding pocket can often lead to high-level resistance against these drugs (3, 25). 
Furthermore, mutations associated with NNRTI resistance can be transmitted to others, 
and this has been documented in both developed and developing countries as occurring in 
between 10 and 20% of newly-infected individuals (1, 19).   
 
Etravirine (ETR) is an expanded-spectrum NNRTI with potent antiviral activity against 
both wild-type (wt) HIV-1 subtypes and against some viruses resistant to narrow-
spectrum NNRTIs (2, 47). Clinical studies have shown that ETR plus optimized 
background regimens consisting of NRTIs, as well as integrase and protease inhibitors, 
significantly decreased viral loads in patients with resistance against narrow-spectrum 
NNRTIs and some PIs (9, 27, 33). 
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The structure of ETR allows it to bind to the RT enzyme in more than one distinct mode 
through conformational adaptations based on changes in the NNRTI-binding pocket.  
This allows ETR to reorient itself and provides alternative binding conformation when 
mutations in the binding pocket occur (12). In vitro selection studies and both the DUET-
1 and DUET-2 (Demonstrate Undetectable viral load in patients Experienced with ARV 
Therapy) clinical trials identified 17 ETR resistance-associated mutations (RAMs) (V90I, 
A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and 
M230L) and have permitted the assignment of a weighted score for each mutation (48).  
In general, three or more ETR RAMs are required for a diminished responsiveness to 
ETR to occur.   
 
 Non-subtype B infections represent >90% of the global HIV problem. Non-B viruses 
predominate in sub-Saharan Africa and are becoming more prevalent even in areas 
dominated by subtype B, such as North America and Western Europe (18). Although 
some studies have established that subtype polymorphisms can play a role in the 
development of drug resistance, based on specific mutations that are selected by antiviral 
pressure (6, 7, 11, 21), most have focused on narrow-spectrum antiretrovirals. It is 
known, however, that naturally occurring polymorphisms at RT sites that correspond to 
ETR RAMs can vary among subtypes (24, 25, 28, 36). We sought to investigate the 
possible importance of such polymorphisms in the development of ETR resistance, even 
though ETR seems to possess similar antiviral activity against various HIV subtypes (A 
to H) and some circulating recombinant forms (CRFs). 
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Materials and Methods 
Virus isolates, cells, drugs and plasmids: 
Three subtype B (BK132, 5326 and 5331), three subtype C (Mole 03, BG 05 and 10680) 
and two CRF02_AG (6383 and 6399) wild-type clinical isolates were studied (Fig. 1). 
BK132 was obtained from the National Institutes of Health (NIH) AIDS Research and 
Reference Reagent Program. The 5326, 5331, 10680, 6383 and 6399 isolates were 
obtained with informed consent from drug-naive individuals at our clinics in Montreal, 
Canada. The two subtype C clinical samples Mole 03 and BG 05 originated in Botswana 
and were obtained courtesy of Dr. Max Essex of Harvard University, Boston MA. 
ETR was a gift from Tibotec Inc., while lopinavir (LPV), NVP and EFV were obtained 
from Abbott Laboratories (North Chicago, IL), Boehringer Ingelheim Inc. and the NIH 
AIDS Research and Reference Reagent Program, respectively. 
Cord blood mononuclear cells (CBMCs) were obtained through the Department of 
Obstetrics, Jewish General Hospital, Montreal, Canada. The HEK293T cell line was 
obtained from the American Type Culture Collection. The AG plasmid (p97GH-AG2) 
was kindly provided by Dr. Masashi Tatsumi, National Institute of Infectious Diseases, 
Tokyo, Japan. The infectious molecular clone pNL4-3 and TZM-bl cells were obtained 
through the NIH AIDS Research and Reference Reagent Program, courtesy of Malcolm 
Martin and John C. Kappes, respectively.  
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Selection of resistance mutations in CBMCs: 
Phytohemagglutinin (PHA)-stimulated CBMCs were infected with viruses (multiplicity 
of infection [MOI] of 0.1) for 2 hours, incubated at 37ºC, and subsequently washed with 
RPMI 1640 medIUM (Invitrogen) supplemented with 10% fetal bovine serum and seeded 
into a 24-well plate at a density of 2.5 x 10
6
 cells per well (14). Selection for resistance in 
CBMCs was performed using increasing concentrations of drugs (ETR and EFV) at 
starting concentrations below the 50% effective concentration (EC50) of the drugs (34). 
As controls, all viruses were simultaneously passaged without drugs. RT assays were 
performed weekly as described to monitor viral replication (26, 35). Based on the ratio of 
RT value in culture fluids of control wells/wells with drug at the previous round of 
replication, drug concentrations were increased at subsequent passages. Selection at a 
particular drug concentration was considered to be  complete when repeated passage 
revealed that RT levels in culture fluids had peaked at the same time as that of a control 
well that did not contain drugs. Virus-containing culture fluids were harvested and kept at 
-80ºC for subsequent genotypic analysis at the same time that drug concentrations were 
increased.  Selections for resistance were performed over 25 to 30 weeks.  
 
Nucleic acid extraction, amplification and sequencing analysis: 
Viral RNA was extracted from culture supernatants using the Qiagen QIAamp viral 
extraction kit (Mississauga, Ontario, Canada). Viral RNA amplification was performed 
by reverse transcription-PCR and nested PCR using a previously published protocol 
(Virco BVBA, Mechelen, Belgium). The resulting PCR-amplified DNA fragment was 
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purified by using a QIAquick PCR purification kit (Mississauga, Ontario, Canada), as 
specified by the manufacturer. The presence of the 1.5kb PR and RT PCR product was 
confirmed by running 5 μL of each product on a 1% agarose gel with sybersafe 
(invitrogen). 
Genotyping was performed by a published protocol (Virco, BVBA, Mechelen, Belgium), 
based on sequencing of a 1,200-bp fragment of the HIV-1 pol gene encompassing up to 
400 amino acids in the RT region, using Virco primers with a BigDye Terminator 
sequencing kit (Version 1.1; Applied Biosystems, Forter City, CA) and automated 
sequencer (ABI Prism 3130 genetic analyzer; Applied Biosystems).  Data were analyzed 
using SeqScape software version 2.5.  
 
Site-directed mutagenesis and virus production: 
The E138K mutation was introduced into pNL4-3 and the p97GH-AG2 plasmid by site-
directed mutagenesis (SDM) using a QuikChange II XL site-directed mutagenesis kit 
(Stratagene, LaJolla, CA). For SDM of E138K in pNL4-3, the forward primer 5'-
GCATTTACCATACCTAGTATAAACAATAAGACACCAGGGATTA-3' and reverse 
primer 5'-TAATCCCTGGTGTCTTATTGTTTATACTAGGTATGGTAAATGC-3' were 
used, while for E138K in p97GH-AG2 the forward primer was 5'-
GCATTCACTATACCTAGTGTAAACAATAAGACACCAGGGATT-3' and the 
reverse primer was 5'-
AATCCCTGGTGTCTTATTGTTTACACTAGGTATAGTGAATGC-3'. The underlined 
codons denote sites at which single nucleotide substitutions were introduced into the 
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plasmids. This was confirmed by sequencing and DNA was ultimately transformed into 
DH5α cells (Invitrogen) for high-yield of plasmid. Viruses were produced by transfection 
of 16µg of pNL4-3 wt (pNL4-3wt), pNL4-3E138K, p97GH-AG2 wt (AGwt) and 
AGE138K plasmids into HEK 293T cells using lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) according to manufacturer‟s protocols.  Two days after transfection, 
supernatants of transfected cells were clarified by centrifugation at 1500 rpm for 5 min to 
remove cellular debris, filtered through a 0.45µm-pore-size filter, and stored in aliquots at 
-80°C. Virus production was confirmed by measurement of RT activity and p24 
production. 
 
Phenotypic drug susceptibility: 
Drug susceptibility to NNRTIs (i.e., ETR, EFV and NVP) was measured in cell-culture 
based phenotypic assays as previously described (26, 40). In brief, CBMCs were infected 
for 2 hours with either wt virus, drug selected variants, or recombinant viruses, washed to 
remove unbound virus; and plated into 96 well plates containing drugs or not. After 3 or 4 
days of incubation at 37ºC, the cells were fed with fresh media containing appropriate 
drug dilutions, and RT assays were performed at day 7. The data were analyzed using 
Prism software (version 5.0; GraphPad, Inc.) to determine the EC50 for each drug tested. 
Resistance to a given drug was determined based on the published lower clinical cutoff 
(CCO), which determines the cutoff fold change value for the sensitivity of NNRTIs (46, 
48). These values are 3.0 for ETR, 3.4 for EFV and 5.5 for NVP (46, 48). 
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Determination of relative replication capacity in TZM-bl cells: 
The replicative capacities of competent clonal wt and E138K-containing HIV-1 were 
evaluated in a noncompetitive infectivity assay using TZM-bl cells (51). Twenty 
thousand cells per well were added into a 96-well culture plate in 100µl of Dulbecco 
modified Eagle medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine 
serum (Gibco), 1% penicillin-streptomycin, and 1% L-glutamine (Invitrogen). Viral 
stocks for both wild-type and mutant viruses were normalized by p24 and recombinant 
viruses from AG and pNL4-3 plasmids were serially diluted 2 and 4-fold respectively 
from viral stock suspensions. After 4 hours, 50µl of DMEM was removed from the wells 
and replaced by 50µl of virus dilution; a control well did not contain virus. Virus and 
cells were co-cultured for 48 hours, after which 100µl of Bright-GloTM reagent was 
added and luciferase activity measured in a luminometer as described (Promega). The 
viral replication level was expressed as a percentage of relative light units (RLU) with 
reference to wild-type virus for each virus studied. 
 
Viral Growth Kinetics in CBMCs:  
PHA-stimulated CBMCs were infected with viruses at an MOI of 0.1 as described above 
for selection of resistance. Culture fluids were collected at various times to determine 
levels of RT activity. 
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Statistical Analysis: 
A two-way analysis of variance (ANOVA) was performed on group means using Prism 
software (version 5.0; GraphPad, Inc.). A P value <0.05 was considered to represent a 
significant difference. 
 
Results 
Baseline genotyping of clinical isolates. 
The first 240 amino acids in RT of all the isolates (BK132, 5326, 5331, 6383, 6399, Mole 
03, BG 05 and 10680) were sequenced at baseline  and compared with the HIV-1 subtype 
B reference strain HXB2 (Fig. 1). Amino acid changes were identified in 37 of 240 
positions in RT and were more frequent in non subtype-B than B isolates. Only one of 
these substitutions, i.e. V90I, present at baseline in the 6383 isolate, is known to be 
implicated in HIV-1 resistance to NNRTIs with a weighted factor of 1.0 for ETR 
resistance (48).  
 
Time to development of resistance to ETR 
ETR-resistance was selected in culture using CBMCs as described above (Table 1). 
Despite attainment of high ETR concentrations at weeks 11-13, only the BK132 isolate 
selected the E138E/K mutation, consistent with previous results on the difficulty of 
selecting resistance to this compound (47). Subsequently, all isolates showed the 
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accumulation of other mutations at week 18-20 (V90I, K101Q, E138K, V179D/E/F, 
Y181C, V189I, G190E, H221Y, M230L). E138K emerged as the first mutation in all 
cases except for isolate 5331, in which it was detected between weeks 25 and 30. All 
selected mutations were maintained in culture under drug pressure as other mutations 
accumulated. A strong association was observed between the presence of E138K and 
Y181C and between Y181C and substitutions at position 179 for all isolates. Isolate 6399 
selected for E138K alone. No differences in patterns of mutations for ETR were observed 
between subtype B and non-B viruses. Novel amino acid substitutions not included in 
lists of published RAMs for ETR (48) were K101Q, E138K, V179E, V189I, G190E and 
H221Y. 
 
Time to development of resistance to EFV 
As expected, all isolates had selected for mutations K103N/Q, V106I/M, V179D/V, 
Y188C/Y, and/or M230L/M that contribute to high level EFV resistance by weeks 11-13 
(Table 2). Additional mutations (L100I, V108I/V, K101E/K, N348N/T) were observed at 
subsequent passages. This demonstrates the low genetic barrier of EFV. V106I and 
V106M were selected in subtypes B and C, respectively, due to a well-described 
polymorphism at this position (6). Other mutations selected by EFV included; L100I, 
K103N/Q, V108V/I, V179D/V, Y188C/L, G190A, H221Y, and N348I. 
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Resistance profile of ETR-selected variants. 
Table 3 shows the phenotypic susceptibility of viruses containing ETR RAMs. At 
baseline, mean EC50s for ETR ranged between 1 to 4.5 nM while those for EFV ranged 
between 1.2 - 3.5 nM. Isolate 6383 that harbored V90I at baseline had the highest EC50 
value of 4.5 nM for ETR. Isolate 6399 that selected for E138K alone after 25-30 weeks in 
culture displayed low-level resistance to ETR, EFV and NVP, with fold resistance of 5.1, 
3.7 and 6.7 respectively. Isolate BK132 (subtype B) variants selected at weeks 25 to 30 
possessed E138K, G190E, and H221H/Y and displayed moderate and low-level 
resistance to ETR and EFV, i.e., 8.7- and 3.8-fold, respectively (Table 3). ETR-resistant 
variants selected by three other non-B isolates at weeks 25-30 contained mutations as 
follows: 6383 (V90I, E138K, V179E Y181C, M230L), Mole 03 (V90I, E138K, V179D, 
Y181Y/C) and BG 05 (E138K, V179F, Y181C, M230L). These viruses all displayed 
very high level resistance to ETR and NVP (> 95-fold) and low-moderate resistance (< 
11-fold) to EFV. The presence of Y181C in combination with other RAMs may have 
contributed to high-level ETR resistance in these situations. As a control, we used the 
isolate BG05 (E138K, V179F, Y181C, M230L) and the protease inhibitor LPV. The 
EC50 values of BG05 wt and the BG05 selected variant (E138K, V179F, Y181C, 
M230L) were 5.5 ± 2.1 and 6.0 ± 2.0 nM, respectively (fold change [FC] =1.1). 
 
Impact of E138K in the pNL4-3and AG plasmids 
We introduced E138K by site-directed mutagenesis into the pNL4-3 and AG plasmids to 
determine its impact on resistance to ETR, EFV and NVP in CBMCs. The EC50s of 
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pNL4-3wt and pNL4-3E138K were 1.6 ± 0.25 and 6.2 ± 1.2 for ETR [fold change (FC) 
=3.8], 1.73 ± 0.25 and 4.8 ± 0.69 for EFV (FC= 2.7) and 26 ± 6 and 38 ± 10 for NVP 
(FC=1.4) (nM), respectively. Similarly, the EC50s of AGwt and AGE138K were 1.3 ± 
0.15 and 5.1 ± 0.17 for ETR (FC=3.9), 1.46 ± 0.15 and 3.2 ± 0.42 for EFV (FC=2.2), and 
40.0 ± 7 and 75.0 ± 2 for NVP (FC=1.8) (nM), respectively.  Decreases in susceptibility 
were modest for ETR, i.e., 3.8 and 3.9-fold for pNL4-3E138K and AGE138K, 
respectively (Fig 2).  EFV and NVP both retained relative sensitivity to the pNL4-
3E138K and AGE138K viruses containing E138K, i.e., FCs of 2.7 and 2.2 for EFV and 
1.4 and 1.8 for NVP, respectively. The EC50s of a control drug, LPV, for pNL4-3wt and 
pNL4-3E138K were 9.5 ± 0.7 and 10.0 ± 0.02 (FC=1.05) (nM). 
 
Viral replication capacity. 
We also studied the relative replication capacity of wt and viruses carrying the E138K 
mutation by infecting TZM-bl cells with serially diluted viral stocks normalized for p24 
production. Infectiousness of the wt and E138K viruses was determined by measuring 
luciferase activity at 48 hour postinfection.  At a p24 input of 10,000 pg/ml, the relative 
replication of E138K compared to wt virus was diminished after 48 hr by 2-and 3-fold for 
pNL4-3E138K and AGE138K, respectively (p <0.01 and p < 0.001) (Fig 3A and 3B). In 
a multiple round infection in CBMCs, viral growth experiments in the absence of drug 
confirmed that the E138K mutation conferred a 2-fold drop in replication rates for pNL4-
3E138K compared to pNL4-3wt by both 6 and 8 days after infection (Fig 3C) (p < 
0.001).  
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Discussion 
Although ETR is currently approved for NNRTI-experienced patients, a number of 
studies have suggested that its use in patients with NNRTI mutations at baseline might 
lead to poor virological response (VR) (22, 29, 30, 37). In most of these studies, the 
presence in the background regimen of newer drugs such as enfuvirtide, darunavir or 
raltegravir was positively associated with VR while previous exposure to NVP and the 
presence of baseline mutations such as E138A, V179I and Y181C were negatively 
associated with VR. We provide here a comprehensive in vitro analysis of the resistance 
pattern of ETR in wild-type clinical isolates of subtype B, subtype C and CRF02_AG 
grown over 25-30 weeks in CBMCs in increasing concentrations of ETR compared with 
EFV. Our data show that ETR RAMs emerged after 18 weeks of drug pressure except for 
one isolate (BK132) that selected for E138E/K at weeks 11-13. The E138K mutation was 
selected in all isolates and was almost always the first mutation to emerge.  
 
Although E138K has been reported in a few cases of ETR treatment failure (44, 49), its 
clinical significance has not yet been elucidated. Site-directed mutagenesis of E138K 
revealed low-level resistance to ETR in both pNL4-3 and AG plasmids, with a fold-
change slightly above the clinical cutoff (CCO). Others have reported a median ETR FC 
of 2.6-fold for E138K with first and third-quartile values of 2.0 and 4.1-fold respectively, 
data that are consistent with site-directed mutagenesis results reported here (4). Although 
E138K cannot on its own exclude ETR as a potentially useful drug, its presence might 
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facilitate the accumulation of other resistance mutations or may result in an increased FC 
for resistance for ETR. In an analysis of the DUET studies, two different groups showed 
that mutations at position 138 were among the most frequent with E138K emerging in 
three patients (44, 49). Furthermore, all patients with E138 mutations demonstrated an 
increased FC for ETR over the upper CCO for resistance for ETR (>13), documenting the 
role of mutations at position 138 in ETR resistance. Of course, the emergence of 
resistance in the treatment-experienced DUET patients may not be comparable to in vitro 
selections beginning with wild-type viruses, especially because several of the NRTI 
mutations that patients possessed in the DUET studies are known to hyper-sensitize to 
ETR. Clinical studies with ETR in NNRTI-naïve patients will be required to validate the 
present results.  
 
In contrast, a FC for EFV below the CCO was observed with the site-directed mutants of 
E138K. This is consistent with the fact that E138K is not selected in vitro by EFV and 
was not observed in EFV-treated patients. One study reported the emergence of E138K 
after in vitro passage of viruses containing amino acid substitutions at position 135 at 
baseline (15). These authors demonstrated a FC for EFV of 2 and 7 for E138K and 
I135T/E138K, respectively.      
 
The ETR RAMs observed here include V90I, K101Q, E138K, V179D/E/F, Y181C, 
V189I, G190E, H221Y, and M230L, a pattern similar to that observed by others who also 
observed a high frequency of L100I if viruses contained some NNRTI mutations at 
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baseline (47). These authors also selected E138G if they began with a virus containing 
the K103N substitution.  
 
We did not observe any difference in the pathway of ETR resistance in B and non-B 
subtypes. The Y181C mutation was associated with either E138K or V179D/E/F. Both 
Y181C and V179F were also observed to co-emerge in the DUET studies (44, 48), a 
finding that is possibly due to the fact that the combination of either E138K and Y181C 
or V179D/E/F and Y181C improve viral replication capacity compared to the presence of 
only a single mutation. In a recent analysis of genotypic and phenotypic changes of 
rebounders in the DUET studies, it was shown that V179 (n=35), E138 (n=17), Y181 
(n=15) and K101 (n=13)(44) were the positions at which new mutations were most 
frequently observed. In contrast, EFV selected for classic mutations including V106I and 
V106M in subtypes B and C, respectively, at weeks 11-13, as previously described (6). 
The specific selection in this study of G190A and G190E by EFV and ETR, respectively, 
confirms the non-association of G190A with ETR (50). However, G190E has been shown 
to be selected by both ETR and another novel NNRTI, rilpivirine (RIL) (4, 47). 
 
Our phenotypic data show that accumulation of several ETR RAMs especially Y181C 
and M230L resulted in high level ETR resistance. Viruses possessing high-level 
resistance to ETR, also displayed moderate and high-level resistance to EFV and NVP, 
respectively. This confirms cross-resistance between ETR and NVP and is also consistent 
with studies showing that the prior use of NVP is associated with resistance to ETR (23, 
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31, 42). The low and moderate level resistance to ETR displayed by isolates 6399 
(E138K) and BK132 (E138K, G190E, H221H/Y) are probably due to the low weight of 
these mutations on resistance to ETR.  
In general, NNRTI mutations that emerge early in treatment-experienced patients e.g. 
K103N, do not impair viral replication capacity to significant extend (10). We found that 
E138K in both pNL4-3and AG exerted only modest impact on replication capacity, a 
finding that helps to explain the frequency of this mutation in our selection as well as the 
fact that E138K was usually the first mutation to emerge. In contrast, M230L impairs 
viral replication capacity by ≈8-fold (51). This is consistent with the selection of E138K 
in all 8 isolates while M230L was selected in only 2 of 8 isolates in this study.  
E138K has previously been selected in vitro by other broad-spectrum NNRTIs (4, 8, 13, 
17, 20). However, it has low prevalence (0.5%) in clinical samples (43) and only little 
impact on susceptibility to narrow-spectrum NNRTIs. E138K (GAGAAG) is found in 
the p51 subunit of RT as part of the NNRTI binding pocket. The K101 side-chain can 
normally form a salt bridge with E138, but the presence of E138K causes residues to 
move away from the NNRTI pocket due to the juxtaposition of like charges that result 
from the mutation (38), potentially preventing the specific binding of drug. In addition, 
interactions of Y318 and E138 in the presence of ETR have been described as unusual for 
NNRTI-RT complexes (45). The emergence of mutations at residues 138 and 318 could 
disrupt drug binding ability (4, 47). The identification of a new E138R mutation selected 
by RIL reinforces the importance of this position (4). E138K and other mutations 
(K101Q, V179E, V189I, G190E and H221Y) selected in our study are not yet included 
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among the list of ETR RAMs. Although G190E was previously selected by ETR and RIL 
(4, 47), its role, alone or in combination with other mutations, remains unknown. Both 
V179E and H221Y have also been previously shown to confer a degree of resistance to 
ETR (28, 31, 32). Additional studies in our laboratory will evaluate whether the 
mutations K101Q, V179E, V189I, G190E and H221Y either alone or in combination 
with E138K might affect susceptibility of ETR and other NNRTIs.  
 
A recent study analyzed the weights of 17 ETR RAMs, based on the DUET 1 and 2 
studies (48). Others have also assigned weighted scores for ETR mutations based on 
different work (32); the assigned scores were 2, 3, 1, and 1 for E138K, V179E, G190E, 
and H221Y, respectively. As new results of ETR resistance are released, there will be a 
need to improve algorithms to also take into account the partial resistance that is 
associated with certain mutations and mutational patterns.  
Our in vitro results confirm that ETR is a potent antiviral drug with a higher genetic 
barrier for resistance than narrow spectrum NNRTIs. Although the data also suggest that 
virological response to ETR in NNRTI-naïve patients might be superior than in 
experienced individuals, clinical studies with patient samples will be needed to provide 
further information on this topic, as well as on the clinical significance of the E138K 
substitution in cases of ETR treatment failure.  
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Table 1. Evolution of viral variants selected with ETR in tissue culture. 
Variant(s) in: 
Week Subtype B CRF02_A/G Subtype C 
BK132 5326 5331 6383 6399 Mole03 BG05 10680 
11-13 E138E/K ND
a
 ND V90I
b
 Wt Wt Wt ND 
18-20 E138K 
G190G/E 
H221H/Y 
E138E/K 
V179D 
Y181C 
K101Q 
V189I 
V90I 
E138E/K 
V179V/E 
Y181C 
M230M/L 
E138E/K V90I 
E138K 
V179D 
Y181Y/C 
 
E138K 
Y181C 
M230L 
E138K 
K238K/N 
25-30 E138K 
G190E 
H221H/Y 
E138K 
V179D 
Y181C 
V90I/V 
K101Q 
E138K 
V189I 
V90I 
E138K 
V179E 
Y181C 
M230L 
E138K V90I 
E138K 
V179D 
Y181Y/C 
 
E138K 
V179F 
Y181C 
M230L 
E138K 
G190E/G 
K238K/N 
 
a
 ND, not determined. 
b
 V90I is a baseline polymorphism in isolate 6383. 
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Table 2. Evolution of viral variants selected with EFV in tissue culture. 
Variant(s) in: 
Week Subtype B CRF02_A/G Subtype C 
BK132 5326 5331 6383 6399 Mole03 BG05 10680 
11-13 K103Q 
V106I 
Y188C 
ND
a
 ND V90I
b 
K103N 
K103N V106M 
Y188C/Y 
M230L/M 
V106M 
V179D/V
Y188C 
Y188C 
18-20 K103Q 
V106I 
Y188C 
K101E/K 
V108I/V 
Y188C/Y 
L100I 
N348I/N 
V90I 
L100I 
K103N 
N348N/T 
K103N 
 
V106M 
Y188C 
 
V106M 
V179D/V 
Y188C 
V106M 
Y188C 
25-30 K103Q 
V106I 
Y188C 
L100I 
Y188L  
L100I 
V108V/I 
H221Y 
N348I 
V90I 
L100I 
K103N 
G190A 
K103N 
 
V106M 
Y188C 
 
V106M 
V179D/V 
Y188C 
V106M 
Y188C 
 
a
 ND, not determined. 
b
 V90I is a baseline polymorphism in isolate 6383. 
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Table 3: In vitro antiviral activity of NNRTIs against ETR-selected variants. 
Isolate
a 
Subtype NNRTI Mutation Mean EC50 ± SD
b
   (fold Change) 
 ETR (nM) EFV (nM) NVP (µM) 
BK132 B Wt 3.7 ± 0.9 3.2 ± 0.4 0.04 ± 0.02 
BK132
⃰ 
B E138K, G190E, H221H/Y 32 ± 3 (8.7) 12 ± 4 (3.8) ND
c 
6383 A/G Wt 4.5 ± 0.7 3.5 ± 0.7 0.041 ± 0.012 
6383
⃰ 
A/G V90I, E138K, V179E, Y181C, 
M230L. 
430 ± 20 (95.6) 40 ± 10 (11.4) >5.0  (>121.9) 
6399 A/G Wt 1 ± 0.2 1.2 ± 0.4 0.031 ± 0.001 
6399
⃰
 A/G E138K 5.1 ± 0.2 (5.1) 4.4 ± 0.1 (3.7) 0.21 ± 0.01 (6.7) 
Mole 03 C Wt 1.3 ± 0.4 1.5 ± 0.1 0.038 ± 0.01 
Mole 03
⃰ 
C V90I, E138K, V179D, Y181Y/C. 140 ± 20 (107.7) 4.7 ± 2 (3.1) >10.0 (>263) 
BG 05 C wt 3.5 ± 0.1 1.5 ± 0.2 0.012 ± 0.002 
BG 05
⃰ 
C E138K, V179F, Y181C, M230L 490 ± 40 (140) 16 ± 1 (10.7) >5.0 (>416) 
 
a Asterisks ( ⃰ ) indicates an ETR-selected variant at weeks 25 to 30. As stated in the text, 
isolate 6383 contained the V90I mutation at baseline. 
b
 The values represent means of two or  three independent experiments, each performed 
in duplicate.  Drug susceptibility was expressed as fold-change in EC50, determined by 
calculating the ratio of EC50s for selected variants and wt viruses (values in parentheses). 
c 
ND, not determined. 
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Figure 1.  
Baseline polymorphisms of HIV-1, as shown in an amino acid alignment (residues 1-240) of RT for all clinical isolates used in this 
study. Subtype B: BK132; 5326 and 5331; CRF02_AG, 6383 and 6399; Subtype C, Mole03, BG05, and 10680. HXB2 was used as a 
reference sequence. All isolates were sequenced at baseline and passaged simultaneously in the presence or absence of drugs. The 
sequence of the wild-type RT at baseline was the same as that of isolates passaged without drugs. The dots represent identical 
positions, while letters indicates variations in amino acids relative to HXB2.  Isolate 6383 at baseline harbored the NNRTI resistance 
mutation V90I that is known to decrease susceptibility to ETR.  
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                    10         20         30         40         50         60         70         80                       
           ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
HXB2       PISPIETVPV KLKPGMDGPK VKQWPLTEEK IKALVEICTE MEKEGKISKI GPENPYNTPV FAIKKKDSTK WRKLVDFREL   
BK132 WT   .......... .......... .......... .......... .......... .......... .......... ..........   
5326 WT    .......... .......... .......... ........P. .......... .......... .......... ..........   
5331 WT    .......... .......... .......... .......... .......... .......... .......... ..........   
6383 WT    .......... .......... .......... ....T...I. .......... .........I .......G.. ..........   
6399 WT    .......... .......... .......... ....T..... ........R. .........I .......... ..........   
Mole03 WT  .......... .......... .......A.. ....T...E. .......T.. .......... .......... ..........   
BG05 WT    .......... ...A.....N .......... ....T...E. .......T.. .......... .......... ..........   
10680 WT   .....X.... .......... .......D.. ....TA..EX ......X... .....X.... .......... .........X   
 
                    90        100        110        120        130        140        150        160                
           ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
HXB2       NKRTQDFWEV QLGIPHPAGL KKKKSVTVLD VGDAYFSVPL DEDFRKYTAF TIPSINNETP GIRYQYNVLP QGWKGSPAIF   
BK132 WT   .......... .......... .......... .......... .K........ ....T..... .......... ..........   
5326 WT    ....X..... P...X..... .......... .......... .K........ HL..T.H... ......H... ..........   
5331 WT    .....E.... .......... .......... .......... .K........ .......... .......... ..........   
6383 WT    .........I .......... .......... .......... .......... ....V..... .......... ..........   
6399 WT    .......... .......... .......... .......... ..S....... .......... .V........ ..........   
Mole03 WT  .......... .......... .......... .......... .......... .......... .......... ..........   
BG05 WT    .......... .......... .......... .......... ..G....... .......... .......... ..........   
10680 WT   .....X.... .......... .....X.... ........XX ..X....... ....T...V. X...X..... X........X   
 
                   170        180        190        200        210        220        230        240               
           ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
HXB2       QSSMTKILEP FRKQNPDIVI YQYMDDLYVG SDLEIGQHRT KIEELRQHLL RWGLTTPDKK HQKEPPFLWM GYELHPDKWT   
BK132 WT   .C........ .......... .......... .......... .......... ...F...... .......... ..........   
5326 WT    .......... ...R..E... .......... .........I .......... .......G.. .R........ ....P.....   
5331 WT    .......... .......... .......... .......... ......X... K..F...... .......... ..........   
6383 WT    .A........ ..TK..EM.. .......... .....E...A ......G... ...F...... .......... ..........   
6399 WT    ....I..... Y.TK..EM.. .......... .....E...A ...Q..E... ...F...... .......... ..........   
Mole03 WT  .A..I..... ..T...EM.. .......... .........A ......E... ...F...... .......... ..........   
BG05 WT    .....I.... ..A...E... .......... .........A ......E... K..F...... .......... ..........   
10680 WT   .......... ..A...X... .......... X......X.A ....X.N... ...X...... .......... .......X..   
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Figure 2. 
Comparative phenotypes of recombinant viruses derived from pNL-4.3E138K and AGE138K and tested for susceptibilities to ETR, EFV 
and NVP in CBMCs. Recombinant clones containing E138K were tested for their susceptibilities to ETR, EFV and NVP in cell 
culture assays. The mean EC50s of mutated variants were compared to those of wt pNL-4.3 or AG plasmids. The results shown are 
means of two or three independent experiments. Bars in the figure represent mean fold-change (FC) while error bars represent ± 
standard deviation (SD). Bars with dots, fold change (FC) to ETR; bars with slashes, fold change to EFV and open bars, fold change 
to NVP.   
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Figure 3. 
 Effect of E138K on viral replication capacity. Viral stocks of both wt and E138K-containing virus were normalized for p24 and used 
to infect TZM-bl cells. (A and B) The Luciferase activity was measured at 48 h postinfection as an indication of viral replication. The 
relative infectivity of wt compared to E138K-containing virus is shown on the y axis while the x axis denotes the input of p24. 
Statistical analysis using a two-way ANOVA shows that replication capacity was decreased by 2-and 3-fold compared to wt for 
pNL4-3E138K and AGE138K, respectively, after 48 hours. A significant difference was observed after a p24 input greater than 10,000 
pg/ml. The points with asterisks (***) indicates a significant difference. CBMCs were also infected as described in Materials and 
Methods and viral growth was measured by determining RT activity in culture supernatants at different times (C). A significant 
difference was observed at the peak of infection (days 6 and 8) are indicated with asterisks (***). In the Figure, a P value of < 0.01 is 
represented by “**” while a p value of < 0.001 is represented by “***”. Values are means of at least two independent experiments ± 
SD. Error bars represent the SD. 
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Abstract 
Objective: The current in vitro study examined HIV-1 drug resistance patterns following 
etravirine (ETR) and rilpivirine (RPV) drug pressure in viruses containing baseline 
NNRTI resistance mutations.  
Design and Method: Several baseline mutations were introduced into pNL4-3by site-
directed mutagenesis together with two subtype C clinical isolates containing baseline 
mutations, were passaged in increasing drug pressure of NNRTIs in cord blood 
mononuclear cells (CBMCs). Genotypic analysis was performed at different weeks. 
Phenotypic resistance for ETR, RPV and efavirenz (EFV) and the replication capacity 
(RC) of several mutations and combinations was tested. 
Results: In wild-type (wt) viruses and viruses containing K103N alone at baseline, 
E138K or E138G mutations were observed following pressure with either ETR or RPV 
prior to the appearance of other NNRTI resistance mutations and these changes were 
observed regardless of viral subtype. However, subtype B viruses containingY181C 
generated V179I/F or A62V/A but not E138K following exposure to ETR or RPV, while 
subtype C viruses containing Y181C developed E138V together with Y188H and V179I 
under ETR pressure. The addition of mutations at position 138 to Y181C did not 
significantly enhance levels of resistance to ETR or RPV and the replicative capacity of 
viruses containing Y181C plus either E138K or E138A was similar to that of viruses 
containing either E138K or E138A alone.  
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Conclusion: These results demonstrate that each of ETR and RPV are likely to select for 
E138K as a major resistance mutation if no or very few other resistance mutations are 
present and that Y181C may be antagonistic to E138K. 
Key words: etravirine, rilpivirine, cross-resistance, second generation NNRTI, 
replication capacity, antiviral activity. 
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Introduction 
Antiretroviral therapy (ART) has significantly decreased HIV-associated morbidity and 
mortality [1]. Two classes of drugs that are used clinically are nucleoside reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) [2]; the latter are noncompetitive inhibitors of HIV-1 reverse transcriptase 
(RT) that bind to a hydrophobic pocket in the p66 subunit near the polymerase active site, 
allosterically inhibiting the activity of the enzyme [2]. NNRTIs are routinely prescribed 
for both treatment-naïve and experienced patients [3-5]. However, non-adherence to 
therapy can result in the selection of drug-resistance mutations [6, 7], and all HIV-1 
subtypes can develop resistance to all currently approved drugs.  
Multiple studies have reported an increasing prevalence of NNRTI drug resistance in 
acute HIV-1 infection [8, 9], and individuals to whom at least one NNRTI resistance 
mutation has been transmitted are less likely to respond positively to treatment regimens 
that include first-generation NNRTIs such as nevirapine (NVP) and efavirenz (EFV) [10, 
11]. The widespread use of single dose NVP to prevent mother-to-child transmission of 
HIV-1 has increased the prevalence of NNRTI resistance mutations (reviewed in [12]). In 
addition, cross-resistance among NNRTIs is common [13], such that the sequential use of 
first generation NNRTIs is excluded in treatment-experienced patients. Etravirine (ETR) 
is a second generation NNRTI that possesses high activity against both wild-type (wt) 
and drug-resistant viruses at nM concentrations and was approved for use in treatment-
experienced patients with NNRTI-resistant viruses [14, 15]. ETR can bind to RT by 
rotating within the NNRTI binding pocket to accommodate resistance mutations and 
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retain activity [16] and has been shown to be effective in treatment-experienced, NNRTI-
resistant patients in the DUET-1 and DUET-2 (Demonstrate Undetectable viral load in 
patients Experienced with ARV Therapy) studies [5, 17]. These same studies identified 
20 ETR resistance-associated mutations (RAMs) that can diminish virological response: 
V90I, A98G, L100I, K101E/H/P, V106I, E138A/K/G/Q, V179D/F/T, Y181C/I/V, 
G190A/S and M230L [18, 19]. Each of these mutations has been assigned a weighted 
genotypic score and three or more of these mutations are required to significantly reduce 
virologic response to ETR [18].  
Rilpivirine (RPV) is another second generation NNRTI whose mode of binding within 
the NNRTI binding pocket is similar to that of ETR [20]. In recent phase III studies 
(ECHO and THRIVE), HIV-1 drug-naïve patients who failed combination therapy 
containing RPV and emtricitabine (FTC) or lamivudine (3TC) were frequently observed 
to have the resistance mutations E138K/M184I and E138K/M184V [21, 22]. The same 
mutations are also selected in culture by RPV and ETR, resulting in high-level cross-
resistance [23, 24].  
 
The most prevalent NNRTI mutations for EFV and NVP include K103N, Y181C and 
G190A [25], of which K103N does not compromise susceptibility to either ETR or RPV 
[14, 23]. However, both Y181C and G190A can affect responsiveness to ETR [26] while 
only Y181C decreases susceptibility to RPV [23].  
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In contrast to the foregoing, the application of ETR pressure against wt viruses 
commonly selects for the E138K mutation that has also been identified in patients who 
have failed first-line regimens that have included RPV. The current study was performed 
to determine the basis for the preferential selection of E138K by ETR in wt viruses 
compared to the selection of other NNRTI mutations in the DUET clinical studies. In 
addition, we wanted to investigate whether HIV-1 that already contained E138K or 
M184I/V or E138K plus M184I/V could develop additional resistance mutations in the 
presence of ETR or RPV. Another NNRTI of the same family and structural similarity 
Dapivirine (TMC120) was also included in the study. TMC120 is licensed for 
microbicide development.  
 
Materials and Methods 
Viral isolates, Cells, drugs, and plasmids 
The subtype C viral isolates 10680 and 4743 were obtained with informed consent from 
HIV-1 infected patients at our clinics in Montreal, Canada. Cord blood mononuclear cells 
(CBMCs) were obtained through the Department of Obstetrics, Jewish General Hospital, 
Montreal, Canada. The HEK293T cell line was obtained from the American Type Culture 
Collection. The infectious molecular clone pNL4-3and TZM-bl cells were obtained 
through the NIH AIDS Research and Reference Reagent Program, courtesy of Malcolm 
Martin and John C. Kappes, respectively. ETR and Dapivirine (TMC120) were gifts of 
Janssen Inc., while RPV and EFV were obtained from the NIH AIDS Research and 
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Reference Reagent Program. Tenofovir (TFV), also used in selections, was a gift of 
Gilead Sciences, Inc, Foster city, California. 
 
Site-directed mutagenesis and virus production: 
Amino acid changes in RT were introduced into the pNL4-3 plasmid by site-directed 
mutagenesis (SDM) using a QuikChange II XL site-directed mutagenesis kit (Stratagene, 
LaJolla, CA). Mutations were introduced individually by PCR in the case of double 
mutants. The list of mutations and primers employed are shown in a table (supplemental 
digital content 1). After SDM, the presence of mutations was confirmed by sequencing, 
and DNA was ultimately transformed into DH5α cells (Invitrogen) for high-yield of 
plasmid. Viruses were produced by transfection of 16µg of wt or mutant plasmid into 
HEK 293T cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to 
manufacturer‟s protocols.  Two days after transfection, supernatants of transfected cells 
were clarified by centrifugation at 1500 rpm for 5 min to remove cellular debris, filtered 
through a 0.45µm-pore-size filter, and stored in aliquots at -80°C. Virus production was 
confirmed by measurement of RT activity and p24 production. 
 
Selection of resistance mutations in CBMCs: 
PHA-stimulated CBMCs were infected with viruses (multiplicity of infection of 0.1) for 2 
hours, incubated at 37ºC, and subsequently washed with RPMI 1640 media (Invitrogen), 
supplemented with 10% fetal bovine serum, and seeded into a 24-well plate at a density 
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of 2.5 x 10
6 
cells per well [27]. Selection for resistance in CBMCs was performed using 
increasing concentrations of drugs (ETR and EFV) at concentrations starting below the 
50% effective concentration (EC50) of the drugs [28]. As controls, all viruses were 
simultaneously passaged in the absence of drugs. RT assays were performed weekly as 
described to monitor viral replication [29, 30]. Based on the ratio of RT values in culture 
fluids of control wells/wells with drug at the previous round of replication, drug 
concentrations were increased at subsequent passages. Selection at a particular drug 
concentration was considered to be  complete when repeated passage revealed that RT 
levels in culture fluids had peaked at the same time as that of a control well that did not 
contain drugs. Virus-containing culture fluids were harvested and kept at -80ºC for 
subsequent genotypic analysis at the same time that drug concentrations were increased.  
Selections for resistance were performed over 25-30 weeks.   
 
Nucleic acid extraction, amplification and sequencing analysis: 
Viral RNA was extracted from culture supernatants using the Qiagen QIAamp viral 
extraction kit (Mississauga, Ontario, Canada). Viral RNA amplification was performed 
by RT-PCR and nested PCR using a previously published protocol (Virco BVBA, 
Mechelen, Belgium). The resulting PCR-amplified DNA fragment was purified using the 
QIAquick PCR purification kit (Mississauga, Ontario, Canada), as specified by the 
manufacturer. The presence of the 1.5kb protease (PR) and RT PCR products was 
confirmed by running 5 μL of each product on a 1% agarose gel with Sybersafe 
(Invitrogen). 
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Genotyping was
 
performed by a published protocol (Virco, BVBA, Mechelen, Belgium),
 
based on sequencing of a 1,200-bp fragment of the HIV-1 pol
 
gene encompassing up to 
400 amino
 
acids in the RT region, using Virco primers with a BigDye Terminator 
sequencing kit (Version 1.1; Applied Biosystems, Forter City, CA) and automated 
sequencer (ABI Prism 3130 genetic analyzer; Applied Biosystems).  Data were analyzed 
using SeqScape software version 2.5.  
 
Phenotypic drug susceptibility in TZM-bl. cells 
Drug susceptibility to NNRTIs (ETR, RPV, TMC120 and EFV) was measured in a single 
cycle cell-culture based phenotypic assay in TZM-bl cells. In brief, 20.000 cells per well 
were added into a 96-well culture plate in 50µl of Dulbecco modified Eagle medium 
(DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (Gibco), 1% penicillin-
streptomycin, and 1% L-glutamine (Invitrogen). Cells were infected with either wt or 
mutant HIV and serially diluted drugs were added.  Standardization of virus infections 
was determined by adding virus at a p24 concentration that would yield ~160.000 
±20.000 relative light units (RFU) as detected by luminescence. All cultures were 
maintained at 37°C under 5% CO2 for 48 h. After 48 h, 100µl of Bright-Glo
TM
 reagent 
(Promega) was added to 100µl of infected TZM-bl cells. Drug efficacy was determined 
by quantifying luciferase activity as a measure of viral replication. RLU were detected 
with a 1450 MicroBeta TriLux microplate scintillation and luminescence counter (Perkin-
Elmer). The 50% effective concentrations (EC50s) were determined by nonlinear 
regression with GraphPad Prism (version 5.01) software. Resistance to a given drug was 
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determined based on the previously published lower clinical cutoff (CCO) of a drug 
which determines the cutoff fold change value for drug sensitivity. These values are 3.0 
for ETR, 3.4 for EFV and 2.0 for RPV [18, 31, 32]. 
 
Determination of relative replication capacity in TZM-bl cells. 
The replicative capacities of competent clonal wt and mutant HIV-1 were evaluated in a 
noncompetitive infectivity assay using TZM-bl cells [33]. Twenty thousand cells per well 
were added into a 96-well culture plate in 100µl of Dulbecco modified Eagle medium 
(DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (Gibco), 1% penicillin-
streptomycin, and 1% L-glutamine (Invitrogen). Viral stocks for both wt and mutant 
viruses were normalized by p24 and recombinant viruses were serially diluted 2-fold 
from viral stock suspensions. After 4 hours, 50µl of DMEM were removed from the wells 
and replaced by 50µl of virus dilution; a control well did not contain virus. Virus and 
cells were co-cultured for 48 hours, after which 100µl of Bright-Glo
TM
 reagent was added 
and luciferase activity was measured in a luminometer as described (Promega). Viral 
replication levels were expressed as a percentage of RLU with reference to wt virus for 
each viral variant studied. 
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Results 
Mutations selected in the presence of RPV drug pressure 
To determine the impact of baseline NNRTI mutations on the pattern of RPV resistance 
the following NNRTI mutations and combinations were introduced into wt pNL4-3 by 
site-directed mutagenesis: K103N, G190A, Y181C, E138K, and M184I/V (Table 1). All 
viral clones were passaged in the absence of drugs and genotyped at the end of each 
passage. Genotyping results revealed that all baseline mutations were maintained at the 
end of the selections, except for viral clones containing the mutations M184I, M184V and 
E138K/M184I, in which case the M184I/V mutations reverted to wt.   
 
In the wt virus, a combination of E138K and L100I was selected after 8 weeks in the 
presence of RPV (Fig 1). Continuous RPV drug pressure resulted in the emergence of 
K101E as a predominant viral variant while viruses containing the E138K and L100I 
mutations, previously selected in the dominant viral population, reverted to wt (Fig 1). At 
week 21, the E138K and L100I mutations re-emerged and predominated at week 26, 
while K101E reverted to wt. In the virus containing Y181C at baseline, only the NRTI 
multidrug resistant mutation A62A/V was selected, even when a RPV concentration of 
300 nM was attained. In viruses containing both K103N and G190A at baseline, E138K 
was the first mutation to emerge at week 12 while L100I was identified in the virus 
containing E138K at baseline (Table 1).  In the viral clones containing E138K/M184I and 
M184V, additional mutations did not develop. In contrast, clonal viruses containing 
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E138K/M184V or M184I at baseline yielded H221H/Y or M41L and I135M, 
respectively, under RPV pressure. 
 
 Mutations selected in the presence of ETR and ETR/TFV drug pressure 
The viral clones containing the mutations K103N, E138K, Y181C, M184I/V, G190A, 
K103N/Y181C, K103N/G190A, E138K/M184I and E138K/M184V as well as two 
subtype C clinical isolates (isolates 4743 and 10680) containing baseline NNRTI 
mutations were exposed to ETR or combination of ETR plus TFV for 20-30 weeks 
(Table 2). Beginning with suboptimal concentrations of ETR for 20-30 weeks in selection 
experiments, we observed distinct mutational pathways. In the subtype B (pNL4-3) wt 
clone and the subtype C wt clinical isolate, E138K/G was observed in all selections 
followed by other ETR RAMs. In contrast, subtype B viruses containing either K103N or 
G190A at baseline generated E138K/L100I and V106I, respectively, while subtype C 
viruses containing G190A developed E138K (Table 2). The clones containing either 
M184I or M184V yielded E138K while the E138K/M184I and E138K/M184V clones 
developed the V189I and V118I mutations respectively. Subtype B viruses containing 
Y181C at baseline commonly developed V179I/F but not E138 substitutions.  
 
The subtype C clinical isolate containing Y181C as a baseline mutation developed 
E138V under ETR pressure together with Y188H and V179I; K238K/N and E399G were 
also frequently observed. When the combination of K103N/G190A was present in pNL4-
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3 (subtype B) at baseline, no mutation was selected, probably because the virus 
containing these mutations was not fit and was difficult to replicate in the presence of 
suboptimal drug concentration. Subtype C clinical isolates subjected to ETR/TFV drug 
pressure developed E138 mutations but not the TFV-associated K65R mutation (Table 2).  
 
Mutations selected in the presence of EFV and EFV/TFV drug pressure 
In the case of the subtype B (pNL4-3) wt and Y181C-containing viruses, the mutations 
selected under EFV pressure were K101E/Q, K103N or Y188H. Viruses containing 
K103N generated the minor NNRTI mutations Y318F and N348I/N (see table, 
supplemental digital content 2). The subtype B pNL4-3virus containing G190A at 
baseline mostly developed V106A. However, viruses containing the combinations of 
K103N/Y181C and K103N/G190A did not select additional substitutions. In the presence 
of M184I and M184V at baseline, amino acid substitutions at position 188 were observed 
whereas viruses containing E138K/M184I or E138K/M184V developed G190A or 
E399G, respectively, under EFV drug pressure. In the clone containing E138K alone at 
baseline, the additional K103N and L100I mutations were observed (see table, 
supplemental digital content 2). 
 
Subtype C viruses that were wt or that contained G190A or Y181C at baseline selected 
V106M, followed by the accumulation of several additional mutations (see table, 
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supplemental digital content 2). The combination of EFV/TFV drug pressure did not 
select for K65R. 
 
Mutations selected in the presence of dapivirine (TMC120) drug pressure 
We also wanted to determine whether any additional mutations would develop in the 
presence of baseline mutations E138K, M184I, M184V, E138K/M184I and 
E138K/M184V under dapivirine (TMC120) drug pressure. The latter is an NNRTI that is 
structurally related to RPV and ETR and that is now undergoing evaluation as an anti-
HIV microbicide. After 20 weeks wt viruses and viruses containing M184I and M184V 
yielded E138K, while viruses containing E138K/M184I or E138K/M184V developed 
L100I and V108I respectively (see table, supplemental digital content 3).  
 
In vitro antiviral activity of NNRTIs against mutated viruses.  
The activity of the NNRTIs ETR, RPV, TMC120 and EFV were tested against pNL4-3 
clones engineered to contain E138 and Y181C mutational combinations. Table 3 shows 
that the E138A and E138K amino acid substitutions conferred low-level resistance to 
ETR, RPV and TMC120, while E138V, that was co-selected with Y181C in tissue 
culture, did not.  Y181C alone conferred a fold-change in susceptibility of 6.0, 2.3, 5.3, 
and 2.5 for ETR, RPV, TMC120 and EFV, respectively. The addition of mutations at 
position 138 to Y181C did not significantly enhance levels of resistance to ETR, RPV or 
TMC120 (Table 3). All of the combinations tested remained susceptible to EFV. 
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Impact of mutations at position 138 alone or in combination with Y181C on viral 
replication capacity (RC). 
Since E138K was not selected by ETR and RPV, when using virus that contained Y181C 
at baseline, we next wished to determine the viral replication capacity of viruses 
containing E138K and Y181C or E138 together with other mutations. For this purpose, 
TZM-bl cells were infected with serially diluted viral stocks (normalized for p24 levels 
and relative light units) of wt virus or viruses containing the E138K, E138A, Y181C, 
E138K/Y181C or E138A/Y181C mutations. The infectiousness of viral clones was 
determined by measuring luciferase activity at 48 h postinfection. The results show that 
the replication capacity of both the E138K and E138A viruses were decreased by ≈3-fold 
compared to wt, while that of Y181C virus was only slightly decreased by ≈ 1.5 fold.  
The addition of E138K or E138A to Y181C further decreased replication capacity to 
about the same level (≈3-fold) as that of viruses containing either E138K or E138A alone 
(Figure 2). 
 
Discussion 
The current in vitro study examined HIV resistance patterns following selection with 
ETR in both wt viruses as well as in viruses containing a variety of NNRTI mutations at 
baseline. We showed that E138K or E138G was selected by each of a subtype B wt or 
K103N virus,  a subtype C wt clinical isolate, and a subtype C virus containing G190A at 
baseline. However, subtype B viruses containing Y181C at baseline selected for V179I or 
V179F, but not E138K. These findings are consistent with previous in vitro data that 
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showed selection of E138K by ETR in wt viruses of multiple subtypes over 18 weeks 
[24]. In the same study, it was shown that E138K emerged first and that Y181C, together 
with V179I/F, was selected subsequently due to increased ETR pressure [24]. Possibly, 
the use of ETR in drug-naïve patients might also select for E138K, if such patients were 
to experience virologic failure. Others have also observed differences in mutational 
patterns among viral subtypes in SUPT1 cells exposed to NNRTI pressure [34]. 
 
E138K was observed following RPV drug pressure in wt subtype B viruses and viruses 
containing either K103N or G190A at baseline, while subtype B viruses containing 
Y181C at baseline did not yield E138K.  This observation is in agreement with the recent 
phase III trials (ECHO and THRIVE) in which RPV was shown to preferentially select 
for E138K in patients undergoing first-line treatment failure [21, 22]. Under RPV drug 
pressure, wt viruses developed a mixture E138K, K101, and E101, that was dominated by 
E138K at the end of the selection experiment. This could be due to the presence of 
quasispecies that existed in the viral population and suggests that K101E and E138K 
cannot exist in the same viral clone possibly due to a salt bridge that exists between these 
two amino acids. Viral clones containing M184I/V at baseline did not select for NNRTI 
mutations after exposure to RPV, as observed with ETR in a recent in vitro study [35]. 
This could be due to decreased viral fitness of both clones and difficulties in increasing 
RPV drug concentration. 
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In the DUET studies that led to the approval of ETR for use in NNRTI-experienced 
patients, only three subtype B patients who previously harbored K103N developed 
E138K and failed ETR therapy, while one patient who harbored Y181C developed 
E138V [19].  However, most ETR related mutations were at positions 138, 179 and 181 
[19]. A different study showed that 12 of 42 ETR failures who harbored mutations at 
position 181 at baseline contained at least one new NNRTI mutation but not E138K [36].  
In an in vitro selection study, using a drug of the same family (TMC120), E138K was 
selected in wt virus but not in viruses containing Y181C at baseline [37]. The present 
study, together with evidence from other studies, suggests that Y181C may be 
antagonistic to E138K. As shown here, the combination of Y181C and E138K may lead 
to a less fit virus. In our study, amino acid substitutions at position 179 were frequently 
observed in viruses containing Y181C at baseline. This pathway has also been observed 
[36, 38].  
 
The complex formed between RPV and wt RT is stable and comparable to the complex 
between RPV and K103N mutant RT. In the presence of RPV and mutant RT containing 
Y181C, there is a loss of aromatic interactions, resulting in a displacement of RPV 
further into the NNRTI pocket [39]. We believe that differences in binding interactions 
that exist between RPV or ETR and the Y181C RT mutant maybe the basis for potential 
antagonistism.  
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Although the prevalence of ≥3 ETR RAMs among viral isolates from patients 
experiencing treatment failure under EFV and NVP therapy was low, ranging from 4.6% 
to 10%, the prevalence of single ETR RAMs was high (17.4% to 35.9%) [11, 26, 40]. 
These studies concluded that there is a low prevalence of ETR resistance at baseline and 
that patients with prior failure to EFV and NVP could potentially benefit from ETR 
therapy. However, these data were obtained in developed countries in which full access to 
potent antiretroviral drugs is the norm. Now, studies in resource-limited settings have 
shown a high prevalence of many NNRTI resistance mutations associated with ETR 
resistance among patients failing EFV or NVP, putting into doubt the potential 
effectiveness of ETR and RPV in such settings [41-43].  There is concern that patients, 
who fail RPV, because of the E138K mutation, will be unlikely to derive future benefit 
from ETR. 
 
In summary, we have shown that each of ETR and RPV are likely to select for E138K as 
a major resistance mutation in tissue culture if no or very few other resistance mutations 
are present. In contrast, viruses containing an array of other common NNRTI mutations 
associated with resistance to EFV and NVP, such as Y181C, may be less likely to select 
E138K following exposure to ETR and RPV, and may develop other substitutions 
instead. In part, this may be due to diminished viral replicative capacity. These tissue 
culture observations are consistent with the clinical experience and help to explain why 
the resistance profile of ETR as a second-line drug is different from what it might have 
been if this drug were to be more commonly employed in first-line therapy. 
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Table 1: Mutations Selected by Serial Passage Experiments in CBMCs in the Presence of RPV Drug Pressure 
Virus Baseline 
Genotype  
Week 12  Week 20  Week 26 
RPV 
(nM) 
Acquired Mutations RPV 
(nM) 
Acquired Mutations RPV  
(nM) 
Acquired Mutations 
NL-4.3 wt  60 K101E/K, E138E/K 60 L100I/L, K101K/E, 
E138E/K 
40 L100I, E138K 
NL-4.3 E138K  60 V108I/V, E138K 70 L100I/L, E138K 100 L100I/L, E138K 
NL-4.3 E138K/M184I
 
60 E138K 40 E138K 90 E138K 
NL-4.3 M184I
 
20 M41L, I135M, M184I 20 M41L, I135M, 
M184I 
20 M41L, I135M, M184I 
NL-4.3 M184V ND
a 
ND 15 none NA NA
b 
NL-4.3 E138K/M184V
 
ND ND 70 H221H/Y NA NA 
NL-4.3 G190A
 
30 E138K, G190A 50 ND NA NA 
NL-4.3 K103N
 
60 K130N, E138E/K 60 L100I, K103N, 
E138K, E399E/G 
60 K103N, L100I, 
E138K, E399E/G 
NL-4.3 K103N/Y181C  20 K103N, Y181C 30 K103N, Y181C 30 K103N, Y181C 
NL-4.3 Y181C  40 Y181C 90  ND 300 A62A/V, Y181C 
Baseline mutations that persisted at time of genotypic analysis are underlined. Amino 
acid substitutions at position 184 in clones containing M184V, E138K/M184I and 
E138K/M184V reverted to wt, while the amino acid substitution in the M184I clone was 
retained in the presence of RPV. 
a
ND, not determined. 
b
NA, not applicable. 
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Table 2: Mutations Selected by ETR and ETR/TFV Drug Pressure After 20-30 Weeks.  
Virus  Baseline Genotype 
(Subtype)  
Week 20-30 
Drug (nM) Acquired Mutations 
NL-4.3a  wt (B) ETR (250) L100I, E138G, H221H/Y, A400A/T  
NL-4.3b  wt (B) ETR (200) L100I, E138K  
NL-4.3a  K103N (B)  ETR (250) L100I, K103N, I135I/T, H221H/Y, 
N348I  
NL-4.3b  K103N (B) ETR (400) V90I/V, L100I, K103N, E138E/K  
NL-4.3a  Y181C (B) ETR (20) V179I, Y181C  
NL-4.3b  Y181C (B) ETR (500) I135L, V179F, Y181C, E399G  
NL-4.3  K103N/Y181C (B) ETR (20) V90I, K103N, V179I, Y181C  
NL-4.3  K103N/G190A (B) ETR (7.5) K103N, G190A 
NL-4.3  G190A  (B) ETR (10) V90I, V106I, G190A  
NL-4.3 E138K (B) ETR (200) E138K, V189I, A400A/T 
NL-4.3 M184I (B) ETR (90) E138E/K, M230L/M 
NL-4.3 E138K/M184I (B) ETR (200) E138K, V189I 
NL-4.3 E138K/M184V (B) ETR (75) V118I, E138K, M184V 
NL-4.3 M184V (B) ETR (75) E138K 
4743  G190A (C) ETR (250) E138K, V189I/V, G190A, E399E/G  
10680  wt  (C) ETR (500) E138K, G190E/G, K238K/N  
10680  Y181C (C)  ETR (5000) E138V, V179I, Y181C, Y188H  
10680  wt  (C) ETR (50) TFV (500)  E138K  
10680  Y181C (C)  ETR (500) TFV (500) E138E/V, Y181C, K238K/N  
Genotypic analysis was done at weeks 20, 25 or 30. Baseline mutations that persisted at 
time of genotypic analysis are underlined. Amino acid substitutions at position 184 in the 
clones M184V, M184I and E138K/M184I reverted to wt, while the amino acid 
substitutions in the clone E138K/M184V were retained in the presence of ETR. 
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Table 3: In vitro antiviral activity of NNRTIs against Viruses Containing Various RAMs 
 
Virus Mean EC50 ± SD (nM)  [FC] 
 ETR RPV TMC120 EFV 
WT 1.65 ± 0.05 0.85 ± 0.07 1.25 ± 0.07 2.15 ± 0.21 
E138V 1.8 ± 0.57 [1.1] 0.75 ± 0.05 [0.9] 1.2 ± 0.14 [1.0] 1.2 ± 0.28 [0.6] 
E138K 5.4 ± 0.14 [3.3] 1.8 ± 0.1 [2.1] 3.5 ± 0.2 [2.8] 4.1 ± 0.14 [1.9] 
E138A 5.35 ± 0.35 [3.2] 2.1 ± 0.57 [2.5] 4.5 ± 0.1 [3.8] 3.8 ± 0.71 [1.7] 
Y181C 9.95 ± 0.35 [6.03] 1.95 ± 0.07 [2.3] 6.3 ± 0.85 [5.3] 5.4 ± 1.0 [2.5] 
E138V/Y181C 12 ± 2.8 [7.3] 3.1 ± 0.28 [3.6] 8.15 ± 0.21 [6.5] 4.1 ± 1.3 [1.9] 
E138K/Y181C  8.45 ± 1.5 [5.1] 1.8 ± 0.42 [2.1] 11 ± 0.42 [9.2] 2.1 ± 0.42 [1.0] 
E138A/Y181C  14.6 ± 0.42 [8.8] 2.85 ±  0.35 [3.4] 14.6 ± 0.56 [12.2] 2.25 ± 0.35 [1.0] 
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Supplemental Digital Content 1: Primers Used in Site-Directed Mutagenesis Studies for 
Amplification of Specific Mutations 
Mutation Primer 
K103N Fw 
5'-CCTGCAGGGTTAAAACAGAACAAATCAGTAACAGTACTGGA-3' 
Rev 
5'-TCCAGTACTGTTACTGATTTGTTCTGTTTTAACCCTGCAGG-3' 
Y181C Fw 
5'-CAAAATCCAGACATAGTCATCTGTCAATACATGGATGATTTG-3' 
Rev 
5'-CAAATCATCCATGTATTGACAGATGACTATGTCTGGATTTTG-3' 
G190A Fw 
5'- CATGGATGATTTGTATGTAGCATCTGACTTAGAAATAGGGC-3' 
Rev 
5'-GCCCTATTTCTAAGTCAGATGCTACATACAAATCATCCATG-3' 
E138K Fw 
5'-GCATTCACTATACCTAGTGTAAACAATAAGACACCAGGGATT-3' 
Rev 
5'-AATCCCTGGTGTCTTATTGTTTACACTAGGTATAGTGAATGC-3' 
E138A Fw 
5'-CCATACCTAGTATAAACAATGCGACACCAGGGATTAGATATC-3' 
Rev 
5'-GATATCTAATCCCTGGTGTCGCATTGTTTATACTAGGTATGG-3' 
E138V Fw 
5‟-TAGTATAAACAATGTGACACCAGGGATTAGATAT-3‟ 
Rev 
5‟-ATATCTAATCCCTGGTGTCACATTGTTTATACTA-3‟ 
M184I Fw 
5‟-CATCTATCAATACATTGATGATTTGTA-3‟ 
Rev 
5‟-TACAAATCATCAATGTATTGATAGATG-3 
M184V Fw 
5‟-CATCTATCAATACGTGGATGATTTGTA-3‟ 
Rev 
5‟-TACAAATCATCCACGTATTGATAGATG-3‟ 
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Supplemental Digital Content 2: Mutations Selected by EFV and EFV/TFV Drug Pressure After 
20-30 Weeks. 
Virus  Baseline Genotype 
(Subtype) 
Week 20-30 
Drug (nM) Acquired Mutation s 
NL-4.3
a
  wt (B) EFV (1000) K101E, V108I, V189I/V  
NL-4.3
b 
Wt (B) EFV (200) K103N, V189I/V, E399G 
NL-4.3  K103N (B)  EFV (500) K103N, Y318F, N348I/N  
NL-4.3
a
  Y181C  (B) EFV (20) V75I, K101Q, V108I, Y181C  
NL-4.3
b
  Y181C  (B) EFV (100) V75L, V106I, Y181C, Y188H, A400A/T  
NL-4.3  K103N/Y181C (B)  EFV (50) K103N, Y181C 
NL-4.3  K103N/G190A (B) EFV (10) K103N, G190A 
NL-4.3  G190A  (B) EFV (7.5) A62V, V106A, V179D/V, G190A  
NL-4.3 E138K (B) EFV  (90) L100I, K103K/N, E138K 
NL-4.3 M184I
 
(B) EFV (60) L100I/L, M184I, H188H/Y 
NL-4.3 E138K/M184I (B) EFV (90) E138K, G190A 
NL-4.3 E138K/M184V
 
(B) EFV (40) E138K, E399G 
NL-4.3 M184V
 
(B) EFV (50) Y188C/Y 
4743  G190A  (C)  EFV (1000) V106M, G190A, F227F/L, E399K  
10680  wt (C) EFV (10000) V106M, Y188C, K275R  
10680  Y181C (C)  EFV (10000) A62A/V, K101E/K, V106M, Y181C, 
F227L, L283L/V  
10680  wt (C) EFV (250) TFV 
(500)  
V106M, F227L  
10680  Y181C (C)  EFV (1000) TFV 
(1000)  
V106M, Y181C 
Genotypic analysis was done at weeks 20, 25 or 30. Baseline mutations that persisted at 
time of genotypic analysis are underlined. Amino acid substitutions at position 184 in all 
clones containing M184V, E138K/M184V and E138K/M184I reverted to wt, while 
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amino acid substitutions in the M184I clone were retained in the presence of EFV 
pressure. 
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Supplemental Digital Content 3: Mutations Selected by Serial Passage Experiments in 
CBMCs in the Presence of TMC120 Drug Pressure 
Virus Baseline 
Genotype  
Week 20 
DPV Conc (nM) Acquired Mutations 
NL-4.3 wt  100 E138K, L100I 
NL-4.3 E138K 70  L100I, E138K  
NL-4.3 E138K/M184I 200 L100I, E138K, M184I 
NL-4.3 M184I
 
80 E138K 
NL-4.3 E138K/M184V
 
90 V108I, E138K 
NL-4.3 M184V
 
70  E138K 
Baseline mutations that persisted at time of genotypic analysis are underlined. Amino 
acid substitutions at position 184 in the clones M184V, M184I and E138K/M184V 
reverted to wt, while amino acid substitutions in the E138KM184I clone were retained in 
the presence of TMC120. 
 
 
 
 
 
 
 
178 
 
 
 
Figure 1: Stepwise accumulation of RPV resistance in cell culture. The graph shows the 
time course of selection of resistant variants in CBMCs using wt virus and virus 
containing Y181C at baseline. CBMCs were infected with viruses at a low MOI of 0.1 
and cultured in the presence of progressively increasing concentrations of drugs starting 
at a concentration below the EC50. 
 
 
 
 
 
 
179 
 
 
 
 
 
 
 
 
 
 
 
180 
 
 
 
Figure 2: Effect of mutations at position 138 together with Y181C on viral replication 
capacity. Stocks of both wt and mutated viruses were normalized for p24 and used to 
infect TZM-bl cells. Luciferase activity was measured at 48 hours post-infection to 
monitor viral replication. The relative infectivity of wt virus compared to mutated viruses 
is shown on the Y-axis while the X-axis denotes input of p24.  
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Abstract 
PL-100 is a novel HIV-1 protease inhibitor (PI) that maintains activity against viruses 
that are resistant to other PIs. To further characterize this compound, we used it to select 
for drug resistance in tissue culture, using two non-B HIV-1 subtypes, viz. Subtype C and 
a CRF01_AE recombinant virus. PL-100 selected for both minor and major PI resistance 
mutations along either of two distinct pathways. One of these involved the V82A and 
L90M resistance mutations while the other involved a mutation at position T80I, with 
other mutations being observed at positions M46I/L, I54M, K55R, L76F, P81S and I85V.  
The resistance patterns in both subtype C and CRF01_AE were similar and an 
accumulation of at least three mutations in the flap and active sites were required in each 
case for high-level resistance to occur, demonstrating that PL-100 has a high genetic 
barrier against the development of drug resistance.   
 
Keywords: HIV-1 subtypes; Drug resistance; Protease inhibition; PL-100. 
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Introduction 
The protease (PR) enzyme of human immunodeficiency virus type 1 (HIV-1) is an 
excellent therapeutic target since its inhibition prevents the proteolytic processing of the 
Gag and Gag-Pol polyproteins (Ventoso et al., 2005). Protease inhibitors (PIs) are 
routinely prescribed for both treatment-naïve and experienced patients and have had a 
profound impact on HIV-associated disease progression, transmission, and morbidity and 
mortality (Palella et al., 1998).  
 
Drug resistance is a frequent complication in patients who fail therapy (Luis Jimenez et 
al., 2005; Turner et al., 2005; Descamps et al., 2009) and many studies have shown that 
drug-resistant viruses can be sexually transmitted (Brenner et al., 2008; Aghokeng et al., 
2009). The problem of drug resistance is compounded by the worldwide dissemination of 
multiple different subtypes of HIV-1 and the fact that natural polymorphisms in both 
HIV-1 and HIV-2 can affect the emergence of drug resistance to currently approved 
drugs (Kantor and Katzenstein, 2003; Stranix et al., 2004; Ntemgwa et al., 2007). 
Furthermore, polymorphisms within the PR enzyme may not themselves be responsible 
for resistance but can contribute to the development of high-level resistance if other 
mutations are present (Vergne et al., 2000; Kantor and Katzenstein, 2003; Velazquez-
Campoy et al., 2003; Liu et al., 2007; Bessong, 2008). It is therefore important to 
understand antiviral activity and drug resistance profiles in viruses of different subtypes. 
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Recently, a novel PI termed PL-100 was shown to be active against both wild-type and 
drug-resistant forms of HIV-1 of subtype B origin (Dandache et al., 2007). PL-100 is a 
lysine-based sulphonamide that was designed on the basis of subtype B PR structural data 
(Stranix et al., 2004). Although PL-100 demonstrates a high genetic barrier for the 
development of drug resistance to subtype B viruses (Dandache et al., 2008), little is 
known about the role that individual polymorphisms in some non-B subtypes might play 
in regard to the development of drug resistance (Kantor and Katzenstein, 2003; Liu et al., 
2007; Ntemgwa et al., 2007). Here we describe in vitro development of resistance and the 
antiviral properties of PL-100 against a panel of wild-type and drug resistant non-B 
viruses. As examples of non-B subtypes we used subtype C and the circulating 
recombinant form (CRF) CRF01_AE that represent the most prevalent subtype and CRF 
in circulation at this time (Hemelaar et al., 2006). 
 
Materials and Methods 
Virus isolates, cells and plasmids: 
Three HIV-1 CRF01_AE clinical isolates (NI1052, M02138 and NP1525) were obtained 
from the AIDS Research and Reference Reagent Program of the National Institutes of 
Health (NIH), Bethesda, MD.  Five HIV-1 subtype C (7208, 8032, 8947, 7906 and HB-1) 
clinical isolates were obtained with informed consent from drug-naive individuals at our 
clinics in Montreal, Canada. The CRF01_AE isolates have been previously characterized 
as X4-tropic viruses (Brown et al., 2005) while the subtype C isolates were non-
syncytium inducing viruses and considered R5 viruses. MT-2 cells were obtained from 
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the NIH AIDS Research and Reference Reagent Program. Cord blood mononuclear cells 
(CBMCs) were obtained through the Department of Obstetrics, Jewish General Hospital, 
Montreal, Canada. The AG plasmid (p97GH-AG2) was kindly provided by Dr. Masashi 
Tatsumi, National Institute of Infectious Diseases, Tokyo, Japan. 
 Drugs:  
Nelfinavir (NFV), amprenavir (APV), lopinavir (LPV), atazanavir (ATV),  PL-100 and 
saquinavir (SQV) as gifts from Pfizer, Inc. (San Diego, CA), GlaxoSmithKline (Research 
Triangle Park, NC), Abbott Laboratories (North Chicago, IL), Bristol-Myers-Squibb, 
Inc., Ambrilia Biopharma Inc, (Verdun, Quebec, CA) and Roche, Inc., respectively. 
Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, was used as a control 
drug and was obtained courtesy of BMS Inc.  
 
In vitro selection of resistance mutations in CBMCs and MT-2 cells: 
PHA-stimulated CBMCs or MT-2 cells were infected with viruses (multiplicity of 
infection of 0.1 for CBMCs and 0.01 for MT-2 cells) for 2 hours, incubated at 37ºC, and 
subsequently washed with RPMI 1640 media (Invitrogen) supplemented with 10% fetal 
bovine serum and seeded into a 24-well plate at a density of 2.5 x 105 cells per well (Gao 
et al., 1993).  Selection for resistance in CBMCs and MT-2 was performed using 
increasing concentrations of drugs (PL-100 and APV) at a starting concentration that was 
below the 50% effective concentration (EC50) of the drugs (Oliveira et al., 2009). As 
controls, all viruses were simultaneously passaged without drugs. With CBMCs, drug 
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concentrations were increased at subsequent passages based on RT levels in culture fluids 
(Loemba et al., 2002; Petrella et al., 2004). With MT-2 cells sub-culturing was performed 
every 3-4 days and the cells studied for cytopathic effect (Vingerhoets et al., 2005). 
Virus-containing culture fluids were harvested and kept at -80ºC for subsequent 
genotypic analysis at the same time that drug concentrations were increased.    
 
Nucleic acid extraction, amplification and sequencing analysis: 
Viral RNA was extracted from culture supernatants using the Qiagen QIAamp viral 
extraction kit (Mississauga, Ontario, Canada).  PCR amplification was performed using a 
previously published protocol (Virco BVBA, Mechelen, Belgium). The resulting PCR-
amplified DNA fragments were purified using the QIAquick PCR purification kit and 
products were used as templates for nucleotide sequencing analysis. Genotyping was 
performed by sequencing a 325-bp fragment of HIV pol (position 2253-2578) spanning 
the entire protease (PR) using Virco primers (Virco BVBA Mechelen, Belgium) with a 
BigDye Terminator sequencing kit (Version 1.1; Applied Biosystems, Forter City, CA) 
and automated sequencer (ABI Prism 3130 genetic analyzer; Applied Biosystems).  The 
sequence of each sample was compared to that of wild–type (wt) subtype B consensus 
virus and to data in the Stanford database. 
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Site-directed mutagenesis and virus production: 
The K55R, I85V and K55R/I85V mutations were introduced into the p97GH-AG2 
plasmid by site-directed mutagenesis (SDM) using a QuikChange II XL site-directed 
mutagenesis kit (Stratagene, LaJolla, CA).  For SDM of K55R, the forward primer 5'-
GGG GGA ATT GGA GGT TTT ATC AGG GTA AGA CAG TAT GAC CAG-3' and 
reverse primer 5'-CTG GTC ATA CTG TCT TAC CCT GAT AAA ACC TCC AAT 
TCC CCC-3' were used while for I85V the forward primer 5'-GGA CCT ACA CCT GTC 
AAC ATA GTT GGA CGA AAT ATG-3' and reverse primer 5'-CAT ATT TCG TCC 
AAC TAT GTT GAC AGG TGT AGG TCC-3' were employed. Introduction of the 
various mutations into the plasmid was confirmed by sequencing and DNA ultimately 
transformed into DH5α cells (Invitrogen) for high-yield of plasmid. 
HEK 293T cells were cultured in Dulbecco‟s modified Eagle‟s medium supplemented 
with 10% fetal bovine serum and transfected with 16µg of plasmid using lipofectamine 
2000 (Invitrogen, Carlsbad, CA) according to manufacturer‟s protocols.  Two days after 
transfection, supernatants of the transfected cells were clarified by centrifugation at 1500 
rpm for 5 min and stored in aliquots at -80°C. Virus production was confirmed by RT 
assay. 
 
Phenotypic susceptibility to PIs in CBMCs and MT-2 cells: 
Drug susceptibility was measured in cell-culture based phenotypic assays as previously 
described (Salomon et al., 1994; Loemba et al., 2002), to determine the extent to which 
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PIs (NFV, SQV, APV, LPV, ATV and PL-100) blocked HIV replication in vitro. 
Efavirenz (EFV), a non-nucleoside inhibitor of reverse transcriptase, was used as a 
control. In brief, cells were infected for 2 hours with either wt or drug selected variants, 
washed to remove unbound virus and plated in duplicates into 96 well plates containing 
drugs or not and incubated at 37ºC. For MT-2 cells, cytopathic effect was confirmed on 
day 4 or 5 and supernatants harvested for RT activity. For CBMCs, cells were fed with 
fresh media containing appropriate drug dilutions and RT assays were performed at day 
7. EC50 concentrations of PIs were determined from RT values.  
 
A preliminary cut-off value had previously been calculated for PL-100 (Dandache et al., 
2007; Dandache et al., 2008). The manner in which preliminary cut-off values are 
calculated is through access to a limited number of clinical samples that have not been 
exposed to PL-100 but that contain mutations associated with resistance against other 
members of the PI family of drugs. The EC50 values of these clinical isolates were 
measured in phenotypic assays in regard to PL-100 and mean fold changes ± 2 standard 
deviations in EC50 in comparison with laboratory wild-type viruses were calculated. The 
mean fold-change ±2 standard deviation corresponds to the preliminary biological cut-off 
value. 
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Results 
Selection of resistance mutations to PL-100 and APV in MT-2 cells: 
Polymorphisms are defined as naturally occurring amino acid variations from the subtype 
B consensus sequence (HXB2) that is present in the Los Alamos HIV database 
(http://www.hiv.lanl.gov). Three CRF01_AE viruses (NI1052, M02138 and NP1525) 
were used for selection in MT-2 cells (Table 1). Polymorphisms at positions I13V, E35D, 
M36I, R41K, H69K and L89M were present in all three CRF01_AE isolates. In addition, 
K20R and R57K were also present in the M02138 and NI1052 viruses, respectively 
(Table 1). Some of these polymorphisms are known to contribute to drug resistance for 
certain PIs (Kantor and Katzenstein, 2003).  
 
In MT-2 cells, mutations emerged through the V82A pathway in the CRF01_AE isolates. 
The novel mutation K45I was observed with one A/E isolate and this mutation persisted 
until the end of the selection experiments. The L76F mutation emerged in one A/E isolate 
between weeks 35 and 66. This mutation was accompanied by other mutations known to 
be associated with resistance to PIs (Table 1). None of the mutations selected by PL-100 
by passage 16 or 17 with isolate M02138 persisted with the exception of L10I. Two 
additional major PI mutations, L33F and I50V, were selected by APV but not by PL-100.  
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Genotypic analysis and selection of resistance mutations to PL-100 in CBMCs: 
Five subtype C clinical isolates were used for selection in CBMCs with each containing 
6-9 polymorphisms at baseline (Table 2). After selection, all viruses passaged without 
drugs (controls) were sequenced to confirm the absence of new mutations. The results 
show that two distinct resistance pathways seem to be associated with PL-100 in subtype 
C in tissue culture drug selection. One pathway consists of active site mutations at either 
positions 82 and 90 or at both positions, and an alternate pathway, unique to PL-100, 
utilized a novel active site mutation at position 80 (Tables 2). The T80I mutation 
occurred with additional changes at active sites 85 and 89 (Table 2). Flap mutations, most 
often at position 46, accompanied both of these pathway options.   
Incidence of mutations selected with PL-100 in CBMC s and MT-2 cells: 
For both subtypes, mutations at positions 46 and 82 were the most prevalent, both being 
observed in 6 of 8 cases (Fig. 1). This was followed by the combinations of M46L/I 
together with V82A in 3 of 8 cases. The T80I mutation or the combination M46L/I + 
T80I were present in 2 of 8 cases. The L90M or V82A + L90M or M46L/I + V82A + 
L90M were each found in one of 8 cases. In addition, the simultaneous presence of 
mutations at positions 46 and 82 was common in all subtypes. The novel T80I mutation 
was always found together with a change at position 46. With the exception of T80I, all 
of the other mutations described have frequently been observed in patients who have 
failed a variety of regimes containing PI drugs. 
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In vitro phenotypic susceptibility in MT-2 cells: 
We next evaluated the in vitro susceptibilities of selected viruses, site-directed mutants, 
and wt viruses by measuring EC50s of several PIs in a cell-based phenotypic assay. In 
each case, a wt isolate was used as a reference for the drug susceptibility assays and PL-
100-resistant variants were compared with their respective wt isolates to calculate fold-
change (FC) for resistance. A lower biological cut-off of 2.5 for PL-100 (arbitrarily 
chosen cut-off value for this analysis pending clinical availability of the drug) was used. 
Lower and upper clinical cut-offs were established as 1.2-9.4 for NFV, 1.5-19.5 for APV, 
6.1-51.2 for LPV, 2.5-32.5 for ATV 3.1-22.6 for SQV and 3.4 for EFV (Van Houtte et 
al., 2009; Winters et al., 2009). As shown in Table 3, all of the selected variants displayed 
cross-resistance to NFV, APV and ATV with the exception of the CRF01_AE isolate 
(NP1525) containing mutations M46L/K70R/Q92L that confers only moderate resistance 
to NFV and APV but retained susceptibility to ATV.   With one CRF01_AE isolate 
(M02138), the mutations L10I, K55R, I85V and Q92H were observed by passage 17. 
This isolate displayed fold changes in drug susceptibility of 8.5, 6.82 and 3.34 for ATV, 
APV and PL-100, respectively and was susceptible to LPV and NFV (Table 3). To 
further confirm the biological relevance of the K55R and I85V mutations, site-directed 
mutants were created in a CRF02_AG plasmid. A very modest reduction in NFV 
susceptibility (1.9 fold) was seen with I85V (data not shown). Neither of these mutations 
affected susceptibility to other PIs since the FC in each case was less than the relevant 
clinical or biological cut-offs. No significant differences were observed when the panel of 
protease inhibitors was used against the combination K55R/I85V mutation (data not 
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shown). In the case of clinical isolate NP1525, selection with PL-100 did not result in 
obvious drug resistance. 
 
 Phenotypic susceptibility in CBMCs: 
 Despite the presence of resistance mutations, all viral isolates retained susceptibility to 
SQV. All selected viruses showed decreased susceptibility to PL-100. Low and moderate 
level cross-resistance was observed in NFV, APV, LPV and ATV with higher level 
resistance being displayed against both NFV and APV (Table 4). The combination 
M46I/T74S/T80I/V82/I85IV/L89M (isolate 8032) possessed a FC of 20.8 for PL-100 and 
a FC of 28.7 and 10.2 for APV and ATV respectively. This isolate was susceptible to 
LPV. The other two isolates with the combinations M46I/V82A/L90M and 
K43N/M46I/T80I/I85V/L89I were resistant to all PIs tested except SQV.  
 
Discussion 
In this study, we show that resistance to PL-100 can emerge via mutations at positions 82 
and 90 or alternatively via a T80I substitution that appears to be unique to this drug. We 
demonstrate the possible role of mutations L76F, K55R and I85V. Although viruses 
containing K55R, I85V, or K55R/I85V are susceptible to PL-100, Table 3 indicates that 
viruses containing the mutations selected at passage 17 (i.e. L10I, K55R, I85V, Q92H) 
showed a 3.3 decrease in susceptibility to PL-100. This might have resulted from 
combinations of mutations together with secondary PI mutations such as L10I. The K55R 
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and I85V substitutions might be considered to be secondary PI mutations. The NP1525 
variant selected by PL-100 was susceptible to PL-100 with a fold-change of 1.45. Thus 
our data confirm that PL-100 possess a very high genetic barrier for development of drug 
resistance.  
The most common mutations selected by PL-100 were at positions 46, 82, 90 and 80 in 
decreasing order of frequency. Although T80I appears to be novel, M46I/L, V82A and 
L90M  have been described in patients failing SQV, NFV, APV, LPV and ATV 
(Marcelin et al., 2004a; Marcelin et al., 2004b; Mo et al., 2005; Svedhem et al., 2005; 
Doualla-Bell et al., 2006; Santoro et al., 2009). While the T80I mutation seems to be 
important, resistance can also occur along a second pathway that is common to other PIs 
that includes the V82A and L90M mutations.  These two pathways appear to be mutually 
exclusive in all cases. This study demonstrates the importance of using a wide range of 
viral isolates in drug selection to ensure that the potential for manifestation of a broad 
array of mutations is fully explored.   
 
We observed similar patterns of resistance to PL-100 with both subtype C and 
CRF01_AE viruses. A recent in vitro selection study showed  that resistance may  
develop slower under PL-100 compared with APV drug pressure in the case of the 
laboratory-adapted HIV/IIIb  (subtype B) virus and that a unique T80I resistance pathway 
is involved (Dandache et al., 2008). The importance of this pathway is confirmed in the 
present study.   
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Our data follow a previous investigation that also identified a L76F mutation in PR (Bold 
et al., 1998). The role of L76F in PI resistance is yet to be explored. Mutations K55R and 
I85V were transiently present during PL-100 selection and have been previously 
observed in cases of PI failure (Svicher et al., 2005; Johnson et al., 2008; Margerison et 
al., 2008; Descamps et al., 2009; Palma et al., 2009). Site-directed mutagenesis 
demonstrated, however, that these mutations were susceptible to PL-100 but only 
impacted moderately on PL-100 susceptibility in the presence of other mutations.  K55R 
and I85V are thought to be able to restore viral replicative capacity (Margerison et al., 
2008). Although previous studies with site-directed mutagenesis in the presence of M46I 
and T80I in an NL4-3 plasmid showed no effect on susceptibility to PL-100 (Dandache et 
al., 2008) additional experiments are ongoing in our laboratory to study the role of these 
mutations including L76F and V82A either alone or in combinations on susceptibility to 
PL-100 and replication capacity using the NL4-3 and AG plasmids.   
 
The genotype of virus 7208 is M46I, V82A and L90M. These are major mutations that 
decrease susceptibility to saquinavir. The mean fold-change observed in two independent 
experiments in our phenotypic assay indicated susceptibility to saquinavir. Phenotypic 
resistance might be of greater value than genotypic data to predict outcome of resistance 
in some cases.   In support of our findings, Piketty et al, (Piketty et al., 1999), showed 
that patients with baseline mutations at position 46, 82 and 90 had a decreased viral load 
of fewer than 50 copies/ml after 24 weeks of r/saquinavir therapy. In both MT-2 cells and 
CBMCs, levels of cross-resistance after selection with PL-100 followed a consistent 
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pattern. First, both NFV and APV were significantly affected by the mutations selected 
by PL-100. Second, LPV and ATV were only partially affected by these mutations 
because the fold-change is just slightly above the lower clinical cut-off  and SQV seemed 
to retain significant activity against viruses that were resistant to PL-100 since the fold-
change of the selected viruses did not reach the lower clinical cut-off value. The fact that 
PL-100 has a distinct resistance profile from other PIs suggests that it might potentially 
be sequenced with ATV and LPV. Given its overall profile, PL-100 could very well be 
placed as a first line or second-line therapy for protease-naïve or experienced patients and 
be a valuable new addition to the HIV drug armamentarium.   
Conclusion: 
Ultimately, similar patterns of resistance to PL-100 seem to exist in both subtype C and 
CRF01_AE, despite important differences in baseline polymorphisms among these 
viruses. High level resistance to PL-100 was observed only in the presence of three or 
more PI resistance mutations demonstrating the high genetic barrier of this compound. 
Our observations have also confirmed the importance of a signature T80I mutation that is 
involved in PL-100 resistance. 
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Table 1 
Development of resistance mutations to PL-100 and APV in MT-2 cells. 
 
 CRF01_AE 
Drug Passage NI1052 M02138 NP1525 
 0 I13V, E35D, M36I, 
R41K, R57K, H69K, 
L89M 
I13V, K20R, E35D, 
M36I, R41K, H69K, 
L89M 
I13V, E35D, M36I, 
R41K, H69K, L89M 
PL-100 15-17 K43L, K45T, L63V L10I, K55R, I85V, 
Q92H 
K14R, P79H 
 24-30 M46I, V82A L10I M46L, K70R 
 35-66 L10I, M46I, L76F, 
V82A 
L10I, K45I, I62V, V82A M46L, K70R, Q92L 
APV 45-66 L10F, L33F, M46L, 
I93V 
ND
a 
L10F, I15V, Q18E, 
L19M, K20R, M46L, 
150V, I62V, L63S, 
C67Y, L89I 
 
a 
ND, not determined 
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Table 2 
Baseline polymorphisms and resistance mutations associated with subtype C viruses in CBMCs 
 Week 7208 8032 8947 7906 HB-1 
Baseline 
Polymorphisms 
0 T12S, I15V, L19I, E35D, 
M36I, R41K, L63P, H69K, 
I93L 
I15V, L19T, M36I, 
N37N/K, R41K/N, L63P, 
H69K, K70K/R, I93L 
L14R, I15V, L19I, 
M36I, R41K, H69K, 
I93L 
I15V, L19I, M36L, 
R41K, H69K, 
L89M 
T12S, L19I, M36I/L, 
R41K, I62I/V, L63P, 
H69KL89MI93L 
PL-100 selected 
mutations 
31 ND
a 
M46M/I, T74S, T80I, 
L89M 
I64V, V82A ND
a 
ND
a 
PL-100 selected 
mutations 
40 M46I, V82A, L90M M46I, T74S, T80I, V82I, 
I85I/V, L89M 
I13I/V, I64V, V82A K43N, M46L, T80I, 
I85V, L89I 
L10R, M46L, V82A 
 
a 
ND, not determined 
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Table 3:  
In vitro efficacy in MT-2 cells of various ARVs against CRF01_A/E viruses containing relevant PI resistance mutations. 
  
Viral isolate Subtype PI mutation Mean EC50 (nM) ± SD
a
 and  Fold Change (FC) 
 NFV APV LPV ATV PL-100 EFV 
Lower and upper clinical cut-offs
b 
1.2-9.4 1.5-19.5 6.1-51.2 2.5-32.5 2.5
c
 3.4 
NI1052 A/E wt 16.5 ± 2 15.0 ± 3 10.1 ± 2 4.0 ± 0.2 9.0 ± 1.8 3.1 ± 0.3 
NI1052 A/E L10I, M46I, L76F, 
V82A 
35.5 ± 7 (2.1) 55.0 ± 3.2 
(3.7) 
82.0 ± 6 (8.1) 15.0 ± 2 (3.7) 262.0 ± 2 
(29.1) 
6.2 ± 0.1 (2.0) 
M02138 A/E wt 18.5 ± 0.7  4.7 ± 0.67 2.95 ± 0.3 0.46 ± 0.03 9.03 ± 2 2.9 ± 0.7 
M02138 (P 
17)
d 
A/E L10I, K55R, I85V, 
Q92H 
36.0 ± 6 
(1.94) 
32.7 ± 3 (6.9) 5.5 ±  2 (1.86) 3.9 ± 0.3 
(8.5) 
30.1 ± 1 (3.3) ND 
M02138 A/E L10I, K45I, I62V, 
V82A 
81 ± 12 (4.5) 120.0 ± 40 
(25.5) 
95.5 ± 0.0.7 
(32) 
19.0 ± 1.4 
(41) 
289.0 ± 4 (32) 2.5 ± 0.6 (0.86) 
NP1525 A/E wt 15.0 ± 4 10.2 ± 1.7 6.0 ± 2 3.0 ± 0.7 11.0 ± 0.7  2.4 ± 0.1 
NP1525 A/E M46L, K70R, Q92L
 
19.0 ± 5 (1.3) 49.4 ± 1 (4.8) 11.0 ± 1.1 
(1.8) 
4.0 ± 2 (1.3) 16.3 ± 6 (1.45) 2.8 ± 0.2 (1.2) 
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The values represent the means of two independent experiments, each performed in duplicates.  Drug susceptibility was expressed as 
fold-change in EC50, determined by calculating the ratio of EC50 value for mutated and wt virus. (Values in parentheses). 
b (Van Houtte et al., 2009) and (Winters et al., 2009). 
c Arbitrarily chosen  lower cut-off value of PL-100 for this analysis pending availability of clinical data.  
d M02138 isolate containing resistance mutations selected at passage 17. 
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a
 The values represents the means of two independent experiments, each performed in duplicates.  Drug susceptibility was expressed 
as fold-change in EC50, determined by calculating the ratio of mutant EC50: wild-type EC50.  (values in parentheses). 
 
Table 4 
In vitro efficacy in CBMCs of various ARVs against subtype C viruses containing relevant PI resistance mutations. 
Viral 
Isolate 
Subtype PI mutation(s) Mean EC50 (nM) ± SD
a and  Fold-Change (FC) 
 NFV APV LPV ATV PL-100 SQV EFV 
7208 C Wt 13.0 ± 7.0 12.6 ± 0.1 11.2 ± 3.7 2.4 ± 0.5 9.2 ± 0.5 40.8 ± 0.6 0.31 ± 0.16 
7208 C M46I, V82A, 
L90M 
222.8 ± 20 
(17.1) 
27.3 ± 23 (2.2) 98.6 ± 15 (8.8) 
 
16.4 ± 12 (6.8) 
 
168.8 ± 21 18.4) 
 
31.0 ± 3.0 (0.8) 0.03 ± 0.01 (0.1) 
7906 C Wt 2.8 ± 0.1 5.1 ± 1.1 1.5 ± 1.0 1.5 ± 1.0 2.2 ± 0.5 15.0 ± 2.0 1.28 ± 0.4 
7906 C K43N, M46L, 
T80I, I85V, L89I 
11.9 ± 2.5 (4.3) 
 
173 ± 15.8 (34.6) 
 
20.8 ± 7.0 (13.9) 14.1 ± 10 (9.4) 
 
129.3 ± 54 (58.8) 22.5 ± 1.0 (0.9) 1.1 ± 0.1 (0.9) 
8032  C Wt 14.7 ± 1.0 39.0 ± 5.0 19.1 ± 19 6.7 ± 0.7 22.2 ± 2.0 46.7 ± 28  0.99 ± 0.08 
8032  C M46I, T74S, T80I, 
V82L, I85IV, 
L89M 
33.0 ±  19 (2.3) 
 
1120 ± 327 (28.7) 
 
34.5 ± 3.0 (1.8) 
 
68.0 ± 8.0 (10.2) 
 
460.8 ± 121 
(20.8) 
22.9 ± 9.8 (0.5) 
 
0.51 ± 0.21 (0.5) 
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FIG1: Frequencies of mutations most commonly selected with PL-100. M46L/I and T82A were the most prevalent, being observed in 
6 of 8 cases each, followed by the combinations M46L/I + V82A  in 3 of 8 cases,  T80I and the combination M46L/I + T80I in 2 of 8 
cases and L90M, V82A + L90M and M46L/I + V82A + L90M  in 1 of 8 cases each. 
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Abstract 
Objectives: HIV-1 protease inhibitors (PIs) are key components of HIV therapy. PL-100 
is a novel lysine sulphonamide that demonstrates potent antiviral activity against multi-
resistant HIV-1 strains as well as a higher genetic barrier for development of resistance 
mutations compared to first generation PIs. In the present study, we compared the 
antiviral activity of PL-100 against HIV-1 subtype B to that of darunavir. 
Method: We used tissue culture experiments to evaluate the in vitro development of 
resistance to PL-100 and tested the antiviral activity of several clinically approved PIs 
against PL-100 selected resistant variants. Structural modeling was also used to compare 
the binding of PL-100 and darunavir to the HIV-1 protease (PR) enzyme. 
Results: PL-100 resistant variants that emerged within 8-48 weeks showed low- to high-
level resistance (3.5 to 21.6 fold) to PL-100 but commonly retained susceptibility to 
darunavir, which, in contrast, did not select for resistance mutations over a period of 40 
weeks. Structural modeling demonstrated that binding of PL-100 was predominantly 
based on polar interactions and delocalised hydrophobic interactions through its diphenyl 
groups while darunavir has numerous interactions with PR that include hydrogen bonding 
to PR backbone oxygens at amino acid positions A28, D29 and D30 via di-
tetrahydrofuran (di-THF) groups.  
Conclusion: Hydrogen bonding contacts and the di-THF group in darunavir, as well as 
the hydrophobic nature of PL-100, contributes to PI binding and a high genetic barrier for 
resistance. Redesigning the structure of PL-100 to include a di-THF group might improve 
it.  
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 Introduction 
HIV protease inhibitors (PIs) are an important component of highly active antiretroviral 
therapy (HAART) (reviewed in).
1
 However, the success of HIV treatment is hampered by 
the emergence of drug resistance 
2, 3
 and newer PIs with improved pharmacological 
profiles are needed. Various strategies including structure-based drug design have been 
used to develop new protease inhibitors (PIs) 
4, 5
 and one such strategy maximizes the 
number of hydrogen bonds between a PI and the HIV-1 protease (PR) backbone, leading 
to activity against drug-resistant HIV. 
4, 6
 PIs with improved resistance profiles have also 
been developed using a solvent-anchoring approach 
7
 and a novel lysine sulphonamide-
based molecular core. 
8, 9
 A survey of five PIs that quantitatively evaluated amounts of 
bound inhibitor outside the substrate envelope concluded that the exterior volume of the 
inhibitors correlated with a loss of affinity to mutant PR enzyme. 
10
 Darunavir is a highly 
efficient PI that is effective against many HIV variants that are resistant to other PIs 
11, 12
.  
This is attributed to its high binding affinity for PR and the fact that darunavir binds 
tightly within the substrate envelope. 
13
 
 
However, other PIs are needed and PL-100 is a novel lysine-based sulphonamide PI that 
is potent, specific, and non-toxic, which was designed on the basis of structural data 
obtained for wild-type (wt) protease variants of HIV-1 group M, subtype B. 
14
 PL-100 
has a favorable resistance profile and is active against many HIV variants that are 
resistant to other PIs. It is active against multiple HIV subtypes and requires an 
accumulation of at least three mutations in the flap region and active site of PR in order 
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for resistance to PL-100 to occur. 
15-17
 In the present study, we have determined the 
mutational profile, antiviral activity, and structural binding of PL-100 compared to that of 
darunavir in HIV-1 subtype B.  
 
Materials and Methods 
Virus isolates and cells: 
Seven HIV-1 subtype B (5269, 5323, 5331, 5346, 5512, BK132, 5326) clinical isolates 
were obtained with informed consent from drug-naive individuals at our clinics in 
Montreal, Canada. MT-2 cells were obtained from the NIH AIDS Research and 
Reference Reagent Program. Cord blood mononuclear cells (CBMCs) were obtained 
through the Department of Obstetrics, Jewish General Hospital, Montreal, Canada. 
 
Drugs:  
Nelfinavir , amprenavir, lopinavir, atazanavir,  PL-100, saquinavir, and darunavir were 
gifts from Pfizer, Inc. (San Diego, CA), GlaxoSmithKline (Research Triangle Park, NC), 
Abbott Laboratories (North Chicago, IL), Bristol-Myers Squibb, Inc., Ambrilia 
Biopharma Inc, (Verdun, Quebec, Canada), Roche, Inc., and Tibotec respectively. 
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In vitro selection of resistance mutations in CBMCs and MT-2 cells: 
In vitro passage experiments were performed in the presence or absence of drug (PL-100, 
amprenavir and darunavir) as described previously. 
17
 Virus-containing culture fluids 
were harvested and kept at -80ºC for subsequent genotypic analysis at the same time that 
drug concentrations were increased.    
 
Nucleic acid extraction, amplification and sequencing analysis:  
Viral RNA was extracted from culture supernatants using the Qiagen QIAamp viral 
extraction kit (Mississauga, Ontario, Canada). PCR amplification was performed 
according to a previously published protocol (Virco BVBA, Mechelen, Belgium). The 
resulting PCR-amplified DNA fragments were purified using the QIAquick PCR 
purification kit and products were used as templates for nucleotide sequencing analysis. 
Genotyping was performed by sequencing a 325 bp fragment of HIV pol (positions 2253-
2578) spanning the entire protease (PR) using Virco primers (Virco BVBA, Mechelen, 
Belgium) with a BigDye Terminator sequencing kit (version 1.1; Applied Biosystems, 
Forter City, CA) and automated sequencer (ABI Prism 3130 genetic analyzer; Applied 
Biosystems). The sequence of each sample was compared with that of the wt subtype B 
consensus virus and to data in the Stanford database 
(http://sierra2.stanford.edu/sierra/servlet/JSierra?action=sequenceInput). 
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Phenotypic susceptibility to PIs in CBMCs and MT-2 cells: 
Antiviral activity was measured in cell culture-based phenotypic assays to determine the 
susceptibility of HIV-1 to different PIs (nelfinavir, sequinavir, amprenavir, lopinavir, 
atazanavir, darunavir and PL-100), as described elsewhere. 
18
 Briefly, cells were infected 
for 2 hours with either wt or drug- selected variants, washed to remove unbound virus 
and plated in duplicate into 96-well plates in the presence or absence of drug and 
incubated at 37ºC.  For MT-2 cells, a cytopathic effect was confirmed on day 4 or 5 and 
supernatants harvested for reverse transcriptase (RT) activity. For CBMCs, cells were fed 
with fresh medium containing appropriate drug dilutions and RT assays were performed 
on day 7. The 50% effective concentration (EC50) of PIs was determined from RT values. 
The preliminary clinical cut off of PL-100 has been described elsewhere. 
15
  
 
Simulation of drug docking 
The isomeric SMILES description for PL-100 was obtained from the two-dimensional 
(2D) structure of PL-100 available on PubChem Compound (CID: 513956) and used to 
generate a three-dimensional (3D) structure using the program AVOGADRO version 
1.0.3. 
19
 The same program was used to perform geometric optimization of unbound PL-
100 with 500 steps of steepest descent using the MMFF94 force field. 
20
 PubChem 
Compound was also the source of 3D structures for darunavir (CID: 213039) and a 
different PI, amprenavir (CID: 65016). All ligands were prepared as flexible docking 
ligands in AutoDock tools. 
21
 The protein databank (PDB) structures of wt protease 
4DQB 
22
 and multi-drug resistant (MDR) protease (D25N, M36V, I84V) 1RPI 
23
 were 
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prepared for docking by removal of cocrystallized ligands. Water molecules were 
retained for the subsequent docking simulations. The protein files were prepared as 
receptors using AutoDock tools. Each ligand was docked into the central cavity of the 
protease dimer using a grid cube measuring 20Å in each of the x, y and z directions in 
AutoDock Vina 
24
. Docking was repeated using DockingServer, 
25
 which uses Autodock 
4 docking parameters and using the Lamarckian genetic algorithm (LGA) and the Solis & 
Wets local search method. 
21
 The Initial position, orientation and torsions of the ligand 
molecules were set randomly. All rotatable torsions were released during docking. Each 
docking study was derived from 10 different runs that were set to terminate after a 
maximum of 250000 energy evaluations. The population size was set to 150. During the 
search, a translational step of 0.2 Å was used and quaternion and torsion steps of 5 were 
applied. A third set of dockings was carried out using SwissDock, 
26
 an online server that 
docks ligands to proteins using EADock DSS docking software and analyzes poses by 
CHARMM c35b1 FACTS. 
27
 In all cases, the top-ranked results are considered. The 
molecular graphics programs UCSF Chimera 1.5.3 
28
 and PyMol 
23
 were used for image 
analysis and processing. 
 
Results: 
Development of resistance mutations to PL-100, APV and DRV in CBMCs and MT-
2 cells. 
To further investigate the unique mutational pathway of PL-100
16
, the wt subtype B clone 
HIV-1/IIIB was selected for drug resistance in CBMCs with both PL-100 and amprenavir 
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for 48 weeks. Genotypic analysis confirmed the unique resistance pathway of PL-100, 
such that a novel T80I mutation appeared first followed by M46I and P81S. A novel 
K45R change was found in one of the isolates; this mutation has also been observed in 
patients receiving atazanavir. 
29
 Accumulation of multiple mutations under PL-100 drug 
pressure in culture was delayed compared to the selections with amprenavir, against 
which multiple mutations appeared quickly (Table 1).  
 
Five subtype B clinical isolates that contained six or fewer polymorphisms were also 
used in selections in CBMCs (Table 2). All viruses passaged in the absence of drug 
(controls) were sequenced to confirm the absence of any additional mutations. The results 
show that two distinct resistance pathways are associated with PL-100, one of which 
involves the T80I mutation while the other involves mutations at either positions 82 and 
90 or both (Table 2).   
 
Two subtype B clinical isolates (BK132 and 5326) were used for selection in MT-2 cells 
(Table 2). At baseline, BK132 displayed polymorphisms at positions I64V, V77I and 
I93L while isolate 5326 harbored polymorphisms at positions E35D, M36I, R41K, L63P, 
and H69Q. Tissue culture selection with PL-100 yielded the PR mutations R41K/R, 
M46L, L63P, V82A, L90M in isolate BK132 and L10I, N37S, K45I/K, I54M in isolate 
5326 (Table 2).  
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We also selected for darunavir resistance using two clinical isolates, 5331 and 5346, in 
CBMCs. After 40 weeks of passage using darunavir concentrations of 0.025 µM and 
0.03µM for 5331 and 5346, respectively, no mutations in PR were revealed by genotypic 
analysis.   
 
Phenotypic susceptibility in CBMCs 
All viruses selected in tissue culture were tested for susceptibility to PIs. Lower and 
upper clinical cut-offs for resistance of approved PIs were previously established as 1.2-
9.4 for nelfinavir, 1.5-19.5 for amprenavir, 6.1-51.2 for lopinavir, 2.5-32.5 for atazanavir, 
3.1-22.6 for saquinavir  and 10-106.9 for darunavir. 
30
  The in vitro antiviral activity of 
relevant PIs against various PL-100 selected variants was tested in CBMCs at weeks 8, 
20, 25 and 48 (Table 3).  All viruses containing mutations conferred low- to high-level 
resistance to PL-100, but retained susceptibility to nelfinavir, lopinavir, saquinavir and 
darunavir (Table 3). The viruses selected after 8 and 25 weeks were susceptible to 
atazanavir while those selected after weeks 20 and 48 showed a 2.9- and 2.4-fold 
decreased susceptibility, respectively, to atazanavir. Susceptibility to amprenavir was 
decreased by 6.5 and 3.3 fold in the case of variants selected at weeks 20 and 25, 
respectively, but full activity was retained with viruses selected at weeks 8 and 48.  
 
One subtype B clinical isolate (5331) containing PL-100  mutations selected in CBMCs 
as well as two additional subtype B clinical isolates (BK132 and 5326) containing PL-
220 
 
 
 
100  mutations selected in MT-2 cells were phenotypically evaluated for PL-100 drug 
susceptibility (Table 4). In CBMCs, the 5331 isolate was highly resistant to PL-100 
compared to other PIs (Table 4). In MT-2 cells, isolates BK132 and 5326 were resistant 
to all PIs tested except for darunavir, with FCs being above the lower clinical cut-off 
(Table 4). Viruses containing the T80I mutation displayed only low-level resistance to 
the other PIs, while viruses containing V82A and L90M conferred high-level cross-
resistance against these drugs (Tables 3 and 4). 
 
Structural Modeling of APV, PL-100 and DRV 
We used available crystal structures in the protein databases, PDB ID: 4DQB 
22
 and PDB 
ID: 1RPI, to try to understand drug-PR interactions and the effect of mutations in the 
binding pocket on drug binding. 
31
 The multi drug resistant (MDR) protease displays an 
enlarged drug-binding domain relative to wt PR (Figure 1). 
 
Using three independent approaches, three drugs (darunavir, amprenavir and PL-100) 
were docked into the wt structure (Figure 2a-c and Figure 3a-d) and into the MDR 
protease (Figure 4a-d). Our docking results show that darunavir has numerous 
interactions with PR (Figure 3b and d), including hydrogen bonding to the backbone 
oxygens of A28, D29 and D30 via its di-tetrahydrofuran (di-THF) groups (Figure 2b). 
Amprenavir binds mainly by hydrogen binding interactions with the backbone oxygens 
of D30 (Figure 2c). The binding of PL-100 was predominantly based on polar 
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interactions and delocalised hydrophobic interactions (Figure 2a and Figure 3a and d). 
All three inhibitors bind in the same region (Figure 2a-c) utilizing similar residues 
through different interactions (Figure 3a-d). Identified PL-100 mutations all affect the 
hydrophobicity of the pocket but do not specifically alter the binding of the inhibitor core 
to protease. Docking of all drugs to MDR protease resulted in different docked 
conformations with severely reduced binding, indicating low reliability of binding when 
the D25 and V84 mutations were present (Figure 4a-d). The diphenyl group of PL-100 is 
flexible around its chiral center and can adjust for changes in hydrophobicity fairly easily 
without losing its core contacts with I51 and D30. 
 
Discussion 
Although newer PIs, such as darunavir, have significantly improved response rates in 
patients with multiple drug resistance, there is still a need for robust new PIs with better 
pharmacokinetic and tolerability profiles. We previously showed that resistance to PL-
100 in non-B HIV-1 subtypes can emerge via mutations at positions 82 and 90 or, 
alternatively, via a T80I substitution that appears to be unique to this drug. 
17
  
The present data demonstrate that resistance-conferring mutations were rapidly selected 
in viruses passaged in the presence of PL-100, which apparently has a lower barrier for 
drug resistance than darunavir, for which no resistance mutations were selected over 40 
weeks.  The high genetic barrier and delayed accumulation of darunavir resistance 
mutations has also been observed by others. 
32, 33
 Viruses selected under PL-100 drug 
pressure showed low to high resistance to PL-100 but retained susceptibility to darunavir 
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and saquinavir. PL-100 selected for mutations at positions R41K/R, M46L, L63P, V82A 
and L90M in isolate BK132, and L10I, N37S, K45I/K and I54M in isolate 5326.  These 
mutations caused only a slight increase in the fold change (FC) for darunavir.   
 
Dimerization of HIV protease subunits is an essential process in the proteolytic activity 
of HIV protease. 
34, 35
 Darunavir can inhibit PR dimerization in vitro in addition to 
blocking PR activity, and this may contribute to its activity against multiple PI-resistant 
isolates. 
36
 
Resistance mutations typically reduce the binding affinity of the inhibitor. 
37
 In the case 
of protease, more than one resistance mutation is usually needed for resistance to occur 
(Figure 1). In the case of amprenavir, the hydrogen bonding of amprenavir to the 
backbone of D30 is important, 
4
 while the THF ring of darunavir may increase its number 
of backbone interactions. 
4
 Here we have shown that darunavir has a superior resistance 
profile to PL-100 and attribute this to its binding to the A28, D29 and D30 backbone via 
its di-THF groups (Figure 2a-c). In contrast, PL-100 has diphenyl groups that bind 
through delocalised hydrophobic interactions. Thus, hydrogen bonding contacts and the 
presence of the di-THF group in darunavir, as well as the hydrophobic nature of PL-100, 
are all important factors in drug binding. A high genetic barrier for drug resistance should 
be important in the design of new PIs. Redesigning the structure of PL-100 to include a 
di-THF group might improve its binding and antiviral activity.  
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NA, Not applicable. 
a
Two wells of IIIB virus were passaged at week 25 in the presence of different concentrations of amprenavir (2.5 and 5.0 uM).  
b
Two wells of IIIB virus were passaged at week 25 in the presence of different concentrations of PL-100 (1.0 and 2.5 uM). 
 
 
 
Table 1: Order of appearance of resistance mutations in HIV-1/IIIB following selection with PL-100 and Amprenavir in CBMCs 
Week PL-100 (µM) Selected mutations Week Amprenavir 
(µM) 
Selected mutations 
8 0.1 T80I 15 2.5 L10F, I84V, Q92K 
15 1.0 T80I 20 2.5 Not done  
18 1.0 T80I 25
a 
2.5 Not done  
20 1.0 M46I/M, T80I 25 5.0 L10F, M46I, I84V, Q92K 
25
b 
1.0 K45K/R, M46I, T80I, P81S 34 5.0 L10F, M46I, I84V, Q92K 
25 2.5 K45R, M46I, T80I, P81S 48 5.0 L10F, M46I, I84V, Q92K 
34 5.0 K45R, M46I, T80I, P81S NA
 
  
48 5.0 K45R, M46I, T80I, P81S NA   
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Table 2: Baseline polymorphisms and resistance mutations observed upon passage with PL-100 in subtype B viruses 
Virus Baseline polymorphism (WT) mutations selected in CBMCs
a 
Week/Passage  mutations selected in MT-2 cells
b 
IIIB None K45R, M46I, T80I, P81S 48
 
NA
 
5269 I15V L10I, M46L, V82A 48 NA 
5323 A41K M46L, L63P, V82A, L90M 48 NA 
5331 K20R, E35D, R41K, A71V, I93L L10I, L63P, V82A, L90M 48 NA 
5346 T12K, I13V, L23Q, L33I, L63P, V77I L90M 48 NA 
5512 Q7L, K14R, L19L/V, K43K/R, I64V, 
H69H/Y 
T12K, I13V, L33I, M46I, L63P, 
V77I, T80I 
48 NA 
BK132 I64V, V77I, I93L NA 15 
30 
66 
M46L, V82A 
M46L, L63P, V82A, L90M 
R41K/R, M46L, L63P, V82A, L90M 
5326 E35D, M36I, R41K, L63P, and H69Q NA 28 
42 
66 
L10I, N37S 
L10I, N37S, K45I/K, I54M 
L10I, N37S, K45I/K, I54M 
NA, Not applicable. 
a
 The isolates 5269, 5323, 5331, 5346, 5512 and HIV-1/IIIB were passaged in CBMCs over 48 weeks. 
b
 The isolates BK132 and 5326 were passaged in MT-2 cells for 66 passages. 
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Table 3: In vitro activity in CBMCs of various PIs against PL-100-selected mutants in HIV/IIIB. 
Week Genotype Mean EC50 (µM) fold change (FC) 
  nelfinavir amprenavir lopinavir atazanavir PL-100        darunavir saquinavir 
Lower and upper clinical cut offs 1.2-9.4 1.5-19.5 6.1-51.2 2.5-32.5 2.5
a 
10-106.9 3.1-22.6 
Wk 0 0.051 ± 0.020 0.164 ± 0.030 0.060 ± 0.010 0.009 ± 0.001 0.043 ± 0.005 0.009 ± 0.001 0.054 ± 0.010 
Wk 8 T80I 0.006 ± 0.001 (0.11) 0.324 ± 0.020 
(2.00) 
0.016 ± 0.010 
(0.26) 
0.004 ± 0.001 
(0.44) 
0.150 ± 0.080 
(3.49)               
0.002 ± 0.001 
(0.22) 
0.011 ± 0.002 
(0.20)  
Wk20 M46I/M, T80I 0.038 ± 0.004 (0.74) 1.065 ± 0.050 
(6.50) 
0.034 ± 0.010 
(0.57) 
0.026 ± 0.003 
(2.90) 
0.563 ± 0.160 
(13.1) 
0.011 ± 0.001 
(1.20) 
0.028 ± 0.002 
(0.52) 
Wk25 K45K/R, M46I, T80I, P81S 0.022 ± 0.008 (0.43) 0.541 ± 0.023 
(3.30) 
0.018 ± 0.010 
(0.30) 
0.016 ± 0.008 
(1.80)  
0.641 ± 0.260 
(15.0) 
0.002 ± 0.001 
(0.22) 
0.036 ± 0.001 
(0.66) 
Wk48 K45R, M46I, T80I, P81S 0.029 ± 0.010 (0.56) 0.328 ± 0.010 
(2.00) 
0.024 ± 0.009 
(0.40) 
0.022 ± 0.001 
(2.40) 
0.930 ± 0.170 
(21.6) 
0.005 ± 0.003 
(0.60) 
0.065 ± 0.006 
(1.20) 
 
a
Arbitrarily chosen lower cut-off value of PL-100 for this analysis pending availability of clinical data. 
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Table 4: In vitro activity in CBMCs or MT-2 cells of various PIs against viruses containing relevant resistance mutations. 
Virus Mutations Subtype Mean EC50 (µM) fold change (FC) 
 nelfinavir amprenavir lopinavir atazanavir PL-100        darunavir saquinavir 
Lower and upper clinical cut offs 1.2-9.4 1.5-19.5 6.1-51.2 2.5-32.5 2.5
a 
10-106.9 3.1-22.6 
5331 Wt B 0.028 ± 0.006 0.035 ± 0.009 0.019 ± 0.009 0.005 ± 0.002 0.017 ± 0.010 0.007 ± 0.002 0.058 ± 0.001 
5331 L10I, V82A, L90M B 0.045 ± 0.002 
(1.60) 
0.034 ± 0.003 
(0.97) 
0.039 ± 0.001 
(2.05) 
0.004 ± 0.001 
(0.80) 
0.146 ± 0.08 
(8.60) 
0.002 ± 0.001 
(0.29) 
0.036 ± 0.009 
(0.62) 
BK132 wt B 0.019 ± 0.002 0.020 ± 0.001 0.012 ± 0.0002 0.008 ± 0.001 0.011 ± 0.003 0.005 ± 0.001 ND
 
BK132 R41K/R, M46L, L63P, 
V82A, L90M 
B 0.082 ± 0.010 
(4.30) 
0.550 ± 0.020 
(27.5) 
0.286 ± 0.001 
(23.8) 
0.062 ± 0.002 
(7.79) 
 0.132 ± 0.030 
(12.0) 
0.022 ± 0.001 
(4.46) 
ND
 
5326 wt B 0.015 ± 0.003 0.018 ± 0.0001 0.014 ± 0.002  0.007 ± 0.001 0.009 ± 0.002 0.004 ± 0.001 ND
 
5326 L10I, N37S, K45I/K, 
I54M 
B 0.176 ± 0.002 
(11.7)  
0.130 ± 0.001 
(7.20) 
0.080 ± 0.002 
(5.70) 
0.067 ± 0.003 
(9.60) 
0.062 ± 0.001 
(6.90) 
0.028 ± 0.003 
(6.90) 
ND
 
 
ND, Not determined 
Polymorphisms at baseline for isolates 5331: K20R, E35D, R41K, A71V and I93L; BK132: I64V, V77I and I93L; 5326: E35D, M36I, 
R41K, L63P and H69Q. 
a
Arbitrarily chosen lower cut-off value of PL-100 for this analysis pending availability of clinical data. 
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Figure 1:  
Comparison of the size of the inhibitor binding cavity in wt (monomers colored green and 
light blue) (above) and MDR protease (monomers coloured grey and light brown) 
(below). The surface of the binding cavity is shown as an opaque surface within the 
partially transparent dimer in both cases. This figure appears in colour in the online 
version of JAC and in black and white in the printed version of JAC. The figure was 
generated in PyMOL
23
 using protein databank (PDB) files 4DQB
22
 and 1RPI
31
.  
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Figure 2: 
PR-inhibitor interactions calculated after docking simulations of (a) PL-100, (b) 
darunavir  and (c) amprenavir to wt PR (grey ribbons) using AutoDock vina.
24
 Ligands 
are shown as transparent space-filling and solid stick models colored based on standard 
atomic coloration; red shows acidic oxygens and blue represents basic nitrogen atoms; 
polar hydrogens are shown in white. Hydrogen binding interactions are shown by a solid 
black line and other residue-ligand contacts are shown by yellow-coloured carbon atoms 
on the ligand as well as by a solid green line for strong ligand-residue contacts. This 
figure appears in colour in the online version of JAC and in black and white in the printed 
version of JAC. Determination of residue-ligand contacts and image processing was 
performed using UCSF Chimera.
28 
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Figure 3: 
Extensive wt PR-inhibitor interactions determined using DockingServer 
25
 for (a) PL-
100, (b) darunavir, (c) amprenavir. Wire-trace outlines of inhibitor (dark blue) and 
protease residues (grey) with catalytic residue D25 are in red. (d) Classification of ligand-
residue interactions. Residue colour code: Pink- mutated during selections with a specific 
drug; green- not mutated during selections but next to position of PR mutated during 
selections; orange- not mutated or not near mutated position, but previously reported to 
be involved in drug resistance. This figure appears in colour in the online version of JAC 
and in black and white in the printed version of JAC. 
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⃰
 Any of the following interactions; Pi:Pi, cation:Pi or indirect interactions.
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Figure 4:  
Extensive MDR PR-inhibitor interactions determined using DockingServer
 25
for (a) PL-
100, (a) darunavir, (a) amprenavir. Wire-trace outlines of inhibitor (dark blue) and PR 
residues (grey) are shown. (d) Classification of ligand-residue interactions. Residue 
colour code: Pink- mutated during selections with specific drug; green- not mutated 
during selections but next to a position mutated during drug selections. This figure 
appears in color in the online version of JAC and in black and white in the printed version 
of JAC.    
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⃰
 Any of the following interactions; Pi:Pi, cation:Pi or indirect interactions.
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Chapter 6    
General Discussion  
(Sections of this chapter were published in a review “Antiviral Drug Resistance and the 
Need for Development of New HIV-1 Reverse Transcriptase Inhibitors”, authored by 
Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. Antimicrobial Agents and 
Chemotherapy. June 2012). 
 
Until recently, only three antiretroviral drug classes were available for treatment of HIV-
1 infected patients; NRTIs, NNRTIs and PIs. Resistance within these classes of drugs and 
extended cross-resistance among drug classes has also been observed. Thus, the 
management of multiclass-resistant HIV-1 infection has been a major challenge to 
clinicians treating HIV-1-infected patients, due to limited options for combination 
therapy. The advent of new antiretroviral drugs against new targets (fusion inhibitors, 
integrease inhibitors, R5 coreceptor antagonists) and new-generation drugs within 
available classes (second generation NNRTIs and PIs with higher genetic barriers for 
resistance and different resistance profiles) has expanded therapeutic options for patients 
with multiclass drug-resistant HIV-1. While some of the second generation NNRTIs 
(ETR and RPV) and PIs (DRV and TPV) have been approved for clinical use, some are 
under pre-clinical (PL-100) investigation. Drugs against new targets and second 
generation antiretrovirals maybe useful in salvage therapy, if patients have failed to 
respond to therapy, due to the presence of resistance mutations selected during first line 
therapy. We wished to explore the role of naturally occurring polymorphisms 
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(represented in different subtypes) and baseline resistance mutations in determining the 
mutational pathways and resistance patterns of some second generation NNRTIs and PIs. 
Resistance to ETR and RPV  
In Chapter two, as reported by Asahchop et al 2011, we provided a comprehensive in 
vitro analysis of the resistance pattern to ETR in wt clinical isolates of subtype B, subtype 
C, and CRF02_AG grown over 25 to 30 weeks in CBMCs in increasing concentrations of 
ETR compared to EFV. Our data show that ETR RAMs emerged after 18 weeks of drug 
pressure, with the exception of one isolate (BK132) that selected for E138E/K at weeks 
11 to 13. The E138K mutation was selected in all isolates and was almost always the first 
mutation to emerge. The selection of E138K under ETR drug pressure has also been 
observed in vitro and in clinical trials by other groups [250,270]. We also showed that 
site-directed mutagenesis of E138K revealed low-level resistance to ETR in both pNL4-3 
and AG plasmids, with a fold change slightly above the clinical cut-off. Amino acid 
substitutions at position 138 of the RT have also been described in ETR therapy [270], all 
of which equally showed low-level resistance to ETR [270,278]. Although the presence 
of one of these mutations at position 138 on its own is not enough to exclude the use of 
ETR, its presence may increase the level of resistance to ETR and/or allow further 
selection of other resistance mutations. Furthermore, genotypic resistance in the DUET 
studies have confirmed the role of E138 mutations in patients failing ETR,  
demonstrating an increased FC for ETR over the upper clinical cut-off (CCO) for 
resistance to ETR (>13). Other ETR RAMs observed in our study included V90I, 
K101Q, E138K, V179D/E/F, Y181C, V189I, G190E, H221Y, and M230L. There was no 
difference in the pattern of mutations selected by ETR in B and non-B subtypes. 
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Although ETR is available in developed countries where subtype B predominates, it will 
be important to validate the results of the present study in resource limited setting where 
non-B subtypes circulate. E138K was recently observed as the most frequent NNRTI 
mutation together with the NRTI mutation M184I/V among HIV-1 naïve patients who 
failed RPV (an NNRTI of the same family and binding mode as ETR) in combination 
with either FTC or 3TC in the ECHO and THRIVE trials [279,280]. These phase 3 
clinical studies are in agreement with our tissue culture observations and demonstrate the 
patterns of resistance mutations that would be seen in HIV-1 naïve patients experiencing 
failure upon ETR treatment in first line therapy. However, ETR is not usually used for 
treatment of HIV-1 naïve patients; this probably explains differences in patterns of 
resistance to ETR in our study and the DUET study.  
 
We also observed diminished replication capacity in the case of pNL4-3 and AG viruses 
containing E138K compared to wt virus and this has been confirmed by other studies 
[408,409]. The replication capacity of the most frequently observed double mutants in the 
ECHO and THRIVE studies (E138K/M184I and E138K/M184V) was also found to be 
comparable to that of wt virus [408,409]. The presence of these double mutants enhanced 
resistance to ETR and RPV, compared to E138K alone, and suggests a mutual 
compensation between E138K and the M184I/V mutations [408,409]. The combination 
of these two mutations results in a highly fit virus and might enhance HIV transmission 
rates.  E138K was also shown to decrease dNTP usage and to compensate for the defect 
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in dNTP usage and the diminished replication capacity of M184I/V [408]. Another group 
has analyzed the fitness of these double mutants using growth competition assays in MT-
2 cells and showed that the E138K/M184I mutant was less fit than wt or the single 
mutants [410]. This result contradicts the observation by our group and others. However, 
additional studies will be necessary to clearly demonstrate how this double mutant 
impacts on fitness. Although still a subject of further investigation, the public health and 
epidemiological consequence of E138K/M184I may be detrimental in regards to 
transmission rate if confirmed to be as fit as wt. Biochemical analysis by our group and 
others has shown that E138K confers resistance through the p51 subunit of RT, while the 
presence of E138K and M184I enhanced dNTP usage via the p51 and p66 subunit of RT  
[411,412]. Our group has also shown that E138K affects the enzymatic activity through 
the p51 subunit of RT by decreasing RNase H activity and the polymerization rate of RT 
(Figure 9C) [411]. The mechanism of resistance to ETR or RPV by E138K has been 
shown to occur through the p51 subunit of RT whereby this mutation leads to a larger 
increase in dissociation rate of inhibitor, which overcomes the enhanced rate of 
association (Figure 9B) [412]. Molecular modeling have also revealed that a salt bridge 
naturally exist between p51(E138) and p66(K101) [412]. This salt bridge has been shown 
to be disrupted in the presence of E138K, specifically in the p51 subunit of RT, resulting 
in a large gap at the bottom of the NNRTI binding pocket and repositioning of RPV in 
the binding pocket [412]. Since E138K of p51 subunit is located in the entrance of the 
NNRTI binding pocket, this demonstrates that E138K confers resistance to second 
generation NNRTIs by interrupting with binding at the entrance of the pocket.  Recent in 
vitro experiments and analysis of patient PBMCs demonstrated the pre-existence of 
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E138K and M184I mutations in proviral reservoirs at a relatively high frequency prior to 
drug exposure as a result of APOBEC3 editing [413]. These mutations may be co-
selected in individuals with polymorphisms in APOBEC3 and in a defective HIV Vif 
variant [413,414]. The implication of these pre-existing mutations selected by APOBEC3 
may be the rapid failure of therapy containing RPV or ETR. This further shows the 
importance of these two mutations and their role in resistance.   
 
We showed that EFV selected for mutations faster than ETR after 12 weeks of EFV drug 
pressure. The mutations selected included; V106M in subtype C and V106I in subtype B.  
EFV and ETR specifically selected for G190A and G190E, respectively. This further 
demonstrates the non-association of G190A with ETR resistance as shown  in another 
study [415]. However, G190E has been shown to be selected by both ETR and RPV 
[264,278]. Site-directed mutants containing the E138K mutation showed an FC below the 
CCO of EFV. This is consistent with the non-association of E138K with EFV resistance 
as observed both in treated patients and in in vitro selection experiments. However, one 
study has observed the selection of E138K after in vitro passage experiment of viruses 
containing mutations at position 135 at baseline [416]. These authors demonstrated FCs 
for EFV of 2 and 7 for E138K and I135T/E138K, respectively. So far, this is the only 
study demonstrating the selection of E138K under EFV drug pressure in a background of 
variants containing amino acid substitutions at position 135 of the RT. It is still unclear 
why first generation NNRTIs (NVP and EFV) did not select for E138K in a wt virus. One 
of the possible reasons could be differences in the structure of first (NVP and EFV) and 
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second (ETR and RPV) generation NNRTIs. Structural modeling studies have shown that 
second generation NNRTIs bind through the amino acid position 138 in the p51 subunit 
that is located at the entrance of the binding pocket. Mutations at this position will 
interfere with binding and reposition the inhibitor. This has only been demonstrated with 
second generation and not first generation NNRTIs. First generation NNRTIs such as 
EFV binds to the NNRTI binding pocket using amino acid positions in the p66 subunit of 
RT [417].   
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Figure 9: Proposed mechanism of resistance of the E138K mutation to ETR or RPV and 
impact on enzyme function. (Adapted from Menéndez-Arias L et al 2011 [303]). In the 
presence of wt or p66 (E138K) RT, a potent inhibition is observed (A), while in the 
presence of p51 (E138K) there is impaired inhibition by large increase in dissociation of 
the inhibitor and/or decreased binding of NNRTI to RT (B). E138K in the p51 unit 
affects enzyme function by reducing RNase H activity (C).  
 
In Chapter 3, HIV-1 resistance patterns following selection with ETR and RPV in both 
wt viruses as well as in viruses containing a variety of NNRTI mutations at baseline was 
explored. Specifically, the basis for the preferential selection of E138K by ETR in wt 
viruses compared to the selection of other NNRTI mutations in the DUET clinical studies 
was examined. In addition, we wished to investigate whether HIV-1 that already 
contained E138K, M184I/V or E138K plus M184I/V could develop additional resistance 
mutations in the presence of ETR or RPV.  
Our in vitro passage experiments showed that E138K was selected by each of wt, 
K103N- or G190A-containing virus at baseline in the presence of ETR or RPV. In 
contrast, the exposure of ETR or RPV to subtype B viruses containing Y181C at baseline 
selected for V179I/F or A62A/V, respectively, but not E138K. In the DUET studies that 
led to the approval of ETR for use in NNRTI-experienced patients, only three subtype B 
patients who previously harbored K103N and who developed E138K failed ETR therapy, 
while one patient who harbored Y181C developed E138V [275]. A different study 
showed that 12 of 42 ETR failures who harbored mutations at position 181 at baseline 
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contained at least one new NNRTI mutation but not E138K [418]. In an in vitro selection 
study using a drug of the same family (TMC120), E138K was selected in wt viruses but 
not in viruses containing Y181C at baseline [287]. Phenotyping of viral clones containing 
E138K, Y181C or E138K/Y181C showed a fold-change in resistance for Y181C and 
E138K/Y181C that was not significantly different. Considering that both E138K and 
Y181C individually confer resistance to either ETR or RPV, one would expect to observe 
an enhanced fold-change in the presence of both mutations compared to each of them 
alone. Additionally, the replication capacity of Y181C and E138K/Y181C compared to 
wt virus was impaired by 1.5 and 3 fold, respectively. Taken together, this implies that in 
a background of Y181C-containing virus, the emergence of E138K does not give the 
virus any additional advantage in terms of resistance and/or fitness. Genotyping analyses 
of samples from the DUET studies have shown that none of the three patients who failed 
ETR therapy and selected for E138K had a background of Y181C-containing virus [270]. 
The three patients who selected for E138K had different mutations at baseline. The fact 
that a larger proportion of patients in the DUET studies were NNRTI-experienced, and 
possessed Y181C mutation at baseline, could be the basis for the rare selection of E138K. 
In another clinical study in NNRTI-experienced patients, it was also shown that patients 
who failed ETR therapy and harbored a background virus containing Y181C selected for 
mutations at position 179 and not E138K [418]. The present study, together with 
evidence from other clinical studies, suggests that Y181C may be antagonistic to E138K. 
As shown here, the combination of Y181C and E138K may lead to a less fit virus 
compared to virus containing Y181C alone. This could be part of the reason why viruses 
containing a Y181C background could not select for E138K in the presence of ETR or 
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RPV since this combination will impair fitness and improve the susceptibility to these 
drugs.  
Biochemical analyses have confirmed this proposed antagonism. In this analysis, it was 
shown that Y181C conferred antagonism to E138K by decreasing dNTP usage, and 
impaired enzyme activity and processivity [419]. In the results presented in chapter 2, we 
showed that E138K was the first mutation to emerge after ETR pressure in most isolates 
followed by accumulation of Y181C and amino acid substitutions at position 179. In an 
in vitro study, it was also shown that RPV selected for E138K in a viral clone containing 
V179F/Y181C at baseline [278]. This suggests that the observed antagonism was 
possibly reversed in the presence of amino acid substitutions at position 179. 
Biochemical analysis, cell culture and structural modeling studies of the triple mutant 
E138K/Y181C/V179I/F are needed to help provide a clear picture of how these mutations 
interact.  
The complex formed between RPV and wt RT is stable and comparable to the complex 
between RPV and K103N mutant RT. In the presence of RPV and mutant RT containing 
Y181C, there is loss of aromatic interactions resulting in a shift of RPV further into the 
NNRTI pocket [420]. We thus hypothesize that differences in binding interactions that 
exist between RPV or ETR and the Y181C RT mutant but not in other mutants is the 
basis of this antagonism. It is not known if the loss of interaction between the RT mutant 
containing Y181C and inhibitor enhances the bond that naturally exists between E138 
and K101. Additional modeling studies with E138K/Y181C will further explain if RT 
mutants containing Y181C will prevent the emergence of E138K by stabilizing the salt 
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bridge between E138 and K101. This will further explain the mechanistic basis of 
antagonism of Y181C on E138K.   
The wt virus under RPV drug pressure showed an intermittent mixture of K101 and E101 
that was dominated by E138K at the end of the selection experiment. This could be due 
to the presence of quasi-species that existed in the viral population. This suggests that 
K101E and E138K cannot exist in the same viral clone, possibly due to the presence of a 
salt bridge between K101 and E138 [412]. Both E138K and K101E are resistance 
mutations associated with decreased susceptibility to ETR and RPV [270,421]. The 
identification of these two mutations in the same viral clone has not been possible due to 
that fact that both mutations in a viral clone will establish the same salt bridge as is the 
case with wt virus. Thus, in a viral population the mutation that results to the most fit 
virus, either in the presence or absence of drugs, will dominate. So far, fitness studies to 
compare viruses containing E138K and K101E are still not available. It seems likely that 
viruses containing E138K have a fitness advantage over K101E because of its 
predominance both in clinical studies and in cell culture experiments. Fitness studies will 
be necessary to confirm this. The viral clones containing M184I/V at baseline did not 
select for NNRTI mutations after exposure to RPV, as observed with ETR in a recent in 
vitro study [411]. This could be due to decreased viral fitness of both clones and 
difficulties in increasing RPV drug concentration. The results presented here are 
consistent with those from a previous study, in which viruses containing the M184V 
mutation were shown to be  less likely to select for mutations under drug pressure [422].  
 
252 
 
 
 
Based on the results presented in this thesis and the results of others, we have proposed 
that different patterns of mutations selected by ETR or RPV may exist in wt virus and in 
viruses containing some of the most common NNRTI mutations (Figure 10). Panel A 
represents the E138K pathway while panel B represents the K101E pathway. These two 
pathways are mutually exclusive. Panel C is a pathway that is specific to Y181C alone. 
However, the proposed patterns of mutations are not exhaustive. Additional mutations are 
been identified both in in vitro studies and in treated patients. 
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Figure 10: Proposed patterns of emergence of resistance -associated mutations for either 
ETR or RPV.   
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A number of studies have observed high level cross-resistance to ETR and RPV 
[421,423]. In addition, due to similarity in binding, the same mutations are selected in the 
presence of RPV or ETR, resulting in high-level cross-resistance [278]. In the context of 
the current study, it seems obvious that patients, who fail RPV because of mutations that 
are associated with resistance to both ETR and RPV, will be unlikely to derive future 
benefit from ETR. In a review by Asahchop et al 2012, it was reported that “Several 
studies have researched the theoretical potential of ETR based on the resistance patterns 
of patients who previously failed NNRTI therapy and accumulated ETR RAMs. These 
studies have shown a prevalence of more than three ETR RAMs among viral isolates 
from patients experiencing NNRTI treatment failure, ranging from 4.6% to 10%, while 
the prevalence of isolates with single ETR RAMs was 17.4% to 35.9% 
[424,425,426,427]. These studies concluded that there is a low prevalence of ETR 
resistance at baseline and that patients with prior failure to NNRTIs could potentially 
benefit from ETR rescue therapy. However, these analyses focused on patients in 
developed countries that had full access to the most potent antiretroviral drugs who were 
constantly monitored for viral load and the development of resistance”.  
 
 In the same study by Asahchop et al 2012, the authors reported that, “patients in 
countries with limited resources often develop resistance faster due to a lack of potent 
antiretroviral drugs, access to viral load, and drug resistance testing. Some studies in 
resource limited settings have observed a high prevalence of NNRTI resistance mutations 
associated with ETR resistance among patients failing an NNRTI containing regimen 
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[428,429,430]. Using NVP in the failing regimen was associated with intermediate and 
reduced response to ETR while use of EFV and co-administration of 3TC reduced the 
risk of ETR resistance [430]. The authors concluded that the frequent occurrence of 
NNRTI mutations in resource limited settings in which drug resistance testing is rare 
might compromise the continuous use of ETR and also its use in second line therapy. 
ETR should be avoided in second line treatment in developing country settings where 
drug resistance testing is not performed and NVP is used for first-line therapy”. 
 
Standard population genotyping is used to routinely detect genotypic resistance in 
patients failing therapy. However, this technique cannot detect viral variants containing 
less than 20% of the viral population [384]. Sensitive assays have been shown to detect 
viral variants as low as 0.1% of the viral population [386,395,431]. The existence of low 
frequencies of HIV-1 variants in infected patients has been demonstrated to impact 
susceptibility to antiretrovirals including ETR [392,393]. Transmitted resistance 
mutations occur frequently in primary HIV-1 infection and most of these, when 
transmitted, exist as minority variants. Clinical studies that explore the impact of minority 
variants on second generation NNRTIs (ETR and RPV) are not available. The selection 
of some resistance mutations in the presence of ETR or RPV is rapid and facilitates the 
development of additional mutations within the genome. It is likely that the presence of 
mutations at low frequency before administration of therapy containing either ETR or 
RPV will result in the accumulation of mutations that will dominate the viral population 
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and lead to therapy failure. This subject should be further confirmed through clinical 
studies.   
 
In the present study we used population genotyping to identify resistance mutations. It is 
likely possible that some ETR and RPV mutations were present at low frequencies such 
that population genotyping was not sensitive enough to detect the presence of these 
minority species. A limitation to our study is the fact we did not use sensitive assays such 
as ultra deep pyrosequencing or allele specific real time PCR to detect low frequency 
mutants.  
RPV is approved for treatment of HIV-1 infected NNRTI-naïve patients while ETR is 
approved for treatment of NNRTI-experienced patients. Both drugs are of the same 
family, and possess a similar binding mode within the NNRTI binding pocket and genetic 
barrier to resistance. At the time of approval of ETR, little was known about its resistance 
profile. We and others have identified mutations that confer resistance to both ETR and 
RPV. It is thus obvious that cross-resistance can occur among these drugs. In addition, 
the frequent use of NVP in developing countries makes it difficult to believe that ETR 
will be effective in NNRTI-experienced patients. The future use of ETR may be 
jeopardized if it is used only in NNRTI-experience patients, because people who fail a 
RPV containing regimen in first line therapy will not benefit from ETR therapy. It should 
also be noted that the use of two NRTIs in combination with ETR in NNRTI-experienced 
patients has resulted in therapy failure because of the presence of NRTI and NNRTI 
mutations at baseline [277,432]. Based on the results presented here and those of others, 
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ETR could be recommended for treatment of NNRTI-naïve patients. If ETR is considered 
for second line therapy, genotyping of patient samples is necessary to identify the 
presence of any mutations associated with ETR failure. In addition, combinations of a 
protease and an integrase inhibitor could be included in ETR containing regimens for 
treatment of NNRTI-experienced patients.     
 
Resistance to PL-100 and DRV 
In Chapters 4 and 5, we described the resistance profile of PL-100 and compared it to 
both first and second generation approved PIs. Chapter 4 specifically compares the 
resistance profile of PL-100 to approved first generation PIs. Asahchop et al 2010 
reported that “resistance to PL-100 emerged via mutations at positions 82 and 90 or, 
alternatively, via a T80I substitution that appears to be unique to PL-100.  The most 
common mutations selected by PL-100 were at positions 46, 80, 82, and 90”. Amongst 
these mutations, T80I appears to be novel, while M46I/L, V82A, and L90M have 
previously been described in patients failing SQV, NFV, APV, LPV and ATV 
[322,328,433,434,435,436]. Resistance to PL-100 can occur through two pathways: the 
first (T80I) is important and specific only to PL-100 while the second (V82A and L90M) 
pathway is common to other PIs (Figure 11). This raises the possibility of cross-
resistance in the class and precludes the sequential use of PL-100 and any other first 
generation PI. The two pathways were mutually exclusive. 
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 Our study in Chapter 4 also demonstrates that the pattern of resistance to PL-100 in 
subtype C and CRF01_AE was similar and that the development of resistance to PL-100 
was delayed compared to that with first-generation PIs, as previously described [437]. 
The K55R and V85I mutations were intermittently co-selected in tissue culture in the 
presence of PL-100 drug pressure. Although site-directed mutagenesis of these 
substitutions either alone or in combination, showed susceptibility to all PIs tested with 
the exception of NFV, they might be considered to be secondary PI mutations. It is also 
thought that K55R and V85I are able to restore viral replication capacity [438]. Thus, 
these mutations might not really have a role in resistance to PIs but rather in restoring 
viral replication capacity. 
 
The sequential use of PIs in PI-experience patients is limited by the high level of cross-
resistance amongst first generation PIs. Although our study in chapter 4 has confirmed 
that PL-100 possess a slightly higher or equivalent genetic barrier compared to first 
generation PIs, the emergence of mutations that confer resistance was not significantly 
delayed in the presence of PL-100. Furthermore, some of the mutations selected by PL-
100 are mutations already observed in patients who fail therapy containing a first 
generation PIs. It therefore seems possible that PL-100 might not be effective in patients 
who fail therapy containing a first generation PI.  
 
The introduction of the second generation PIs DRV and Tipranavir (TPV) that possesses 
a high genetic barrier to development of resistance and potent activity against multiple 
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PI-resistance mutations has dramatically enhanced the response of PI-experienced 
patients. There is thus the need for robust second generation PIs with activity equivalent 
to DRV and TPV or even better. As a follow up of Chapter 4, we compared the resistance 
profile of PL-100 to a second generation PI (DRV) (Chapter 5). Using the lab strain HIV-
1/IIIB and clinical isolates we determined the time to development of resistance to PL-
100, APV and DRV. Genotypic analysis of the protease gene of the lab strain HIV-1/IIIB 
showed that the first mutation selected was T80I at week 8. At week 18 and beyond, the 
mutations K45R, M46I, and P81S were selected. We experienced difficulty in selecting 
for DRV resistance after 40 weeks using wt clinical isolates. Other groups have also 
experienced difficulties in selecting for DRV-resistance mutations or for the 
accumulation of mutations at passage 30 and beyond [439,440]. Phenotypic susceptibility 
of HIV-1 variants selected under PL-100 drug pressure showed low- to high-level 
resistance to PL-100, while all variants selected retained susceptibility to DRV and SQV. 
This is probably due to the high genetic barrier of DRV and the fact that mutations 
selected by PL-100 are different from DRV-resistance mutations. An important aspect of 
proteolytic activity of HIV protease is the dimerization of HIV protease subunits 
[32,112]. DRV can inhibit PR dimerization in vitro in addition to blocking PR activity, 
and this may contribute to its activity against multiple PI-resistant isolates [441]. 
The Gag cleavage site mutations have been shown to contribute to resistance and loss of 
fitness in patients failing PI containing regimen [348,350]. Despite this evidence, Gag is 
not routinely sequenced to monitor the development of resistance in patients failing a PI 
containing regimen. A limitation to our study is that we did not sequence the gag gene to 
identify mutations selected by any of the PIs used.    
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Resistance mutations typically reduce binding affinity of an inhibitor by removing an 
interactive side-chain or by making the active site/inhibitor binding domain more open 
and solvent exposed; this causes easier dissociation of the inhibitor from the enzyme and 
thus reduces overall inhibition [117]. In the case of protease, more than one resistance 
mutation is usually needed for resistance to occur. We have shown that APV possess 
hydrogen-bonding with the backbone of D30 of protease, and DRV has increased the 
number of backbone interactions due the presence of its tetrahydrofuran (THF) ring, 
resulting in higher potency and a higher genetic barrier for resistance. PL-100 has 
diphenyl groups that bind through delocalized hydrophobic interactions and account for 
its slightly higher genetic barrier to development of resistance, relative to APV, because 
the HIV-1 protease has a hydrophobic core. The improved genetic barrier to resistance of 
PL-100, compared with first generation PIs, is because the diphenyl group of PL100 is 
flexible around its chiral center and can adjust for changes in hydrophobicity fairly easily 
without losing its core contacts with I51 and D30. The difficulty of selecting DRV 
resistant mutants in our cell culture experiments could be due to the presence of a di-THF 
group that is involved in the binding of the inhibitor to the enzyme. Our results presented 
here demonstrate that PL-100 might not be of clinical advantage in the treatment of HIV 
infected patients compared to the use of approved first generation PIs.  
Thus, hydrogen bonding contacts and the presence of the di-THF group in DRV, as well 
as the hydrophobic nature of PL-100, are all important factors in drug binding. A high 
genetic barrier for drug resistance should be important in the design of new PIs. 
Redesigning the structure of PL-100 to include a di-THF group might improve its binding 
and antiviral activity.  
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Figure 11: The resistance pathways of PL-100. 
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Conclusion 
We have examined the resistance pattern to second generation NNRTIs (ETR and RPV) 
and the potential of PL-100 as a second generation PI. Our in vitro analysis demonstrated 
the different patterns of resistance to ETR or RPV in a wt virus compared to a virus 
containing Y181C at baseline. E138K was the first to emerge and most frequently 
observed in wt virus of all subtypes tested on exposure to ERT or RPV drug pressure. 
There was no difference in the pattern of mutations observed in the different subtypes. 
The fact that viruses containing Y181C mutation at baseline are less likely to develop 
E138K suggests that Y181C is antagonistic to E138K. Figure 9B shows the proposed 
mechanism of resistance of E138K to ETR and RPV. PL-100 on its part showed a 
resistance profile that is comparable or better than the resistance profile of old PIs. In 
vitro and structural modeling studies demonstrated that PL-100 possesses a lower genetic 
barrier to resistance compared to DRV and suggest that redesigning the structure of PL-
100 to include a di-THF group of DRV might improve it genetic barrier.  
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